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ABSTRACT 
Acute increases in glucocorticoids (GCs) during a perceived stressful event are 
functionally important for many biological processes that include energy homeostasis. 
Perpetual hypothalamic-pituitary-adrenal (HP.A) axis activity continually elevates GC 
secretion and may induce many metabolic complications, such as peripheral insulin 
resistance, ectopic fat accumulation, hyperglycemia, and dyslipidemia that can increase 
risks of developing type 2 diabetes mellitus (T2DM). The progression into T2DM 
remains complex and many controversies hav1e yet to be resolved. In particular, the effect 
of GCs on pancreatic islet function remains relatively understudied. Therefore, we set out 
to develop a novel rodent model ofT2DM in young male Sprague-Dawley rats. First, we 
demonstrated that 2 weeks of elevated GCs and HFD induced rapid-onset diabetes 
(ROD), which included the following symptoms: body weight loss, hepatic steatosis, 
increased glucose intolerance, insulin resistance, and ectopic fat accumulation. Next, we 
further examined the effects of ROD on pancreatic islet function and found that ROD 
animals had increased ~-and a-cell mass, but impaired ~-cell glucose responsiveness, 
resulting in hyperglycemia. Regular exercise restores alterations in HP A activity and 
helps to protect against GC-induced hyperglycemia. This led us to investigate if regular 
exercise in our ROD model would help to protect against T2DM development. We found 
that volitional exercise was sufficient to attenuate symptoms of ROD, however not all 
symptoms were successfully restored, i.e. normalized glucose control and peripheral 
insulin resistance. We next investigated if pharmacologic agents would be able to fully 
reverse ROD. We demonstrated that non-selective GC receptor (GRII) antagonist fully 
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normalized our ROD phenotype, whereas selective GRII antagonists only partially 
attenuated some of the ROD symptoms. Collectively, these studies take an integratiive 
approach to T2DM development induced by GCs and HFD. We developed a model that 
mimics symptoms ofT2DM and concluded that GCs and HFD synergistically, not 
independently act to induce severe insulin resistance that burdens islet adaptive capacity. 
Regular exercise and pharmacological interventions were sufficient to attenuate ROD 
development and these therapies may be useful techniques to individuals suffering from 
HP A axis hyperactivity and dyslipidemia. 
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LITERATURE REVIEW Chapter 1 
1. Thesis Objectives and Hypothesis 
Type 2 diabetes mellitus (T2DM) is a widely recognized disease that plagues ,..., 
300 million people worldwide (1). Interestingly, although T2DM is extensively studied, 
this multifaceted disease remains poorly understood. Various risk factors have been 
identified as contributing to the onset of T2DM:, such as increased whole body insulin 
resistance, ectopic fat accumulation in insulin sensitive tissues, physical inactivity, poor 
nutrition, and genetics. Many of these factors exist in combination with other factors, but 
usually they are studied independently of one another. It is widely accepted that increased 
levels of "stress" deteriorate glucose homeostasis, which overwhelms pancreatic islet 
function. The literature is unclear about the role that "stress" plays in T2DM progression 
as it is unknown whether elevations in stress, secreted as glucocorticoids (GCs), have a 
direct role on T2DM development. Previous research suggests that acute elevation in GCs 
in vivo increases P-cell secretory capacity (2), butt GC exposure in vitro results in P-cell 
dysfunction (3). Rodent models of diabetes are useful as they mimic symptoms and 
disease progression displayed in T2DM humans, but are usually limited by spontaneous 
gene mutations that are rare in the human population or require daily injections of 
pharmacological agents, which can artificially elevate stress levels. Thus, an adequate 
rodent model of T2DM is necessary to enhance our integrative approach into the effects 
of stress-induced diabetes. 
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Objectives 
The main focus of this thesis was to develop a novel rodent model ofT2DM 
induced by elevations in GCs and high-fat diet (HFD). There are many studies that 
investigate these risk factors independently, but rarely have they been examined 
concomitantly, as they exist in individuals with T2DM. Secondly, this thesis aimed to 
determine the involvement of the islet function on T2DM development caused by 
elevated GCs and HFD. Thirdly, the focus ofthis thesis was to determine if therapeutic 
approaches, such as regular exercise and GC recieptor II (GRII) antagonists were 
sufficient to reduce risks of metabolic dysfunction with our rodent model of T2DM. 
Hypothesis 
Both acute GCs and HFD independently promote widespread whole-body insulin 
resistance, but typically do not result in T2DM onset, at least in the short-term, as ~-cell 
compensation tends to occur. We hypothesized that in combination, acute elevations in 
GCs and HFD would rapidly promote T2DM development by overwhelming the 
pancreatic ~-cell compensatory system, thus resulting in lower efficacy in islet glucose 
responsiveness. In contrast, we also predicted that regular exercise via voluntary wheel 
running or GRII antagonism via pharmacological intervention would attenuate the 
development of metabolic dysfunction, through pr~:servation in ~-cell function and 
protection against whole body insulin resistance. 
The following is an extensive review of the literature, as this thesis takes an 
integrative approach to examine elevated levels of stress and T2DM development, and as 
such requires examination of various topics. It encompasses an explanation of healthy 
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pancreatic function, diabetes onset, GC metabolism and physiology, GCs and T2DM, 
exercise and GC metabolism, exercise and T2DM, non-selective and selective GC 
antagonists. 
1.2. Pancreas Overview 
1.2.1. The Pancreatic Islet 
The pancreas is a vital endocrine organ that regulates energy homeostasis by the 
secretion of a variety of hormones. It consists of an array of endocrine cell types clustered 
into masses called the islets of Langerhans that make up tiny, but essential cells of the 
pancreas. The different cell types that exist within the islets are p, a, 8, F and €-cells that 
secrete hormones such as insulin, glucagon, somatostatin, pancreatic polypeptide and 
ghrelin, respectively (4). The bulk of the islets(....., 70% of total islet volume) consist of the 
P-cells, responsible for managing glucose home:ostasis through the secretion of the 
hormone insulin. The P-cells are typically located centrally within the islets of rodents 
and are surrounded by the other cell types, a-cells (....., 20% ), 8-cells (....., 5-10% ), F-cells (....., 
5%) and €-cells(.....,< 1 %) along the perimeter of the islet. In humans, however, all the 
different islet cell types are interspersed among the P-cells, but the majority of cells are 
aligned along the islet blood vessels in no particular sequence ( 5). This intricate structure 
suggests that microcirculation within the islet does not have an effect on paracrine 
dynamics in the human islet (6). The orientation of the P-cells is an integral part of the rat 
islet, as it allows blood flow to drain from the central portion of the islet outward; other 
islet cell types are exposed to high concentrations of insulin, which, in turn, can 
dramatically influence stimulation or inhibition on hormone secretion. Healthy and highly 
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functional islets, especially ~-cells, are critical for insulin secretory capacity that assists 
glucose uptake into skeletal muscle and adipose tissue and inhibits hepatic glucose 
production from the liver, ultimately contributing to blood glucose clearance. In the case 
of abnormal or dysfunctional ~-cells, the development of diabetes can occur (either 
TlDM or T2DM). 
TlDM develops as an autoimmune disease that targets and down-regulates 
pancreatic insulin-producing ~-cells, leaving individuals unable to synthesize their own 
insulin. The body's resistance to insulin defines T2DM, where individuals are able to 
produce large amounts of insulin, but remain insulin insensitive (reviewed in, (7)). 
However, if this condition remains untreated, individuals may become dependent upon 
exogenous insulin as ~-cells become exhausted with trying to maintain euglycemia (8). 
1.2.2. Insulin 
Insulin secretion is a coordinated response from various stimulatory factors 
including nutrient stimuli, neural input, and varying levels of paracrine/endocrine islet-
produced hormones. In healthy individuals, ~-cdls release enough insulin in the fasting 
and postprandial(~ 2 hours) state to maintain basal insulin concentrations(~ 0.4 ng/ml) 
(9). This small amount of insulin released into the portal circulation helps to limit 
excessive hepatic glucose production between meals. There are two phases of insulin 
secretion that follow a distinct pattern, postprandial of a mixed meal: the first phase of 
insulin secretion occurs between ~ 8-10 minutes followed by a second phase that occurs 
between~ 30--45 minutes afterwards and can stay elevated for 120 minutes. These levels 
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of insulin can vary depending on the carbohydrate content of a meal and the insulin 
sensitivity of the individual ( 10). In non-diabetic individuals, after the ingestion of a meal 
(,...., 90-120 minutes), insulin concentrations should be enough to return blood glucose 
levels back to basal levels (11). Therefore, P-cell function is considered to be "impaired", 
if blood glucose concentrations do not return to pre-meal basal levels and depending on 
the level of hyperglycemia may result in the clinical diagnosis of pre-diabetes or diabetes 
mellitus. Potential causes of impaired insulin secretion are P-cell dysfunction, reduced P-
cell mass, or both. Pancreatic P-cell dysfunction may be considered a desensitization of 
normal P-cells to either glucose- or insulin-signaling or impaired glucose responsiveness 
(12). If an individual displays any abnormalities in their first or second phase of glucose 
stimulated insulin secretion, then this is usually a sign of early onset of T2DM (13). 
These characteristics of T2DM individuals win be further discussed in section 2.4. 
Glucose-stimulated insulin secretion (G-SIS) is promoted by the closure of ATP-
senstive potassium (KATP) channels on the P-cell membrane, as a result of depolarization 
of the cell. Prior to the electrical closure of the KATP channels, glucose enters the P-cell 
through the Na+-independent glucose transporter protein (GLUT2), which has a very high 
affinity for glucose in the plasma. Glucose entry into the P-cell increases the activity of 
glucokinase, which converts glucose into glucose-6-phosphate (G6P), which in turn, 
yields pyruvate, leading to the generation of ATP molecule from the mitochondria. The 
elevated ratio of ATP/ADP depolarizes the P-ce:ll membrane potential and drives the 
KATP channels to close, allowing the entry of extracellular calcium (Ca2l via voltage-
dependent Ca2+ channels, as well as from mobilization of cytosolic Ca2+. Subsequently, 
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the rise in Ca2+ levels induces the activation of several pathways that increase GSIS, such 
as phosphorylation of protein kinase A (PK.A) and C (PKC). These proteins help facilitate 
the fusion of insulin-containing granules to the ~-cell plasma membrane for exocytosis of 
insulin into circulation. PK.A is activated by the rise in cAMP levels from the influx of 
Ca2+ into the cell, and PKC is translocated to the plasma membrane as a result of the 
increase in Ca2+ and diacylglycerol (DAG) concentrations. These Ca2+-stimulated protein 
kinases are thought to regulate myosin light-chain kinase, which phosphorylates secretory 
granules and modulates their movement to the surface of the ~-cell membrane that 
initiates the release of insulin (14). Refer to Figure 1.1. Image adopted from Beaudry and 
Riddell, 2012 (15). 
Plasma 
Membrane 
CYtosol 
• f Glucose Ca2• 
Depol:a~iz~tl:pn r , 
~ 
Py1te --~1¥J 
f K+ f Ca2• 
l 
~ 
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Ii::: d ~lin Secrefi()n I 0 Q 
Figure 1.1. Glucose-stimulated insulin secretion. A rise in blood glucose levels 
stimulate GLUT2 proteins on the P-cell membrane to take up glucose into the :cell. 
The GK enzyme acts to convert glucose into G6P that later breaks down ;into 
pyruvate that is utilized by the mitochondria to yield ATP. The increase in the 
ATP/ADP ratios depolarizes the plasma membrane and promotes the closure of the 
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KATP channels that drives Ca2+ into the 1cell through the Ca2+ voltage-dependent 
channels. The entry of Ca2+ into the cell inc;:reases the pbospbo·rylation of PKA/PKC 
that helps to mobilize the insulin fl-granul1es from the ER to e~it the fl-cell through 
exocytosis. Glucose transport 2, GLUT2; glucokinase, GK; glucose 6 phosphate; 
protein kinase A and C, PKA/PKC; endoplasmic reticulum, ER. 
1.2.3. Glucagon 
Another major hormone secreted by the pancreatic islets is glucagon, which 
signals the liver to release glucose into the circulation. Glucagon is responsible for the 
counter-regulation of blood glucose concentrations and is released during hypoglycemia. 
A fall in the plasma glucose levels will shut off the secretion of insulin in ~-cells, and will 
stimulate glucagon and epinephrine release from the adrenal gland (5). Glucagon 
stimulates hepatic glucose output by stimulating glycogenolysis and gluconeogenesis, 
while concurrently reducing glycogenesis and glycolysis, thus helping to return blood 
glucose levels to a euglycemic level(.-... 4-6 mM) (16). The exact mechanisms that 
stimulate glucagon secretion are still controversial in the literature and many hypotheses 
exist. It is not clear if circulating glucose levels directly influences a-cells or if glucagon 
secretion is stimulated by the autonomic nervous system and/or paracrine/endocrine 
products secreted by other islet cell types. Most literature supports the latter argument 
that the effects of paracrine/endocrine secretory products play a significant role in 
glucagon secretion (5, 17). In brief, glucagon is released downstream by the entrance of 
Ca2+ into the a-cell, similar to the mechanisms involved in insulin secretion (18). In the 
presence of low glucose, sensed by the GLUTl protein, the a-cell is electrically active, 
unlike the ~-cell in this condition, primarily because of the increase in ATP/ADP ratio. 
This process activates the closure of KATP channel that depolarizes the a-cell membrane 
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allowing for the transfer of the action potential to the voltage-dependent Na+, Ca2+ and K+ 
channels (17). Thus the Ca2+ channels open and permit the entry of Ca2+ into the a-cell, 
triggering the movement of the glucagon-containing secretory granules to the cell 
membrane for exocytosis. The increase in circulating plasma glucose immediately lowers 
the influx of Ca2+ in the a-cells and therefore decreases the release of glucagon stores (6). 
The ion channels in the a-cells mimic similar channels found in the ~-cells; however, the 
Na+ channels are thought to play a more prominent role in the secretion of glucagon in the 
a-cells ( 5). These mechanisms just described are a brief explanation as to how low 
glucose levels can stimulate the release of gluc:agon. Recently, investigators have argued 
that the stimulation of glucagon is more likely a result of other factors such as 
paracrine/endocrine products and autonomic output (19). In this case, factors such as 
insulin, Zn2+ and y-aminobutyric acid (GABA), co-secreted with insulin, play major roles 
in inhibiting the release of glucagon secretion in euglycemic conditions. They cause a-
cell membrane hyperpolarisation induced by further closure of KATP channels that leads 
to inactivation of Na+ channels, thereby decreasing glucagon secretion (19). There is still 
much debate about the exact role and mechanisms of glucagon secretion in the healthy 
islet, as well as in the disease state. 
1.2.4. Introduction to Insulin Resistance/T2DM Pathology 
Insulin resistance develops when peripheral organs such as skeletal muscle, liver, 
adipose and pancreas lose their ability to respond to insulin. In particular, skeletal muscle 
loses the ability to translocate the glucose transporter 4 (GLUT4) to the surface 
membrane, which would normally act to allow the uptake of glucose into the myocyte, 
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resulting in higher levels of glucose in the circulation (20). The liver can also develop 
insulin resistance, which disables insulin action to suppress gluconeogenic mechanisms, 
and hepatic glucose production becomes elevated (21, 22). As a result, glucose is 
continually produced from the liver through gluconeogenesis (non-glucose sources), 
perpetuating the state of hyperglycemia. In adiipose tissue, insulin resistance leads to 
suppressed glucose uptake and increased lipolysis, as well as the release of 
proinflammatory adipokines (23). In an attempt to return the systemic glucose 
concentrations back to euglycemia ( 4-6 mM), pancreatic ~-cells increase their cellular 
mass and release of insulin (24). Therefore, as insulin resistance is left untreated, it is 
likely that ~-cell compensation will fail and eventually hyperglycemia will prevail (8). 
There is still much debate in the literature whether hyperinsulinemia drives insulin 
resistance, or vice versa, however, it appears that hyperinsulinemia is often the result, as 
well as a driver, of insulin resistance (25). 
Poor glucose control in diabetes is well known to promote secondary 
complications or comorbidities, including cardiovascular disease, retinopathy, 
nephropathy and neuropathy (26). Therefore, diabetes control is essential and there are 
several interventions that help to reduce risks of adverse effects, such as insulin, diet, and 
exercise management (27, 28). A cluster of risk factors is linked to diabetes development, 
such as insulin resistance, obesity, physical inactivity and increased stress; however, the 
exact mechanism for diabetes development remains unknown (reviewed in (15)). 
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1.2.5. Impairments in Islet Function and Progression into T2DM 
Maintenance of P-cell mass is critical to preserve normal GSIS and glucose 
homeostasis. In healthy pancreatic P-cells, glucose tolerance is sustained by proper P-cell 
adaptation to surrounding substrate conditions that balances P-cell mass through 
controlled up-regulation of proliferation/neogenesis mechanisms and regulated P-cell 
death. Therefore, as there is a greater insulin demand in the body, P-cell turnover changes 
by increasing proliferation/neogenesis and decreasing P-cell death that up-regulate P-cell 
mass. This is termed compensation (24). An imbalance in P-cell compensation 
demonstrates impaired P-cell growth and responsiveness, resulting in more P-cell death 
than growth (29). Prolonged disturbance in P-cell regulation pathways may result in the 
onset of T2DM development, where individuals display decreased P-cell mass and 
dysfunction (30). 
During the progression of diabetes development, there are several steps that 
gradually limit P-cell compensation and ultimately survival (refer to Figure 1.2., image 
adapted from (15)). These include healthy compensation to various short-term stimuli, 
but long-term exposure induces altered adaptation leading to P-cell dysfunction, eventual 
reduction in P-cell mass and/or possibly exhaustion (8, 31 ). In brief, P-cell compensation 
typically occurs gradually as an individual's need for insulin increases with age, 
inactivity and increased body fat content. In the incidence of further insulin requirement, 
the islets compensate by inducing P-cell hyperplasia and hypertrophy mechanisms that 
result in an increase in insulin release and plasma levels (8). Blood glucose levels remain 
relatively normal as compensation ensues, although P-cells become highly sensitive to 
10 
glucose levels resulting in an overall increase in GSIS and sometimes hyperinsulinemia 
(32). Over time, if individuals maintain inactive lifestyles or an excessive caloric intake, 
~-cell compensation is no longer able to attain euglycemia (33). At this point, individuals 
may be classified as 'pre-diabetic' and may exhibit impairments in GSIS, however retain 
some ability to respond and avoid hyperglycemia (34). These individuals may 
demonstrate impaired glucose tolerance, in response to an oral glucose challenge, as well 
as elevated fasting glucose levels (6.1-6.9 mM); however, they do not exhibit overt 
hyperglycemia (>7.0 mM). It is important to note that being pre-diabetic may still put an 
individual at risk of developing cardio metabolic diseases. Interestingly, obese-insulin 
resistant individuals may take years to develop hyperglycemia and can sustain their state 
for long periods of time, sometimes up to several years (35-37). Finally, as the pre-
diabetic condition is left untreated, individuals start to deplete their ~-cell population, 
through up-regulated pathways of ~-cell apoptosis/death, and ultimately develop T2DM 
(8). It has been reported that individual ~-cells may reduce their functionality by up to -
75% with the onset of T2DM (38). Furthermore, as T2DM progresses, individuals lose 
the ability to synthesize insulin altogether and are forced to rely on exogenous insulin to 
regulate glucose uptake. The mechanisms of ~-cell dysfunction have not been fully 
uncovered, but a vast number of studies have shown a variety of factors that play a role in 
limiting adequate ~-cell compensation. These factors include increased levels of free fatty 
acids, glucose (i.e. lipo- and gluco-toxic effects), obesity, oxidative stress, GCs, and 
physical inactivity (39). An excellent model to study ~-cell dynamics in the development 
of obese T2DM is the ultization of the classic model, the obese Zucker diabetic fatty 
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(ZDF) rat. Previous studies have shown that these animals demonstrate spontaneous 
hyperglycemia due to insufficient amount of ~·-cell mass and compensation ( 40) (ZDF 
will be discussed further in section 1.4.1). Unfortunately, ~-cell dynamics in individuals 
with T2DM have yet to be fully elucidated, but similar to the ZDF rats, individuals with 
T2DM demonstrate reduced ~-cell mass when compared to obese non-diabetic subjects 
(30, 41). However, the reduction in ~-cell mass is suggested to be a consequence of, and 
not a reason for, T2DM, but further investigations are required to draw conclusions (42). 
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Figure 1.2. Development of T2DM. Pancreatic P-cells regulate blood glucose levels 
by increasing insulin synthesis and secretion, termed compensation. If an individual 
develops insulin resistance or becomes obese, P-cell populations may compensate by 
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increasing in size and mass that increases fovels of insulin to maintain euglycemia. If 
P-cell compensation is continued for long :periods of time then it could fail leaving 
depleted P-cell populations, termed pre-diabetes. If this ccmditicm remains untreated 
then individuals may progress to an even further reduction 1in P-cell popul~tions 
that are insufficient to maintain euglycemia and hyperglycemia ensues leaving an 
individual with T2DM. Eventually if T2DM is not reversed then P-cells become 
exhausted and an individual may become i11tsulin dependent. 
Many studies have investigated P-cell dynamics and diabetes development, 
whereas very few studies have examined a-cell function in diabetes progression. As 
diabetes develops, there are major complications in the release of glucagon from the a-
cells, as shown in rodent and cell-line studies. This is termed, "glucose blindness", where 
a-cells are unable to detect low levels of glucose in the plasma (17). This area of research 
is poorly understood, but it is thought that a-cell dysfunction is secondary to P-cell 
destruction with diabetes onset (17). Some research that has highlighted P-and a-cell 
populations in diabetes has suggested that in cases of TlDM, a-cells make up - 75% of 
the islet, but no differences in mass were found when compared to control subjects (43). 
Moreover, individuals with T2DM exhibit a-cell hyperplasia, and since a-cells comprise 
a greater proportion of the islet, leading to greater a-cell mass (6). Together, these results 
demonstrate that there are major differences between P- and a-cell regulation, 
compensation and progression with the onset of diabetes, and the type of diabetes 
development. More studies need to be carried out to further the understanding of these 
mechanisms underlying the pathogenesis of diabetes. 
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1.2.6. Hyperlipidemia, Obesity and T2DM development 
Many risk factors contribute to the onset of obesity including genetic and 
environmental factors, i.e. increased social stress and poor dietary habits. It is unlikely 
that there is one factor alone that may induce obesity and more likely that a combination 
of factors combine, such as food consumption and decreased physical activity (44). A 
common model in rodents used to study obesity or increased levels of lipids is diet-
induced obesity (DIO). In these studies, a diet typically high in saturated fat is used to 
induce obesity in otherwise healthy rodents, such as Wistar (45), Sprague-Dawley rats 
(46) or C57BL/6J mice (47-49). It is important to keep in mind that not all high-fat diets 
(HFD) administered in experimental models of obesity are similar. In general, a HFD 
consists of an increased caloric range between 30-60% of calories from fat compared to a 
standard laboratory chow diet (50), where the source of fat usually comes from animal 
lard. It is likely that animals sustained on a HFD for less than 2 weeks will develop early 
signs of obesity and insulin resistance (51 ), and animal strains more resistant to DIO take 
typically longer periods(> 8 weeks in Sprague Dawley rats) to show signs of metabolic 
dysfunction (52). These studies are applicable in today's society as there has been a 
dramatic epidemic of obesity, where more than 60% of people with T2DM in the United 
States are categorized as being overweight (53). Moreover, as obesity is the most 
common cause of insulin resistance in humans, it is the rate of obesity that is driving the 
parallel to the increased incidence of T2DM (54). It is important to note that rodent 
studies of DIO may not exactly relate to human obesity, as there appears to be a 
complexity of other factors that may induce weight gain, including increased 
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psychological and emotional stress (55). Taken together, obesity-induced insulin 
resistance factors do not necessarily act separately, but rather synergistically with other 
factors such as increased levels of stress to induce metabolic abnormalities and, 
potentially, T2DM. 
1.3. Metabolic Effects of Stress and Glucocorticoids 
1.3.1. General Overview of Stress 
Scientifically the term, 'stressor' is difficult to define, partly because of the 
complexity of the stress response and partly be:cause of individual differences in what 
people perceive as being stressful. Therefore, a general definition of 'stress' is "when 
homeostasis is threatened or perceived to be" (56). The stress response initiated by 
intrinsic or extrinsic factors involves sophisticated and integrated biological reaction 
mechanisms that occur at the molecular, cellular, and physiological levels. The primary 
mediators of the stress response are detected and achieved through activation of the 
hypothalamic pituitary adrenal (HPA) axis that act on peripheral tissues such as the liver, 
muscle and adipose tissue to mobilize energy substrates (56). The amount, predictability 
and perceived control of the stressor determine whether or not an organism is able to re-
establish homeostasis (57). Thus, if equilibrium is not recovered and the individual 
remains in a state of chronic stress, then the risk of developing various diseases is greatly 
heightened. In rodent models of stress, research incorporates a number of areas including: 
exercise, physical restraint, electric shock or near drowning, exposure to extreme cold 
and an introduction of a socially dominant member of the same species (58). The stress 
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response, in humans, is more likely to increase to psychological rather than physical 
adverse events, which include emotional, social, or professional factors. In addition, the 
onset of a stressor becomes even more multifaceted as it may include hardship developed 
in a number of social and emotional situations and is difficult to simulate in a laboratory 
environment. The stress response during psychological stress may be more damaging 
than the stressor itself, as it may accumulate overtime if the presence of the stressor is not 
removed and it becomes viewed as a chronic type of stress. Chronic stress is associated 
with a number of metabolic disturbances including cardiovascular disease, insulin 
resistance and central obesity (59-62); however, physical activity, a stressor in and of 
itself, provides beneficial adaptations rather than deleterious effects to the body in rodents 
(63), as well as in humans (64). Despite differences in the causations of psychological 
and physical stress, both responses activate the HP A axis, but it is the adaptive ability of 
the stress response system to re-establish homeostasis that determines the degree of 
damage of the stressor. 
1.3.2. The Hypothalamic-Pituitary-Adrenal (HPA) Axis 
Typical acute activation of the HP A axis is present in a diurnal, pu.lsatile pattern 
(65) that in humans is decreased in early evening hours( ....... 6-10 pm) and increased in 
early morning hours( ....... 6-10 am) (66). This activation is also present in rodents, but 
because of their nocturnal nature they display increased activity in the early evening 
hours and decreased activity in the early morning hours (67). The HPA axis is centralized 
in the brain and the hypothalamus and can be activated by many different neural 
pathways through various internal and external stimuli. These signals converge at the 
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parvocellular neurons located in the dorsomedial region of the paraventricular nucleus 
(PVN) to stimulate the release of corticotroph:in releasing hormone (CRH) and arginine 
vasopressin (AVP) into the median eminence (68). Both of these hormones travel through 
the hypophyseal portal circulation to corticotrophs located in the anterior pituitary where 
they stimulate the secretion of adrenocorticotrophin hormone (ACTH) and its precursor 
pro-opiomelanocortin (POMC) (69). About half of the parvocellular neurons contain 
A VP (70), which indirectly increases ACTH synthesis and release in response to 
prolonged stress (71). AVP on its own does not stimulate POMC gene transcription, but 
distinctly promotes the stimulatory effect of CRH on the activation of ACTH secretion 
(72). AVP increases the effect of CRH on ACTH secretion by binding to the Vlb 
receptors (73), a process that increases the phosphorylation of PKC, ultimately increasing 
the release of intracellular stores of Ca2+ (72). CRH stimulation of ACTH secretion is up-
regulated by CRH binding to the CRHl receptor (74). This receptor is classified as a G-
protein coupled receptor, which activates through adenylate cyclase to increase 
intracellular cAMP levels subsequently activating PKA, increasing the influx of 
extracellular Ca2+ and resulting in the release of ACTH from the anterior pituitary gland 
(74). Once in the circulation ACTH binds to th(;: melanocortin 2 receptors (MC2R) 
located in the zona fasciculata (7 5) of the adrenal cortex that stimulates the synthesis and 
release of glucocorticoids (GCs) through the PK.A pathway leading to steroidogenesis 
(76). 
GCs are secreted into the systemic circulation and are taken up into every tissue in 
the body where GC receptors (GRs) are expressed. They play key roles in several 
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metabolic pathways, regulating salt and water metabolism, blood pressure, immune 
function, and energy homeostasis such as glucose metabolism (77). These functions allow 
for sophisticated synchronization between brain and body that manages situations of 
stress, recovery and adaptation. GRs are expressed ubiquitously throughout the body in 
virtually every organ, but most widely express1~d in neural tissue that provides negative 
feedback of the HP A axis (78). There are two closely related types of receptors that GCs 
can bind to: the mineralocorticoid or type I receptor (MR) and GC or type II receptors 
(GR) that initiate GC actions and suppress HPA axis activity (79, 80). The GR is 
expressed with highest density in the parvocellular PVN and in the pituitary 
corticotrophs, while the MR is localized in the limbic neurons (81 ). There is a 
considerable amount of co-expression of the GRs and MRs within the hippocampus and 
the dentate gyrus. The MR binds to GCs with a 10-fold greater affinity than the GR, and 
is highly occupied at basal levels ofHPA activity (59). It is thought that the role of the 
MR is mostly to maintain basal HPA activity, and the GR is responsible for terminating 
the HPA activity during stress and the circadian peak of GC secretion (59). GC negative 
feedback on the HP A activity is primarily mediated through inhibition at the level of the 
hypothalamus, anterior pituitary, and the hippocampus, which subsequently inhibits the 
synthesis of CRH, A VP (82) and ACTH (72). These feedback mechanisms can occur 
within minutes of the rise in GC concentrations in the circulation and can act through 
both fast and delayed feedback. These types of feedback mechanisms act through either 
non-genomic or genomic mechanisms, respectively (83). Ultimately, the reinstatement of 
basal HP A axis activation is highly dependent upon the complete removal of the stressor. 
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1.3.3. Glucocorticoids (GCs) 
Active forms of GCs are secreted by the adrenal gland either as cortisol or 
corticosterone, in humans and rodents, respectively. They reach virtually every tissue in 
the body via the circulation, a process which gears the brain and body to cope with 
various survival mechanisms such as stress, recovery and adaptation (81 ). 
Steroidogenesis is a biological process regulated by the gene expression of steroidogenic 
acute regulatory (StAR) protein that initiates the increase in cholesterol delivery to the 
inner mitochondrial membrane and is the rate-limiting step in GC synthesis and 
production (84). The enzyme 17a-hydroxylase catalyzes the synthesis of cholesterol into 
cortisol (in humans) in the area of the zona fasciculata located in the adrenal cortex. 
Another region of the adrenal gland, called the zona glomerulosa, does not contain the 
enzyme 17a-hydroxylase and as a result cannot synthesize GCs. Instead, this region is 
responsible for the synthesis and release of mineralocorticoids such as aldosterone, which 
plays a central role in water/electrolyte balance and blood pressure regulation. This 
pathway of GC synthesis is not the same in rodents as they do not process 1 7 a-
hydroxylase enzyme and are unable to move cholesterol in the mitochondria to make 
GCs. Therefore, rodents do not produce cortisol, but instead produce GCs such as 
corticosterone and the inactive GC, 11-deoxyco:rticosterone (11-DHC) (85). Inactive GCs 
are also released into the circulation from the adrenal gland, such as cortisone and 11-
D HC in humans and rodents, respectively. It has: been reported that the circulating active 
to inactive ratios range from as high as 8: 1 (active to inactive ratio) (8·6), to as low as 3: 1 
(87); however, the physiological relevance is not fully understood. This reported 
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difference in active versus inactive ratios is likely due to the enzyme, 11 ~-hydroxysteroid 
dehydrogenase (11~-HSDl) that acts to convert GCs from their inactive to active form. 
This enzyme will be discussed in further detail in section 1.3.5. 
Cortisol and corticosterone are hydrophobic hormones that are not able to 
circulate in the body without assistance of a carrier protein. Albumin is a water-soluble 
globular protein that binds - 15% of the body's cortisol during basal circadian 
circulation, while - 80% of the cortisol circulates with the assistance of the cortisol 
binding globulin (CBG) and - 5% is considered free cortisol (88). CBG is released from 
hepatocytes and circulates in the bloodstream with a concentration of 32-50 pg/ml (89). 
In instances of high stress where cortisol levels reach - 400-500 nmol/L, CBG becomes 
saturated and this development raises the levels of free cortisol significantly to levels 
higher than 20% in the circulation (90). The role of the CBG in the body is traditionally 
viewed as being a carrier protein; however, it may help buffer a large flush of free 
cortisol into the tissues during a stressful even1t or as a reserve for the body's store of 
cortisol in cases of inhibited or reduced cortisol in the circulation (89). There are other 
stimuli that are able to manipulate the amount of CBG in the circulation, ultimately 
altering the amount that enters the tissue. For example, patients with post-traumatic stress 
disorder, which traditionally exhibit low cortisol levels, exhibit elevations in CBG levels 
(91). Moreover, a stress response that activates: cortisol, as well as interleukin-6 (IL-6) 
directly hinders the CBG gene transcription up-regulation, thereby indirectly increasing 
free cortisol levels and GC activity within the tissue (92). In humans, exogenous IL-6 has 
been shown to decrease CBG by- 50% as have illnesses such as sepsis and burns (90, 
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93). Very few studies have addressed the measurement of CBG in various stimuli such as 
exercise (94) and obesity (95), and no studies have investigated the levels in T2DM 
patients. An acute bout of exercise results in an up-regulation of CBG, from highly 
trained athletes to sedentary individuals (94). Interestingly, whole-body massive weight 
loss, as well as conditions such as obesity results in a decrease in CBG levels and 
increase in free cortisol (96). It has been sugge:sted that CBG plays a role in people's 
adaptation to stressful environmental conditions (95). More research in this area of work 
would be beneficial to further understanding o:f GC physiology and may provide insight 
into various roles that GCs play in exercise and disease models. 
1.3.4. Glucocorticoid Receptor (GR) 
Cortisol is only considered to be biologically active when it is free and not bound 
to any carrier protein (97). Free cortisol or corticosterone is capable of entering the 
tissues, thus only a small portion of active GCs are able to enter into the cells, which 
helps to protect against GC excess in the tissues. On the other hand, inactive GCs 
(cortisone and 11-DHC) are very capable of circulating in the system without the 
assistance of a carrier protein and, because of this characteristic, can readily enter the cell. 
Upon crossing the tissue membrane or being converted from the inactive state by 11 P-
HSD 1, active GCs bind to the GR and elicit their functions. The GR exists in the 
cytoplasm of the cell without a ligand bound as a large multi-protein complex made up of 
polypeptides, two molecules of hsp90, and many other proteins (98). Once the GCs 
occupy the binding sites on the GR, they dissociate from the hsp90 proteins, protein 
complex and undergo a change in the conformation. The GR complex translocates to the 
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nucleus where it homodimerizes or heterodimerizes with another GR complex. 
Depending on the type of dimerization it will bind to the GC-response element (GRE) 
found in the promoter region of GC-induced target genes and cause either activation or 
repression of gene transcription (81 ). Moreover, gene expression is not always 
manipulated by the binding of GR to the GRE, but, in fact, it can interact with other 
transcription factors and activate other proteins such as activating protein- I (AP-1) and 
nuclear factor-KB (NF-KB) (98). 
The GR is a member of the nuclear recieptor family and contains a complex 
structure composed of various independent binding sites. It contains the following 
domains: amino-terminal regulatory, DNA-binding, hinge region, ligand-binding, and 
carboxyl-terminal domains (99). The whole body knockout model of GR in mice results 
in respiratory failure and eventual death of the animal at birth, thus demonstrating the 
critical role that the GR plays on the entity of biologic function (100). The GR gene exists 
in multiple splice variants on exon 9 that produce GRa, GRP and MR (101). Ligand 
binding where it translocates to the nucleus and. forms two homodimers between two 
GRa proteins activates the GRa. On the other hand, GRP is unable to bind the ligand; 
suggestive of its shortened length compared to GRa, it does not participate in gene 
regulation or GC responsiveness (102). Moreover, GRP resides in the nucleus and is 
thought to inhibit GRa activity. Therefore, it is classified as a dominant negative 
regulator of GC-induced gene expression that binds to the GRa, creating an inactive 
heterodimer (101, 103). As a result of the nature: of these isoforms, it is suggested that 
they manipulate the role of GC within the tissues, possibly playing a more predominate 
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role of GR~ in various disease states such as those thought to be GC resistant (102). 
Moreover, to add to the complexity of GC regulation there are recent reports suggesting 
that as many as 7 GRa isoforms reported, and that each of them has its own set of gene 
regulation (99). 
The activated GR complex (ligand bound) is responsible for the up-regulation of 
various anti-inflammatory proteins in the nucleus as well as the inhibition of the 
expression of proinflammatory proteins in the cytosol (prohibits movements of 
transcription factors from the cytosol into the nucleus). The former mechanism of action 
is referred to as transactivation, while the latter is transrepression (104). The binding of 
the GR complex to the positive GRE areas initiates the up-regulation of gene 
transcription of various anti-inflammatory proteins such as IL-10, annexin-al and 
inhibitor of nuclear factor (I-KB). This process, transactivation, is known to be the 
regulator of adverse effects of GCs. In contrast, the process known as transrepression is 
also regulated by the GR complex, where it inhibits the transcription of proinflammatory 
genes such as IL-6, NF-KB and AP-1(104). This: pathway is the most targeted by anti-GC 
action agents that act through anti-inflammatory and immunosuppressive mechanisms. 
1.3.5. The pre-receptor enzyme llP-HSDl 
Tissue exposure of GCs is manipulated through the number of GCs in the 
circulation reaching the tissues, but also is controlled by the pre-receptor enzyme 11 ~­
HSD 1 that is a low-affinity nicotinamide adenine dinucleotide phosphate (NADPH)-
dependent enzyme, which acts to convert inactive GCs into active GCs. This enzyme is 
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expressed in most tissues such as those in the liver, adipose tissue, central nervous 
system, immune cells, skeletal and smooth muscles that arbitrate actions via GR (105). 
An isoenzyme similar to 1 IP-HSDl is the high-affinity NADPH-dependent 
dehydrogenase, I IP-HSD2 which is predominately found in MR target tissues such as 
those in the kidney, colon, placenta, sweat ancil salivary glands (105). 11 P-HSD2 is 
unique as it catalyzes the reverse mechanism of I lP-HSDI, whereby it converts cortisol 
to cortisone, in humans. The significance of the l lP-HSDI regulation is interesting as it 
is known to increase the concentration of active GCs in the tissue by,...., 2-fold in 
transgenic mice (106). Also, higher 1 IP-HSDl activity within the tissues has been 
associated with abnormal GC activity in the adipose tissue of obese individuals which 
leads to larger amounts of GCs within the tissues, promoting adverse effects of GCs 
(107). In addition, a mouse model knockout of l IP-HSDl showed improved glycemic 
control and reduced body and visceral fat mass gain, concomitantly with chronic high-fat 
feeding (108). Together these investigations into this enzyme and its activity have 
isolated a role for its abnormal activity in relation to obesity and T2DM development. 
Further explanation of the role of 11~-HSDI on pancreas specific abnormalities will be 
discussed in section 1.4.2.5. of this literature review. 
1.3.6. Peripheral GC action 
The peripheral actions of GCs are exertc:d in virtually every tissue as almost all 
tissues express GR. The tissue-specific responses are dependent upon the availability of 
the hormone, activity of 1 lP-HSDl and the density of the GR (109). Acute stress helps to 
mobilize fuels from storage to be utilized in working tissues. In the adipocytes, greater 
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increases in GCs have been shown to cause greater lipolytic effects, which increase the 
release of fatty acids (110). In the liver, GCs up-regulate the increase in hepatic glucose 
production from non-glucose sources by influencing the transcription of rate-limiting 
enzymes such as phosphoenolpyruvate carboxykinase and glucose-6-phosphate (111). 
Skeletal muscle also helps to liberate fuels in times of acute stress by decreasing protein 
synthesis and increasing proteolysis. This process helps to increase the amino acid pool 
for the liver to drive gluconeogenesis (112). Therefore, acute stress is beneficial to an 
organism in times when fuel substrates are low, but prolonged activation of HP A axis and 
these pathways demonstrates perpetual hypercatabolism resulting in adverse effects. 
1.3. 7. Stress and Food Intake 
The physiology of feeding behaviour and HP A axis has been a topic of study for 
many years as they are highly associated with one another. Elevations in GCs are shown 
to rise postprandially in humans (113, 114), as well as in rats (115). Many correlations 
exist between the activation of the HP A axis and food intake. The feeding centres in the 
brain are located in the PVN of the hypothalamus, which is the same location where the 
neurons synthesize and secrete CRH. Adrenalectomy in the rat results in hypophagia, as 
lower GCs decrease feeding behaviour regulation, and the administration of 
corticosterone reverses this effect (116, 117). In constrast, humans who typically practice 
"dietary restraint" (sic), such as those who are constantly watching their weight or are 
very conscious of their eating behaviours, show to have an increase in GC levels as this 
behaviour results in chronic stress (118). In addition, individuals who are non-dieters 
show an increase in stress with the absence of food (119). Stress-induced eating is likely 
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to initiate after a stressor or with the incidence of being presented with highly desirable or 
palatable foods (118). Chronically high levels of perceived stress are related to an 
increase in feeding (120) specifically for more: palatable foods such as those with high fat 
and sugar content, whereas people who are in a state of contentment will be more lik!ely 
eat healthy foods such as dried fruit (reviewed in, (121)). Interestingly, people who are 
able to perceive their own increased level of stress are more likely to change their regular 
eating habits. It is estimated that ,...... 40% of people will increase their feeding behaviour in 
a highly stressed state and·,...... 40% of people wiill do the opposite and decrease their eating 
behaviour. The other,...... 20% will not change th·eir habits (121, 122). Moreover, it is 
suggested that those who are more likely to be overweight will generally increase food 
intake in the stressed state whereas those who are underweight are more likely to eat less 
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(123). The relationship between weight gainers and losers may be related to levels of 
circulating insulin, as it is an anabolic hormone, thus increasing energy stores. Therefore, 
those people who have a higher body mass index generally have an increase in insulin 
levels, which may be indicative of their increas1~d storage capacity (121, 124). 
Importantly, acute physical and emotional stress in laboratory environments is up-
regulated with food intake and shifts desires towards foods with higher fat and sugar 
content (125) even if the subjects are not hungry or do not have a homeostatic drive for 
more calories (118). Although in conditions of chronic stress rats will decrease their total 
food intake, given the choice they will choose more palatable foods (126). This response 
has been suggested to help "dampen" the stress response under conditions of chronic 
stress (126). It is important to note that as a result of chronic or sustained stress, animals 
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will decrease food intake eventually causing a reduction in body weight (127). Moreover, 
the removal of the stressor from chronically s1ressed animals does not appear to help 
regain the weight lost (128). Therefore, it appears that chronic elevations in GCs play a 
major role in food intake and body mass regulation that could induce permanent or long-
lasting detrimental effects to whole-body phys.iology. 
1.3.8. GC-Induced Ectopic Fat Deposition 
Adipose tissue is particularly essential in the body that helps mobilize energy 
stores when fuel substrates are needed and stores excess energy in basal conditions. 
Lipids are stored in the adipose tissue as triglycerides (TGs) and upon mobilization they 
are broken down by lipases, which results in molecules of fatty acids and glycerol (110). 
GCs play a role in regulating energy flux within the adipose tissue and can influence 
adipose tissue morphology. GCs are classically defined as being catabolic as they induce 
lipolysis and liberation of fatty acids; however, GCs act differently in the adipose tissue 
when given exogenously or in a chronically elevated state. A clear link now exists 
between increased levels of GCs and ectopic adliposity. A meta-analysis conducted 
showed that increased perceived stress in adolescence and abdominal obesity were highly 
correlated and demonstrates the relationship between increased GCs and fat accumulation 
(129). Moreover, other studies investigating the effects of environmental, social, and 
psychosocial stress have been linked to increases in the incidence of obesity (130). GCs 
may cause adipocytes to hypertrophy, as a result, increase storage or GCs may induce 
hyperplasia, which promotes more adipocytes (131 ). Excess GCs, as found in individuals 
with Cushing's syndrome (132) and rodents given exogenous GCs (106, 133), result in 
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both enlarged and more adipocytes, thus demonstrating the link between GCs and ectopic 
fat. 
1.3.9. Cushing's syndrome 
Cushing' s syndrome results in abnormal elevation in GCs that induce detrimental 
physiological effects over the body. It is sugg~~sted that the most common cause of 
Cushing' s syndrome is the administration of pharmacologic doses of oral or topical 
steroids (134). Other ways patients can develop Cushing's syndrome is through an 
ACTH-secreting pituitary tumor, ectopic (non-pituitary) ACTH production, or an adrenal 
tumor (135). A commonality with these different origins is that there is loss of the diurnal 
secretion of GCs and negative feedback on the HP A axis, thereby leading to a constant 
elevation in circulating GCs. Cushing' s syndrome is hard to detect because sometimes the 
symptoms can take years to develop, and the vast metabolic and physiologic dysfunctions 
are complex. Hypercortisolism can lead to numerous abnormalities such as an increase in 
central obesity, muscle atrophy and weakness, bone loss, depression, glucose intolerance, 
hypertension, insulin resistance and adrenal suppression possibly leading to adrenal 
insufficiency (135). Cushing' s syndrome exists in,...., 3% of obese individuals possibly 
leading to poor glycemic control (136). Moreover, patients with Cushing's syndrome 
who develop central obesity have an increased risk ( 60-80%) of developing glucose 
intolerance and perhaps diabetes if the disease persists without intervention (137, 138). 
Several therapeutic options can help to control hyperglycemia (GR antagonists, discussed 
in section 1.5) in Cushing' s syndrome patients; however, most patients rely on insulin to 
reduce glucose levels (135). Hyperglycemia usually prevails after the onset of 
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hypercortisolemia and therefore, glucose control might be easier to treat once elevated 
levels of cortisol have been lowered (63). Although the exact prevalence of Cushing's 
syndrome in individuals with T2DM has been hard to identify as many symptoms of 
these two diseases overlap, it is suggested that ,..., 25% of those using steroids could 
potentially develop T2DM (138). If surgery is unsuccessful, there are several 
interventions that Cushing' s syndrome patients can pursue to help lower 
hypercortisolemia, including diet, exercise and. pharmacological agents such as GC 
antagonists. Interestingly, very few studies have been conducted in all of these areas on 
Cushing's syndrome patients and therefore more studies would provide further insight 
into the disease prevalence and intervention. Further discussion will follow in section 
1.5.7. 
1.4. Stress and T2DM 
1.4.1. GCs and Insulin Resistanceff2DM 
Many factors have been identified with the onset of T2DM such as increased 
whole-body insulin resistance as a result of elevated ectopic fat (139) and pancreatic~­
cell dysfunction due to lipid and glucose toxicity (140, 141). One aspect that these 
symptoms have in common is that they can be induced with increased levels of GC 
exposure (142, 143). Interestingly, elevated GCs: have been shown to precede 
hyperglycemia in humans (135) and in rodents (63, 144), and are related to the severity of 
diabetes. Moreover, as previously mentioned the use of topical, inhalant, and cream 
steroids is greatly associated with an increased incidence of glucose intolerance/insulin 
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resistance and possibly diabetes development (145). In addition, Hoes et al., 2011 (]46) 
reported that they discovered that 11 % of their subjects with arthritis had undiagnosed 
cases of T2DM and 35% had impaired glucose metabolism. The elevation of GCs have 
been linked to T2DM development for many years (147), but to this date the exact 
mechanisms by which short- and long-term GC excess influence ~-cell function remain 
inconclusive. 
There are many rodent models of T2DM that researchers choose to study the 
development of diabetes and its link to elevated GCs. One in particular is the ZDF rat 
model that exhibits a mutation in the leptin receptor gene and spontaneously becomes 
hyperinsulinemic....., 4-7 weeks of age, then becomes hyperglycemic by....., 7-12 weeks 
(148, 149) and displays many other similar characteristics of obese T2DM individuals. 
Research shows that the increase in GC levels precedes symptoms of diabetes, as ZDF 
rats develop hypercortisolemia at....., 3 weeks into experimental protocol (63, 144, 150). 
These ZDF model studies provide strong evidence that there is an association between the 
elevation of GCs and the onset of diabetes. Therefore, it is important to identify the direct 
and indirect effects of GCs on islet/~-cell function as this may provide a link to T2DM 
onset or at least ~-cell dysfunction. 
1.4.2. GCs and Islet Function 
Some studies have examined the effects of GC exposure and islet function, but the 
exact mechanisms of action remain unclear, as some studies suggest that GCs promote 
and others suggest that GCs inhibit ~-cell function. It does appear that results may be 
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related to duration, dose and how GCs are administered in vivo or in vitro. Therefore, the 
following paragraphs have been divided into the appropriate headings to provide the· 
clearest explanation of the literature. 
1.4.2.1. Acute GC treatment and In vivo P-cell Function 
Peripheral insulin resistance is a major concern with GC therapy, but studies 
suggest that it may be dependent on the duration and the dose (151, 152). In rodent 
studies, acute in vivo administration ( < 5 days) of dexamethasone, a synthetic GC agonist, 
induced many morphological and physiological alterations to Wistar rat islets such as 
increased P-cell compensation/adaptation mechanisms through an increase in P-cell mass, 
size and proliferation (153). Moreover, another study demonstrated that raising doses of 
dexamethasone increased levels of cyclin D and phosphorylation of insulin receptor 
substrate 2 (IRS2), indicative of augmented islet proliferation and compensatory 
mechanisms (154 ). Dexamethasone treatment also induced hyperinsulinemia and 
increased basal, glucose and arginine-stimulated islet insulin secretion, which was also 
found to be dependent upon varying, doses of GCs (0.1-1.0 mg/kg) (152) and duration of 
doses in lean C57BL/6J mice islets (155). In another study, high doses of dexamethasone 
(1 mg/kg) were shown to increase GSIS, indicating that dexamethasone increased Ca2+ 
influx after glucose uptake (2). PK Ca levels were found to be up-regulated in islets of the 
dexamethasone-treated rats as well as an increase in docking of secretory granules to the 
P-cell membrane, indicating that dexamethasone: induces hyperinsulinemia by increased 
PKCa activation, insulin exocytosis and peripheral insulin resistance (2). 
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There is still much debate as to the exact mechanisms for the diabetogenic actions 
of acute elevations in GCs in humans, but some recent studies suggest that it deteriorates 
islet function. Two days of GC administration (prednisolone, 7 5 mg) in humans, results 
in a blunted first-phase glucose- and arginine-stimulated c-peptide secretion (156) and 
diminished islet glucose sensitivity, but no changes in fasting insulin levels. Moreover, in 
the same study (156), similar results were found in individuals using chronic GCs for less 
than 14 days, evidence which paralleled other studies (157, 158). These results are 
important, as there are very few studies in the literature that have examined these links 
between acute GC administration and ~-cell dysfunction, in humans. Moreover, the 
differences between acute administration of GCs in rats and humans are unclear, as it 
appears that in rats, GCs induce increased islet compensation while in humans they cause 
~-cell dysfunction or glucose insensitivity. Moreover, rodents that overexpress islet 
specific GR demonstrate a reduction of insulin secretion and ~-cell function (159, 160), 
which further supports the hypothesis that GC excess may play a direct role on islet 
dysfunction and T2DM development. 
1.4.2.2. Acute GC treatment and In vitro ~-cell Function 
Although there have been various studies conducted on in vitro GC administration 
in rodent islets, there is still much debate over what GCs do to islet function, and the 
varying effects observed may be related to dose and duration of GC exposure. As 
dexamethasone exposure (1-6 hours) and concentration (1-100 nmol/L) were increased in 
a serial fashion, ~-cell function was increasingly impaired, as evident by a lowering of 
insulin synthesis (161 ). Similar results were also reported in isolated healthy mouse islets 
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as higher levels of dexamethasone and longer incubation periods resulted in lower insulin 
secretory capacity impairing the efficacy of Ca2+ on the secretory process (3). The effect 
of 4 hours of dexamethasone treatment in the ]insulin secreting cell line (INS-1 E) 
demonstrated that abnormal Na+ /K+ ATPase activity in P-cells caused P-cell membrane 
hyperpolarization (162). This treatment increased voltage-gated K+ channel activity, 
lowering appropriate Ca2+ influx into the cell and consequently decreasing insulin 
secretion (163). Another study indicated that D~S-lE cells subjected to 20 hours of 
prednisolone showed impairments in insulin bfosynthesis, GSIS, and increases in 
apoptotic markers (164). This study found that prednisolone treatment induced irregular 
amount of ER stress through unfolded protein 1response elements, which caused P-cell 
dysfunction in the INS-IE cells. A supraphysiological level of corticosterone (10-500 
ng/ml) for 3 days also results in abnormal islet function in isolated P-cells from Wistar 
rats (aged 8-12 weeks) ( 165). This study also found that corticosterone-exposed P-cells 
had a blunted first-phase Ca2+ response to increased concentrations of glucose (8.3 mM). 
This study confirmed that the blunted response of the P-cell was mediated through the 
GR as RU486 treatment, a non-selective GRII antagonist normalized P-cell Ca2+ influx 
and insulin response to glucose challenge. Together these findings suggest that acute GC 
treatment in vivo in humans and in vitro in rodents is mediated through the GR that cause 
major P-cell dysfunction and possibly T2DM onset. 
1.4.2.3. Prolonged GC treatment and 11-cell Function 
In contrast to acute GC treatment, evidence suggests that prolonged GC treatment 
(> 5 days) increases GSIS via P-cell expansion in healthy rodents, thereby limiting 
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diabetes development. In a study that administered dexamethasone to Wistar rats for 24 
days reported that less than 20% of the animals became diabetic (166). Interestingly, 
hyperglycemic rats induced by dexamethasone had significantly lower GSIS suggesting 
failure of ~-cell compensation, while rats that remained healthy (normal glycemic) 
demonstrated elevated ~-cell compensation through increased ex vivo arginine-stimulated 
insulin secretion. Moreover, GCs (2 mg/kg, for 12 days) administered to healthy male 
Sprague-Dawley rats induced hyperglycemia and hyperinsulinemia, as a result of 
increased peripheral insulin resistance (167). Further analysis of the islets ex vivo 
revealed that the ~-cells adaptively increased glucose responsiveness, but not efficacy of 
glucose to stimulate insulin secretion (167). 
Moreover, unlike long-term GC treatment in healthy rats the Zucker (fa/fa) rats 
treated with dexamethasone for longer than 10 days reduced GSIS (166). These results 
suggest that GC excess, similar to the example of islet specific GR transgenic mice (159, 
160), compromises appropriate islet responses to increased peripheral insulin resistance 
(168). Therefore, it may be concluded that in animal models that already have increased 
levels of GCs and metabolic dysfunction, such as the ZDF rat, the addition of more GCs 
(via dexamethasone injections) overwhelms the itslet compensatory system, thereby 
resulting in lower GSIS. 
Chronic exogenous GC therapy in humans (> 1 year) is common for a many 
inflammatory conditions such as rheumatoid arthritis, cancers and dermatitis. In these 
instances, even in healthy individuals given a low- (7 .5 mg) and high-dose (30 mg) of 
prednisolone for 2 weeks, insulin secretion can become impaired along with hepatic 
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glucose production (146, 156). It is extremely important that physicians prescribing even 
low-doses of GCs to be aware of the detrimental implications that can take place with GC 
therapy (146). Recently, a study investigated the incidence of elevated GCs associated 
with hyperglycemia and T2DM in children and found 80% of patients admitted to the 
paediatric unit had blood glucose levels > 200 mg/di (169). In addition, mortality was 
also correlated to increased blood glucose levels> 200 mg/di which was associated with 
increased GC levels. Unfortunately, the issue that chronic GC treatment induces 
diabetogenic effects in patients with inflammatory or autoimmune conditions continues to 
be under-monitored. 
In general, acute GCs promote P-cell compensation in vivo in otherwise healthy 
rodents, but alter glucose sensing mechanisms in vitro, as the islet is unable to 
compensate appropriately. Prolonged GC treatment in humans is a concern for longer-
term users and especially in children; however, GC treatment may be most detrimental to 
those who exhibit a compromised metabolic system and GCs in excess may induce P-cell 
dysfunction. 
1.4.2.4. GCs and a-cell Function 
There are limited studies on effects of acute and prolonged GC treatment on a-cell 
function and glucagon secretion. Dexamethasone treatment increases fasting plasma 
glucagon concentrations in insulin resistant first: degree relatives of patients with T2DM 
(170) as well as in rodents (154). Moreover, it is reported that early onset diabetes is 
associated with a-cell dysfunction as glucagon is secreted at abnormally high levels 
during oral glucose challenge (171) and a-cell mass increases linearly with a rise in 
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peripheral insulin resistance (172). Although the mechanisms of GC-induced a-cell 
function and glucagon secretion are virtually unknown, they may result as a secondary 
defect of GC-induced P-cell dysfunction. 
1.4.2.5. llP-HSDl Activity and Islet ][function 
Elevated 1 lP-HSDl is found in pancreatic islets of obese/diabetic rodents (173) 
as well as in islets from ZDF rats (174). It is thought that the increase in GC action in the 
islet caused by elevated 1 lP-HSDl activity suppresses insulin secretion (155, 173), 
thereby promoting diabetes development. In lean healthy mice increased islet 1 lP-HSDl 
activity was associated with increased GSIS, thus demonstrating a link between GC 
activation and regulation of genes involved in insulin secretion (155). Recently, however, 
the use of a P-cell specific 1 lP-HSDl-overexpression model suggests that elevations in 
this enzyme actually improve insulin release m1~chanisms and protects against HFD-
induced diabetes (175). These results are supported by previous work, showing that islets 
cultivated with the inactive GC (11-dehydrocorticosterone) result in a rapid doubling in 
1 lP-HSDl protein (176). Therefore, the increase in 1 lP-HSDl protein may help the P-
cell to compensate during increased levels of insulin resistance. A threshold may exist 
where increased levels of GCs override the system and induce P-cell decompensation, but 
these studies remain under reported. 
1.4.3. Lipids and Islet Function 
Elevations in free fatty acids (FF As) are usually found in obese, insulin resistant 
or diabetic individuals and more importantly in those who suffer from hypercortisolemia 
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(135). Acute accumulation of FF As in the circulation has been shown to increase P-c:ell 
. mass as a defense mechanism against insulin resistance that promotes P-cell 
compensation. Lipotoxicity within the P-cell induced by increases in FF A levels has long 
been known to result in impairments in P-cell function in vivo and in vitro (177). 
Prolonged elevations in FF As have been shown to decrease P-cell insulin secretion (178, 
179), in addition to reducing the expression of the insulin gene thereby inducing insulin 
biosynthesis (180). In contrast, administration of HFD or lipid infusions in rodent models 
has not consistently demonstrated impairments of P-cell function in vivo and it is 
suggested that this may be the result of varying degrees of insulin sensitivity among 
individual subjects (140). 
FF As are normally taken up into the P-cell by proteins along the mitochondria 
membrane and utilized for P-oxidation. FF As enter into the P-cell via the plasma 
membrane or they are mobilized from TG stores found within the P-cells. They are 
broken down into long-chain fatty acids (LCF A) and transported into the mitochondria. 
Simultaneously, glucose is also taken up into th~~ P-cell and utilized by glycolytic 
mechanisms that yield pyruvate. This substrate i:s helpful towards FF As usage in the P-
cell as pyruvate is also utilized by the mitochondria in combination with FF As for P-
oxidation. This process increases the amount of citrate produced by the mitochondria and 
as P-oxidation continues to cycle there is an accumulation of citrate in the cytosol. Citrate 
can be broken down into acetyl-CoA and then into malonyl-CoA that blocks activity of 
camitine palmitoyltransferase I and subsequently inhibits LCF A uptake into the 
mitochondria (181, 182). LCFAs accumulate in the cytosol along with by-products such 
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as ceramides that are damaging to the P-cell (183). Although LCFAs in excess do not 
have an effect on insulin secretion, they have been shown to inhibit insulin gene 
expression (180). This impairment in P-cell function creates stress on the mitochondria 
and greatly contributes to overall P-cell dysfunction. Studies show that only palmitate and 
oleate FF As are known to decrease insulin secretion, and further, palmitate is the only 
FF A known that induces a reduction in insulin gene expression factors (180) and causes 
lipid peroxidation products which are known to cause impaired insulin secretion. In 
addition to the rise in lipid intermediates such as ceramides, within P-cells, increases in 
FF As have also been shown to directly contribute to an activation of c-Jun NH2-terminal 
kinase (JNKs) (184, 185). Up-regulation of the JNK is associated with the impairment of 
insulin signaling pathways by phosphorylating serine residues of IRS2 and decreasing 
downstream effects of GSIS (185). This is not the only mechanism of P-cell dysfunction 
induced by elevations in FF As, as oxidative stress also plays a role in FF A-induced P-cell 
impairments (186, 187). It is known that pancreatic P-cells have low antioxidant defenses 
(188) and these features increase islet vulnerability to reactive oxygen species that 
decrease function (189). Moreover, increased FF As have been linked to endoplasmic 
reticulum stress and unfolded protein response that promotes P-cell apoptosis (190). As 
shown, FF As may disrupt several processes in f~-cells, which impair GSIS and insulin 
biosynthesis. Therefore, in addition to detrimental effects of GCs, lipids also induce 
harmful conditions that can destroy healthy P-ccll function and compensation. 
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1.4.4. Combined effects of GCs and HFD trt~atment on Islet Function 
There are very few studies that have investigated the combined effects of GCs and 
HFD on ~-cell function, but some have shown that both factors induce impairments to 
normal ~-cell function. For example, Holness t:t al., 2005 (191) examined the combined 
effects of repeated dexamethasone injections (1.00 µg/kg of body weight) for 5 days and 
HFD in Wistar rats for 4 weeks. These treatments resulted in extreme glucose intolerance 
after acute intravenous glucose challenge despite major ~-cell compensation, evidenced 
by hyperinsulinemia. This study suggested that the observed results were in part because 
of impaired first and delayed second-phase insulin response. In addition, ex vivo 
experiments confirmed those islets from dexamethasone-HFD rats had an impaired first-
phase insulin response, but had an overall higher GSIS than those animals that were 
treated with a HFD alone. Gremlich et al., 1997 (192) also showed similar effects in 
isolated male Sprague Dawley rat islets, where GLUT2 and subsequent insulin release 
was impaired with fatty acid (palmitate) administration into the islet media. These results 
were even more apparent when islets were subjected to dexamethasone as GLUT2 
protein content decreased by 65%, thus lowering: insulin secretion. These data suggest 
that HFD in addition to GC treatment impairs in vivo and ex vivo glucose sensitivity. 
1.5. GCs and Exercise 
1.5.1. Exercise Protocols; Forced vs. Volitionall 
Forced training in rodents is a good laboratory method that provides precise 
control over the amount, intensity and duration of exercise being performed. It also can 
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provide beneficial effects such as lower body weight gain and increased skeletal muscle 
citrate synthesis activity indicative of mitochondrial biogenesis (193). There are 3 main 
categories that forced training methods for rodents can be divided into: 1) treadmill 
running, induced by foot shocks at the base of the treadmill (194) or bursts of air, 2) 
forced swimming, often with weighted attachments (144) and 3) ladder climbing, usually 
encouraged with electrical shock (195). Although forced exercise training has its 
advantages, it also invokes fear in order to encourage animals to exercise (electrical 
shock, bursts of air, or drowning). In addition, forced exercise training is usually 
conducted during the daytime when animals ar1e usually sleeping and GC levels are at 
their lowest (196). Therefore, forced exercise training can exhibit various alterations in 
the body that are similar to chronic stress and not due to exercise training alone, such as 
adrenal hypertrophy, decreased CBG protein concentration in the plasma and ultimately 
artificially raised plasma GCs (193). Therefore, it is hard to differentiate the outcomes of 
exercise or increased stress levels especially when monitoring HPA axis activity. 
Voluntary wheel running is also a beneficial exercise regime that involves 
attaching a running wheel to a standard rodent c:age and allowing animals to exercise on 
their own. This exercise will typically commence during the evening hours and it is 
preferrable to forced trained exercise protocols because it allows the effects of exercise to 
be studied without psychological/circadian disturbances to the HPA axis (197). Most 
laboratory housed animals such as mice, rats, squirrels, hamsters and even rabbits will 
voluntarily run on a running wheel apparatus (63, 198-201). Voluntary exercise can be 
quantified by tallying the number of wheel revolutions completed by the animal; 
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however, it is difficult to control the amount of running each animal is doing and the 
intensity of the exercise. It is interesting because there are noticeable differences between 
rats and their various running behaviours, some will run > 10 km per evening and some 
will run < 2 km. These observations are consistent within certain animals, as some will 
always run more than others. It is very unlikely an animal that does not typically run > 10 
km a night will suddenly start to run much longer distances than it has in the past. 
However, all rodents are likely to run more if they are food deprived. Interestingly, the 
quantity of exercise in voluntary running depends on the species of animal (201) and, age 
of the animal, as younger animals typically exercise more than older ones (202). 
Typically, hamsters will reach maximal activity almost immediately after being put into 
running wheels, while rats will need an inhabitation period and this will take them ,.... 4 
weeks to reach their maximum running distances (203). Moreover, in contrast to forced 
exercise training, rodents exposed to voluntary mnning will press a bar for wheel access. 
This behaviour indicates that rodents are motivated to exercise and giving them wheel 
access is viewed as a reward (204). Interestingly, a recent study by Cook et al., 2013 
(205) suggests that forced treadmill exercise is a worse training model than voluntary 
exercise in a rodent model of colitis. They found. that forced training greatly increased 
incidence of gut inflammation and induced higher mortality rates than voluntary wheel 
running which showed to be protective against colitis onset. In regard to these and 
previously mentioned findings, voluntary wheel running may be a better regulator of 
HP A function while forced training exercise may exacerbate HP A activity inducing 
excess GCs. 
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1.5.2. Acute vs. Chronic Exercise and HP A :lctivation 
Acute exercise is often neglected as a major physiologic stressor, but, in fact, it 
does stimulate the HP A axis resulting in an increase in GCs, that can remain elevated for 
several hours into recovery (....., 2 hours) (206). However, the activation of the HP A axis 
appears to be reflective of the intensity and dmation of the exercise. For example, light to 
moderate intensity exercise does not increase n.~lative activation of the HP A axis, but as 
exercise intensity progressively increases, as does GC release and secretion (207). 
Surprisingly, as exercise intensity reaches higher levels, GC circulation is reduced (207). 
This is thought to result as a protective mechanism to prevent the complete depletion of 
energy stores and possibly limit GC excess (207). The mobilization of various energy 
stores is important during exercise so that organs and tissues have a proper supply of fuel. 
GCs induce fuel yielding mechanisms in the body during exercise as a mechanism to 
prevent hypoglycemia. This is evident in a study of adrenalectomized rats that underwent 
4 hours of swimming to show that they had less of a decrease in liver and muscle 
glycogen stores when compared to healthy rats. Moreover, the adrenalectomized rats 
displayed an episode of hypoglycemia following exercise (208). There appears to be a 
different relationship with the effect of acute exiercise and adipose tissue regulation, as 
adrenalectomized rats do not have alterations in lipolytic rates after exercise (209). The 
mechanisms of acute exercise on peripheral tissue exposure to GCs are not known. 
Moreover, in endurance-trained men the effect of acute exercise lowered monocyte GC 
sensitivity suggesting adaptations to exercise training in the HP A axis (210), but more 
studies are needed to be conducted to confirm these results. 
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As acute exercise elevates GCs in the circulation and sometimes hours after 
exercise (210), it would be reasonable to believe that regular exercise training might 
extend episodes of endogenous hypercortisolemia. This is not the case with exercise 
training, where exercise leads to positive adaptations and encourages improved insulin 
sensitivity in peripheral tissues (211 ). Therefore, it is hypothesized that chronic exercise 
leads to various adaptive mechanisms that decrease both peripheral sensitivity to GCs and 
activity of the HPA axis, which prevents adverse effects ofhypercortisolemia (212). Over 
the years there has been a lot of focus on the effect of forced exercise training and the 
regulation of the HP A axis. There is much diversity over these findings reported in the 
literature on exercise training and HP A activity as some studies find a decrease (207, 
213-215) whereas some find increases (216) in HPA activity. Interestingly, some suggest 
that different stressors may result in either activation or adaptation to the stressor ( 193, 
214). As previously mentioned, forced exercise training creates variability in the data as it 
is difficult to decipher if the activation of the HP A axis is due to the forced nature of the 
exercise or if it related to the exercise itself. 
In brief, < 4 weeks of volitional wheel nmning induces an increase in HP A axis 
activity (197), but with sustained training HPA axis activation lowers back to basal levels 
prior to wheel axis in rodents (217-220). The effoct ofregular exercise and HPA axis 
activation appears to be regulated at the level of the hypothalamus as exercise training 
has been shown to decrease mRNA and protein levels of CRH in mice (217). Moreover, 
HP A activation appears to have less of an impact on peripheral tissues with exercise 
training. For example, elite trained men showed decreased sensitivity to exogenous GCs 
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in their blood monocytes following exercise (210). This was also found in trained rats 
that had lower GR expression in renal and myocardial tissues (221 ). Another study in 
hamsters showed that 4 weeks of volitional running induced lower hepatic and skeletal 
muscle expression of 11~-HSDl as well as lower GR expression (200); interestingly, 
there were increases in 11~-HSDl expression in the adipose tissue. Together it is evident 
that there are clear differences in acute versus chronic exercise training in rodents and in 
human studies, however, in general acute exercise stimulates HP A axis and prolonged 
exercise training induces variations in HPA activity, but both protect individuals against 
insulin resistance and insensitivity. 
1.5.3. Exercise and Islet Function 
Prolonged exercise training promotes decreases in insulin secretion regardless of 
the exercise protocol in both rodents and hunrnns. For example, long-term swim training 
(8-12 weeks) in rats lowers GSIS in isolated islets (222), while increasing islet insulin 
storage (223). Similar results were found with voluntary wheel running (36 days) in rats 
(224), as well as treadmill trained rats (8 weeks) (225, 226), where insulin release 
measured directly from a single ~-cell was also significantly lower after the training 
(225). These effects of exercise and islet function are similar to findings in human studies 
(227-229). It is important to note that measurements of insulin secretion are indirect 
measurements of islet function, as it is not possible to measure GSIS from healthy human 
subjects at this point in time. Moreover, exercise training promotes ~-cell survival, 
growth, and restoration that may contribute to healthier populations of islets in rodents, 
(i.e. balance in oxidative species) that may limit unnecessary ~-cell compensation (230-
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232). Moreover, resistance training ( 4 days) in rats increases arginine-stimulated insulin 
release, but not GSIS (233) and short-term exercise stimulated more GSIS in exercise 
trained rats compared to sedentary rats (223). These findings may be a result of acute 
exercise training rather than the type of exercise, but it is known that exercise training 
decreases GSIS in rodents and humans, possibly due to improved insulin action in the 
peripheral tissues. See Figure 1.3. for summary of acute elevations in GCs and exercise 
on ~-cell function. Image adapted from Beaudry and Riddell, 2013. 
Acute Glucocorticoids Exercise Trainiing l G,lucose-uscle 
t 
Uptake -- • • Mu-t ~~~:: 
Fat Mass 
• ~ •Increased J3 cell mass • Increased P cell mass ! lnflammatio n • Hyperin sulinemia • Preserved p cell mas~ A~~~~~e ~ ,._L_o_n_g--t.,.-e-nn---=E-x-po_s_L·-1re_._________ • Adioose 
n ____,~cell Death l l ~ Ii!lli 
t Insulin L W • -~iv.er. Resistance 
• LowerGSIS ·Lower insulin release Insulin 
•De-creased insulin signaling •Enhanced insulin signaling (IRS-2) ! Resistance 
• Impaired f3 cell function • Improved P cell funietion 
Figure 1.3. Acute elevations in GCs and eu~rcise training on P-cell function. Acute 
elevations in GCs promotes insulin resistance that indirectly increases P-cell mass 
and hyperinsulinemia. On the other hand, if GCs remain elevated then this may 
induce severe insulin resistance and lead to P-cell dysfunction an.d eventually P-cell 
death. Acute exercise training maintain P-c1ell mass, but preserves P-cell function. 
Longer periods of exercise training tend 1to promote lower i1nsulin secretion in 
response to lower peripheral insulin resistam:e and increased insulin sensitivity. 
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1.5.4. Exercise and HFD/Obesity/lnsulin resistance 
Exercise is a known HP A stressor as i1t works to mobilize fuels for energy, but it 
also helps individuals improve insulin action in the peripheral tissues (211 ). The benefits 
of exercise are thought to limit tissue sensitivity to stress or GC excess. Therefore, the 
absence of exercise is likely to promote metabolic dysfunction and emotional unrest. 
Evidently, a way to avoid early onset of metabolic dysfunction and prevent GC 
insensitivity, is to perform regular exercise (234). Diets that are high in fat induce 
increased incidence of insulin resistance and can lead to early onset T2DM (235). 
Moreover, HFD induces ~-cell mass expansion and proliferation as the islets attempt to 
compensate with increased insulin secretion to help normalize glucose levels in blood 
(236) and with constant consumption of a HFD can lead to T2DM as ~-cells 
decompensate (23 7). Thus, 12 weeks of exercise training in 90% pancreatectomized rats 
on HFD improved levels of ~-mass through increased levels of proliferation and 
neogenesis similar to the levels of controls, thereby demonstrating that exercise has a 
positive effect on ~-cell function even in a compromised state (238). 
Cytokines are released due to increases iln inflammatory markers from the adipose 
tissue such as tumor necrosis factor a and IL-6 (23 9) that are exceedingly high in obese 
and insulin resistant individuals (240). These inflammatory markers are thought to drive 
insulin resistance (54), which potentially could override the system and exhaust ~-cell 
function (23). However, regular exercise has been shown to improve inflammatory 
regulation and GC sensitivity in obese rats (241 ), while forced exercise increases 
inflammation and exacerbates the abnormal obese condition. In humans, moderate 
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intensity exercise (-- 1200 kcal per week at 40-55% V02max) in overweight sedentary 
adults for 8 months improved islet insulin secretion more than vigorous exercise ( -- 2000 
kcal per week at 65-80% V02max) (242). The moderate intensity group had a better 
improvement in insulin secretion, as there were no alterations in their first phase insulin 
response. The higher intensity group augment1ed their insulin sensitivity, but had greater 
decline in their compensatory first-phase insulin secretion. However, the exact 
mechanisms behind exercise intensities are not clear, but there are differences in the 
adaptation to the type of exercise performed. These differences may result with more 
vigorous exercise intensities as they tend to promote elevated GC action that could 
disrupt normal ~-cell function. 
1.5.5. Exercise and ZDF rat 
It is important to study various forms of exercise and stress on the body as 
diseases may respond differently depending on the type and intensity of the exercise. For 
instance, it may be more important to study a more intense exercise in individuals with 
T2DM that already have depleted ~-cell populations, as it may stimulate ~-cell growth 
and function. To investigate the effect of exercise on ~-cell function in a T2DM 
population researchers typically utilize the ZDF rat model. In particular, 5 weeks of swim 
training in ZDF rats demonstrated improved glycemic control as they exhibited lower 
glucose and higher insulin concentrations compared to sedentary ZDF rats. In a follow-up 
study in ZD F rats, swim training showed to decrease circulating GCs and increase ~-cell 
proliferation, mass and islet volume (144); as a result, the exercised ZDF rats compared 
to sedentary controls showed elevated insulin levels in the basal state and greater 
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improvements in glycemic control. These results were attributed to higher expression of 
GLUT2, PKB, and lower ubiquitinated protein aggregates within islets compared to 
sedentary controls suggesting that forced exercise stimulates GSIS, decreases cellular 
stress and prevents ~-cell depletion. Similar re:sults were found in ZDF rats that were 
exercise trained with 6 weeks in voluntary running wheels (150). Regular exercise 
preserved insulin mRNA transcription levels and reversed hyperglycemia. Isolated islets 
responded normally to glucose and fatty acids;. however, there were no differences in 
glucose and fatty acid cycling in active compared to inactive ZDF rats. Therefore, this 
study demonstrates that the defect in ZDF animals is simply due to the loss of normal 
lipid regulation at the ~-cell level. Unfortunately, voluntary exercise was unable to fully 
reverse this effect in ZDF rats but it was suggested that ~-cell dysfunction can be linked 
to ER stress which may be induced by accumulation of toxic lipid by-products such as 
ceramides in the ZDF rat (150). Moreover, treadmill exercise in ZDF rats improved ~-cell 
morphology and prevented diabetes development attributed to improved AMPK 
activation, thought to increase Ca2+ influx simulating insulin secretion (243). 
In addition to improvements in ~-cell function, exercised ZDF rats have lower 
circulating GCs compared to inactive controls, after 5 weeks of forced training (63, 144, 
213), which is reported to be even lower after 3 weeks of voluntary running (63, 150). It 
may be plausible that lower GC activation might contribute to better ~-cell function in the 
exercised ZDF rats, but no studies have investigated the effect of exercise in the ZDF rat 
and GC activity in the ~-cell. Thus, it can be concluded from these studies that non-
volitional and volitional exercise help to prevent early onset of T2DM in the ZDF rats 
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perhaps by improving ~-cell compensation, reducing islet oxidative stress and in part 
lowering basal HP A axis activity. 
1.5.6. Exercise and T2DM 
It has been established that diet and exercise are important factors that help to 
prevent insulin resistance, and early onset T2DM in humans (244, 245). Endurance 
exercise and training improves glucocorticoid sensitivity in humans (246), and regular 
daily exercise decreases the risk of developing T2DM in rodents (63, 200, 219, 220) and 
in humans (24 7-249). Moreover, acute exercise, which is often overlooked by prolonged 
training periods, has been shown to induce effoctive health benefits, as 1 week of exercise 
was able to restore normal glucose tolerance in T2DM individuals (250-252). One of the 
first studies to investigate endurance training in T2DM was Krotkiewski et al., 1985 
(253) and they confirmed that 3 months of an individualized exercise training program 
enhanced insulin secretory response to exogenous glucose and arginine challenge. The 
elevation in insulin secretory capacity was thought to occur as a result of augmented ~­
cell mass; however, the direct measurement of tl-cell mass is not probable in living 
humans at this moment in time. Exercise interv(mtion is important to help improve ~-cell 
compensation as Dela et al., 2004 (254) showed that after 4 weeks of exercise individuals 
classified as 'moderate' insulin secretors were alble to improve their insulin response to a 
glucose-arginine test by evidence of higher c-peptide concentrations compared to 'low' 
insulin secretors. A recent study showed that aerobic and resistance training improved 
metabolic parameters and insulin sensitivity, but no change occurred in ~-cell function; 
this may have resulted due to changes found with truncal fat (255). 
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Indeed, exercise is an important modulator of ~-cell function, but it also helps to 
promote insulin action in the peripheral tissues of T2DM individuals. For example, 
exercise improves glucose intolerance as it increases GLUT4 translocation in skeletal 
muscle that helps to contribute to glucose clearance and is protective against T2DM 
development (28, 256). Moreover, voluntary wheel running prevented the rise in 
oxidative stress and inflammatory markers such as hepatic expression of JNK and serine 
IRS 1 in diabetic rats (257), that are typically found elevated in diabetic individuals (258). 
Therefore, exercise may help to limit circulating inflammatory markers thought to drive 
early onset T2DM, potentially preserving ~-cell function. 
However, not all exercise training programs are beneficial for T2DM. Burns et al., 
2007 (259) showed that early-onset obese T2DM individuals were less likely to exhibit to 
clinical benefits of exercise training. This study shows that there are still unresolved 
issues in regard to the mechanism involved with T2DM and exercise training. In addition, 
it also shows that exercise therapy in T2DM patients is multifaceted and an 
individualized program may be an appropriate method to treat these individuals. 
1.5.7. Exercise and Cushing's syndrome 
Currently there are no studies that have directly investigated the role of any 
exercise regime in Cushing' s syndrome patients, but there are exercise therapy 
recommendations for patients after surgery has been completed. It is advised that patients 
slowly start to introduce exercise into their daily routines and gradually increase the 
exercise intensity as they feel it is appropriate. However, there is no literature that 
supports these claims and exercise prescribed as a therapy is only based on evidence that 
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exercise lowers HP A axis activation ( 64, 260). One case study, which follows a young 
boy during his treatment of Cushing' s syndrome (261) reports that the individual 
maintained a healthy normal life following 15 years after surgery due to a regimented diet 
and exercise program (261 ), but there are no specifics about the exercise therapy 
indicated in the study and there is no way of knowing the exact amount, duration or 
intensity of exercise that was performed. 
Some studies have investigated the effects of forced exercise on chronic 
dexamethasone injections in rodents (262-264). Aerobic exercise training was effective at 
improving blood prolife as well as cardiometabolic alterations such as hyperglycemia, 
glucose intolerance, dyslipidemia, liver steatosis, muscular atrophy and improved blood 
profile (262). Additionally, swim training improved insulin sensitivity (264) in 
dexamethasone injected rats suggesting that exercise training can override the negative 
feedback of the HP A axis activation induced by dexamethasone. Moreover, 8 weeks of 
treadmill training improved dexamethasone-induced hyperinsulinemia, muscular 
glycogen loss and muscle atrophy in male Wistar rats (263). There are no studies reported 
that investigate the effects of voluntary wheel rwming on hypercortisolemia. 
1.6. GR Antagonism 
1.6.1. GR antagonism therapy 
There are associated pathologies, as previously mentioned, in individuals with 
hypercortisolemia (Cushing's syndrome) such as cardiometabolic abno,rmalities, obesity, 
insulin resistance, impaired glucose control and the early onset of T2DM (265). As a 
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result of these links between excess GCs and metabolic dysfunction, it has become quite 
urgent in the pharmacological field to develop a novel therapeutic agent that will reduce 
the effects of chronically elevated GCs, especially since a number of individuals with 
T2DM are now being identified as having Cushing's syndrome or elevated GCs (266). To 
date, several GC inhibitors, such as the non-sellective GRII receptor antagonist, 
Mifepristone (11P-[P-(dimethylamino)phenyl}-l 7P-hydroxy-17-(l-propynl)estra-4,9-
dien-3-one) or RU486, several selective GRII antagonists, none of which has been 
approved to be used in human subjects, and lastly, 1 IP-HSDI inhibitors, that act to help 
regulate local, tissue and specific GC exposure:; however, they are not safe for 
pharmacological distribution. In the following sections the non-selective and selective 
GRII antagonists will be further discussed. 
1.6.2. Non-selective GR antagonists 
GRII are found ubiquitously throughout the body tissues, and active GCs are 
allowed to bind freely as a ligand. Once the GRII is occupied by a ligand, the complex 
translocates to the nucleus where it acts as a transcription factor to activate or repress the 
expression of genes necessary for a variety of cdlular events. GR antagonism results in 
the competitive blockage of the GC ligand binding to the GR complex, which hinders the 
receptor from releasing the associated hsp90 proteins, and prevents nuclear translocation. 
Some of the complexes still reach the nucleus, but the transcriptional activity is rapidly 
weakened (98). RU486 code is named after its inventor, Roussell-Uclaf, and is a known 
as a non-selective GRII antagonist that inhibits the GRII. It is considered to be non-
selective as it also inhibits the androgen and progesterone receptor (PR) (267), but has no 
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affinity for the MR. It has recently gained FDA approval as the pharmacological agent, 
Korlym TM, 2012, for the specific treatment of patients with hypercortisolemia or those 
suffering from Cushing' s syndrome (268, 269). 
RU486 administration has demonstrated great improvements on metabolic 
abnormalities and dysfunctions induced through hypercortisolemia. For example, RU486 
improves glycemic control, body weight gain, and insulin sensitivity in rodents given 
HFD for 4 weeks ( 48). In addition, RU486 treatment actually results in clear activation 
of the HP A axis, but without clinical abnormalities (270) and normal weight gain in 
healthy men (271 ). RU486 has been reported to be given to a variety of patients with 
Cushing's syndrome (272), where it improves metabolic symptoms ofT2DM and glucose 
intolerance such as lower glycated hemoglobin, fasting glucose, blood pressure, insulin 
resistance, and waist circumference (272). It is considered an ideal pharmacological 
agent, as it is absorbed quickly, exists for a long time in the circulation (half-life up to 48 
hours), and has a greater binding affinity to GRII than other GC agonists such as 
dexamethasone (3 to 4 times) and cortisol itself (18 times) in humans (273-275). 
RU486 appears to be the ideal agent for itndividuals with hypercortisolemia, but it 
is nowhere near perfection. It requires consistent patient monitoring as it can result in 
many debilitating side effects such as elevated circulating GCs, endometrial hyperplasia, 
hypokalemia (overstimulation of the MR) and aborted pregnancy, due to its occupancy 
with the PR (267, 276). The potent inhibition of the GRII is a potential problem with 
RU486 treatment as it interrupts GC negative feedback to the HPA axis. Indirectly these 
properties can lead to increased concentrations of circulating GCs (reviewed in (267)), 
53 
potentially leading to adrenal insufficiency. In addition, one dose of RU486 (600 mg) will 
bind to the PR and blocks its action, resulting iln endometrial wall thickening, which 
causes early termination of a pregnancy (276). Evidently this side effect remains to be 
one of the greatest ethical issues with the use of RU486 and the only solution is constant 
patient monitoring and cycling on and off RU486 treatment to try and reduce high GC 
levels. 
1.6.3. Selective GR antagonists 
Currently, there is a race to replace RU486 with more specific selective 
antagonists for the GRII (277), ideally with no affinity for the PR, MR, ER and AR. To 
date, there are no antagonists of this nature that: have been tested in humans and very few 
studies have been conducted in rodent models (48, 278, 279). Of these studies in rodents, 
selective GRII antagonists have been shown to play a role in the attenuation of 
detrimental GR-dependent pathways in the brain (compound C108297) (278), whole-
body steady state glucose metabolism ( 48), dekterious effects of electroconvulsive 
shock-induced retrograde amnesia (280) and body mass gain (279). Moreover, the 
selective GRII antagonists such as Cl 12716 and Cl 13083 have been reported to reverse 
mass gain induced by olanzapine, aserotonin inhibitor, administered for anti-psychotic 
effects (279). No studies have been published that show the effects of selective 
antagonists on models of hyperglycemia or diabetes. However, previous studies 
published present anticipatory effects of selective GRII antagonists; but sometimes these 
compounds do not act as ideal antagonists. For e:xample, C108297 does not completely 
reverse adverse GC effects in the brain. Previous research shows that this antagonist may 
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actually work partly as a partial agonist, as per in vitro assay results thus counteracting 
the GRII antagonist effects (278, 281 ). Although selective GRII antagonists have some 
major advantages over non-selective GRII antagonists, they still have a long way to go to 
reach the ideal anti-hypercortisolemic pharmacological agent. To date there are no 
selective GRII antagonists that have been approved for human clinical trials and RU486 
so far is best agent accessible to patients to help to eliminate adverse effects of excess 
GCs in humans. 
Objectives 
The central aim of this thesis was to investigate the role of elevated GCs and 
HFD on T2DM development in young health male Sprague-Dawley rats and the effect of 
these conditions on pancreatic islet adaptations. In addition, the aim of this thesis was to 
examine the role of therapeutic options, such as regular exercise and the administration of 
GC receptor II (GRII) antagonists in our rodent model ofT2DM. 
Hypothesis 
We hypothesized that elevations in GCs and HFD would promote T2DM 
development by impairing islet adaptation in otherwise young healthy male Sprague-
Dawley rats. We also hypothesized that regular wheel running exercise would reduce the 
development of T2DM in our rodent model and the administration of GRII antagonists 
would attenuate, if not reverse T2DM development by improving ~-cell function and 
whole body insulin resistance. 
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MANUSCRIPT-#1 Chapter 2 
Short-term Elevations in GCs and HFD in the Male Sprague-Dawley Rat 
Rationale for Manuscript #1 
It is obvious that T2DM encompasses a significant portion of the world's 
population and the prevalence is only projected[ to rise if no effective therapy is soon 
developed (53). An efficient way to study the progression or onset of T2DM is to utilize 
rodent models that share similar pathogenesis to that of T2DM humans. However, it is 
difficult to obtain adequate results and majority of the time the disease progression varies 
between rodent and humans. There are many rodent models of pre-diabetes and T2DM, 
such as partial pancreatectomy, long-term high-fat diet, and ZDF rodent models, to name 
a few (282). The ZDF rodent is one of the most widely utilized and accepted model of 
T2DM as it shares similar phenotypes with T2DM patients. A link between elevations in 
GCs and T2DM has been established in humans, however concrete mechanisms of 
T2DM onset have yet to be determined (145, 266). Similarly, ZDF rats develop 
hypercortisolemia prior to symptoms of T2DM, such as insulin resistance, 
hyperglycemia/hyperinsulinemia, and ~-cell dysfunction. Unfortunately the ZDF model is 
limited as rats develop diabetes due to leptin receptor gene deficiency, unlike many 
humans who develop T2DM (283). Moreover, it is doubtful that T2DM is induced solely 
by elevations in GCs, and more likely to develop in combination with increased F As and 
ectopic lipid accumulation (63), which very few studies have accomplished. Therefore, 
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the goal of this study was to develop a relativdy inexpensive rodent model ofT2DM 
induced by GCs and HFD that possessed similar characteristics as humans with T2DM. 
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Abstract 
Glucocorticoids (GCs) are potent pharmacological agents used to treat a number 
of immune conditions. GCs are also naturally occurring steroid hormones (e.g. cortisol, 
corticosterone) produced in response to stressful conditions that are thought to increase 
the preference for calorie dense 'comfort' foods. If chronically elevated, GCs can 
contribute to the development of type 2 diabet·es mellitus (T2DM), although the 
mechanisms for the diabetogenic effects are not entirely clear. The present study proposes 
a new rodent model to investigate the combined metabolic effects of elevated GCs and 
high-fat feeding on ectopic fat deposition and diabetes development. Male Sprague-
Dawley rats (aged 7-8 weeks) received exogenous corticosterone or wax (placebo) 
pellets, implanted subcutaneously, and were fed either a standard chow diet (SD) or a 
60% high-fat diet (HFD) for 16 days. Animals given corticosterone and a HFD (cort-
HFD) had lower body weight and smaller relative glycolytic muscle mass, but increased 
relative epididymal mass, compared with controls (placebo-SD). Cort-HFD rats exhibited 
severe hepatic steatosis and increased muscle lipid deposition compared with placebo-SD 
animals. Moreover, cort-HFD animals were found to exhibit severe fasting 
hyperglycemia (60% increase), hyperinsulinemia (80% increase), insulin resistance (60% 
increase) and impaired ~-cell response to oral glucose load (20% decrease) compared 
with placebo-SD animals. Thus, a metabolic syndrome or T2DM phenotype can be 
rapidly induced in young Sprague-Dawley rats by using exogenous GCs if a HFD is 
consumed. This finding might be valuable in examining the physiological and molecular 
mechanisms of GC-induced metabolic disease. 
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Introduction 
Presently, there are a number of available rodent models used to represent both 
the pre-diabetic or insulin-resistant disease (284, 285) and hyperglycemic conditions 
associated with the development of type 2 diabetes mellitus (T2DM) (282). These animal 
models are important because they allow for examination of the disease state at the tissue 
and cellular level, and thus might help to develop new treatments and therapies for 
patients. Ideally, a good rodent model of T2DM should represent a similar metabolic 
profile and pathogenesis to humans with pre-diabetes or T2DM. However, few models 
fully capture all characteristics of the disease pathophysiology (ectopic fat deposition, 
insulin resistance and hyperglycemia), and sometimes the models used do not reflect 
what typically occurs in humans, perhaps because genetic models or chemical agents are 
used to induce hyperglycemia, rather than attempting to examine the established risk 
factors for diabetes (286). For example, the Zucker diabetic fatty (ZDF) rat, first 
established in the early 1980s (287), is one of the most commonly used models of T2DM 
because it develops severe insulin resistance, ~-·cell compensation then decompensation, 
and eventually overt hyperglycemia by - 8-10 weeks of age ( 40). Although ZDF rats are 
leaner than the original Zucker fatty rat strain, the former express higher basal glucose 
and insulin levels and excessive ectopic fat deposition because of leptin receptor 
deficiency, which causes hyperphagia and altered substrate metabolism (287). One major 
limitation of the ZDF model is that it does not mimic the vast majority of humans who 
develop T2DM with an intact leptin receptor gene (283), not to mention that it is a costly 
and genetically spontaneous model that is not easily manipulated. Indeed, non-genetic 
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lifestyle-induced models of T2DM are scarce because most rodent species are relatively 
resistant to prolonged periods of high-fat feedling and/or physical inactivity and might not 
develop the hyperglycemic phenotype desiredl by the researcher (282). 
Considerable evidence from human studies (58, 266) and various rodent models 
(22, 288, 289) suggest that elevations in glucocorticoids (GCs) are tightly linked with 
diabetes development, either at the circulating or cellular level. At the cellular level, the 
pre-receptor enzyme 11-P-hydroxysteroid dehydrogenase type 1 {l l-PHSD-1) and the 
glucocorticoid receptor (GR), act to modulate intracellular GC action, which can 
dramatically influence tissue function (liver, muscle, adipose tissue and brain) to promote 
metabolic syndrome (290). The activity of 11-PHSD-1 has also been closely followed in 
those with diabetes and is suspected to be involved in the pathogenesis of the disease 
(291). Interestingly, elevations in GCs alter food intake, energy expenditure and ectopic 
fat deposition, and promote widespread whole body insulin resistance (110). In particular, 
elevation of GC levels in rodents ( 121 ), or even increases in stress levels in humans 
(292), promotes the consumption of energy dense 'comfort' foods. These associations 
between GCs and altered metabolism suggest a possible role of these stress hormones in 
the etiology of T2DM development. Indeed, exogenous GCs are potent diabetogenic 
agents that, when prescribed for the treatment of many acute and/or chronic conditions, 
increase whole body insulin resistance and plasma glucose levels and cause muscle 
proteolysis, all features ofT2DM development. In one study, a striking tenfold increased 
risk of diabetes development was calculated for patients receiving hydrocortisone at a 
dose of - 120 mg/day (293). 
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Generally, it is believed that the transition from an insulin resistant or pre-diabetic 
state into overt T2DM occurs when the secretory capacity of the pancreatic ~-cells is no 
longer able to maintain euglycemia to combat insulin resistance. It is plausible that the 
chronic up-regulation of GCs could act directly on pancreatic islets, inducing insulin 
resistance (151 ). However, it is also possible that increased circulating free fatty acid 
levels and excessive ectopic lipid deposition, which clearly induce whole body insulin 
resistance, in addition to elevations in GCs themselves, are the combined driving forces 
behind disease development (55, 63, 294). 
Surprisingly, very little research has been done on the collective effect of GCs and 
high-fat feeding, although each stressor on its own can result in insulin resistance (284, 
295). The purpose ofthis present study is to develop a cost-effective, GC- and high-fat-
fed-induced rodent model of diabetes mellitus. ·we believe that this model of rapid-onset 
diabetes (ROD) mimics many of the symptoms observed in patients with T2DM (285), as 
well as provides evidence that elevated GCs induce diabetes advancement if susceptible 
individuals do not consume a balanced diet. 
Methods 
Ethics statement 
All experiments were approved by the York University Animal Care Committee in 
accordance with the Canadian Council for Animal Care guidelines. 
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Animals 
Forty young ( -- age 7-8 weeks; initial weight 200-250 g) male Sprague-Dawley 
rats were purchased from Charles River Laboratories (Montreal, QC, Canada). Only male 
rats were selected for this study because female rats have differences in reproductive 
hormones throughout their ovulatory cycle that could affect glucose metabolism (296). 
All animals had a 7 day habituation period to a 12-hour light-dark cycle (lights on at 
08:00 hours and lights off at 20:00 hours) in a temperature (22-23°C) and humidity (50-
60% )-controlled room. The animals (body mass 200-250 g) were then randomly assigned 
to one of four groups: placebo-treated and fed a rodent standard diet (placebo-SD); 
placebo-treated and fed a high-fat diet (placebo-HFD); corticosterone-treated and fed a 
standard diet (cort-SD) and corticosterone-treatcd and fed a high-fat diet (cort-HFD) 
(n=8-10 per group; all individually housed). A timeline of the treatment protocol is 
presented in Fig. 4. 
Surgical procedures and design 
Following habituation, all placebo-treated animals had 4x 100 mg wax pellets 
( --0.2 cm in diameter each) implanted subcutaneously between their scapulae under 
aseptic conditions (termed day 0), whereas glucocorticoid-treated animals had 4xlOO mg 
of corticosterone (C2505, Sigma-Aldrich, Oakville, Ontario, Canada) pellets surgically 
implanted in an identical surgical procedure (see below). Pilot data from our laboratory 
found that a 200 mg corticosterone implant failed to significantly increase peak 
corticosterone levels over a 2 week period (see supplementary material Fig. S 1 ). In 
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addition, these rats did not develop fasting hyperglycemia when given with a HFD. 
Pellets were created by similar protocols to those published by Meyer et al. (297). 
Briefly, this involves the subcutaneous implantation of solid corticosterone pellets formed 
from the molten hormone and weighing -100 mg. Purified corticosterone was carefully 
melted in a small stainless steel spoon over a low gas flame and then poured into a 6 mm 
diameter hole drilled in a paraffin block. After the pellet cooled and solidified, it was 
removed from the wax with the aid of a scalpel and trimmed to the correct weight. Rats 
were anesthetized at 5% isoflurane and maintained at 2.5% isoflurane for the remainder 
of the surgery while steroid pellets were implanted in the nape of the neck. After the skin 
in the area had been shaved and treated with an ethanol-alcohol solution (Betadine, 
Purdue Products, Stamford, CT), a small incision was made, and the underlying fascia 
was spread and separated with a hemostat and inserted into the opening. The pellet was 
placed under the skin at least 2 cm caudal to the: incision, which was then closed with 9-
mm wound clips (VWR, Mississauga, ON, Canada). Rats then recovered in individually 
housed sterilized, standard rodent cages. Following recovery from surgery, SD-fed 
animals were given rodent SD (14% fat, 54% carbohydrate, 32% protein and 3.02 
calories/ g) ad libitum, whereas HFD-fed animals were provided with a 60% HFD ( 60% 
fat, 21% carbohydrate, 18% protein and 5.1 calories/g) ad libitum (Cat# TD. 06414, 
Harlan Laboratories, Madison, WI). The composition of the fat in the HFD was as 
follows: saturated: 37%; monounsaturated: 47%; polyunsaturated: 16%. Food intake and 
body weight were measured every other day. 
64 
Plasma analyses 
Whole blood was collected via the tail-nick procedure and placed in EDTA 
microvette tubes ( ....... 50 µl) at 20:00 hours on day 6 and 14 and at 08:00 hours on day 7 and 
15 to determine 'peak' and 'trough' corticosterone levels, as previously described 
(Campbell et al., 2010), and insulin and leptin levels. Immediately following blood 
collection, plasma samples were separated from whole blood by centrifugation (90 
seconds at 13,000 g) and frozen at -20°C until further analysis. Commercially available 
kits were used to measure insulin (INSKR020, Crystal Chem, Downers Grove, IL), 
corticosterone (07-120102, MP Biomedicals, Solon, OH), non-esterified free fatty acids 
(HR Series NEFA-HR, Wako Chemicals, Richmond, VA), triglycerides (TROIOO, 
Sigma-Aldrich, Oakville, ON, Canada) and lep1tin (RADPK-81K, Milliplex rat adipokine 
kit, Millipore, Etobicoke, ON, Canada) at select time points (see below) from blood 
collected via tail-nick or from trunk blood collected at the end of the experimental period 
(i.e. decapitation). 
Oral glucose tolerance test 
On day 12, following an overnight fast, body mass was determined and blood 
glucose level assessed via tail-nick and a hand-held glucometer (Contour blood glucose 
meter, Bayer, Toronto, ON, Canada). In addition, ....... 40 µl of plasma was collected via tail-
nick for basal insulin measurements (see above). Following this, an oral gavage of 50% 
glucose (1.5 g/kg body weight) was performed on each animal (time 0), followed by 
blood collection for insulin and glucose every 30 minutes. At 120 minutes after oral 
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glucose gavage, animals were returned to their regular housing conditions and respective 
diets. HOMA-IR values were calculated according to the formula: [insulin(µ units/ml) x 
glucose (mmol/l)]/22.5. HOMA-~ values were calculated according to the formula: 
[insulin (µ units/ml) x 20]/[glucose (mmol/l) - 3 .5]. Values represent fasting glucose and 
insulin levels (298). 
Intraperitoneal insulin tolerance test 
On day 15, all animals were fasted overnight with body weights and blood 
glucose recorded, as stated above. The following morning (day 16), the animals were 
injected intraperitoneally (IP) with 0.75 units insulin/kg body weight (time 0). Blood 
glucose levels were measured at 5, 10, 20 and 30 minutes post IP injection. At the end of 
the 30 minutes, animals were killed via decapitation and trunk blood was collected and 
separated into plasma as described above. Gastrocnemius, soleus, plantaris and 
epitrochlearis muscles, left and right adrenals, inguinal subcutaneous and epididymal 
adipose depots, and liver were removed, weighed and flash frozen in liquid nitrogen. 
Insulin resistance was measured as the AUC for the glucose concentrations during the 
insulin tolerance test. All tissues were stored in -80°C until further analysis. 
Tissue processing 
Pancreas was excised from animals, weighed and cut into ten randomized pieces. 
Each piece was washed in saline and then placed into 10% buffered formalin for 48 
hours. After the incubation period, pancreas pieces were placed into 70% ethanol and 
prepared for paraffin embedded sectioning. Pancreas pieces were sectioned into 5-µm 
66 
thick sections and mounted onto microscope slides, stained with eosin and counterstained 
with hemotoxylin. Representative islets from each animal treatment group were identified 
at 20 x magnification and analyzed for islet areas using the slide scanner software 
(Aperio Scanscope CS, Vista, CA, scanned at the Advanced Optical Microscopy Facility, 
University Health Network, Princess Margaret Hospital, Toronto, ON, Canada). 
Frozen liver and muscle tissue from each animal were snap frozen, cryosectioned 
(10-µm thick) and stained with Oil Red 0 for m~utral lipid content as previously 
described (299). Briefly, muscle and liver sections were fixed in 3.7% formaldehyde at 
room temperature. During this time, Oil Red 0 solution consisting of 0.5 g Oil Red 0 
powder (Sigma-Aldrich, Canada) and 100 ml of 60% triethyl phosphate (Sigma-Aldrich, 
Canada) was combined and filtered. Following fixation in paraformaldehyde, slides were 
then immersed in filtered Oil Red 0 solution for 30 minutes. Immediately after, slides 
underwent three washes with ddH20, were allowed to air dry for 10 minutes and were 
then sealed with Permount (Sigma-Aldrich, Canada). Images were acquired at 1 Ox 
magnification using a Nikon Eclipse 90i microscope (Nikon, Canada) and Q-Imaging 
Micro Publisher 3 .3 RTV camera with Q-capture software. 
mRNA expression 
Epididymal and subcutaneous fat pad total RNA was isolated using the Trizol 
reagent (lnvitrogen, Carlsbad, CA) and Eppendo1rf spin columns were used to concentrate 
RNA. Total RNA concentrations were quantified by ultraviolet spectrophotometry at 260 
nm, and RNA purity was verified by the 260- to 280-nm ratio (Nanodrop ND-1000; 
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Fisher Scientific, Wilmington, DE). Total RNA was diluted to 1 µg/µl using RNA-free 
water and the first-strand of cDNA was synthesized with DNase I (Invitrogen) and 
reverse transcribed to cDNA using SuperScript II RNase H-RT (Invitrogen). Duplicate 
samples of 5 µl of mRNA were quantified using a Bio-Rad My IQ single color real-time 
PCR detection system using SYBR green (Bio--Rad, Mississauga, ON, Canada). Each 
reaction contained 12.5 µl SYBR green mix, 1 µl of each forward and reverse primer (5 
µM), and 5.5 µl RNase-free H20. The PCR protocol conditions consisted of an initial 
denaturation for 3 minutes at 95°C, followed by 30 cycles at 95°C for 15 seconds, 
annealing at 60°C for 45 seconds and extending at 72°C for 30 seconds. Analysis was 
conducted using the 21v' method. All samples were normalized to the expression level of 
the housekeeping gene ~-actin, which did not significantly change among experimental 
treatments. Primer sets were as follows: 11-~HSD-1 Forward: 5'-
GGGAGGCCATGTGGTATTGAC-3', Reverse: 5'-CGAGTTCAAGGCAGCGACAC-3'. 
Glucocorticoid Receptor (GR) Forward: 5'-CCAAAACTCACTCGGATGCA-3', 
Reverse: 5'-AGGTGCTTTGGTCTGTGGGATA-3'. Beta Actin Forward: 5'-
TGTGGCATCCATGAAACTAC-3', Reverse: 5'-CTCAGGAGGAGCAATGATCT-3'. 
Statistical analyses 
For all experiments, the appropriate one-or two-way ANOVA was performed as 
required to identify significant differences between treatment groups using Statistica 6.0 
software (StatSoft, Tulsa, OK), with significance found when P<0.05. If significant 
differences were found by a one- or two-way ANOVA, then the Tukey's honestly 
significant difference post-hoc test was performed. Data are presented as mean± s.e.m. 
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Results 
Corticosterone treatment results in attenuated body mass gains despite 
hyperphagia, but increases relative central adipose mass and muscle atrophy 
At day 11 of treatment, all corticosterone-treated rats exhibited attenuation in 
body mass growth and less gross caloric intake compared with placebo-treated rats (Table 
1). Caloric intake (expressed relative to whole animal body mass) was -twofold higher in 
animals given corticosterone and a high-fat diet (cort-RFD), compared with all other 
treatment groups (Table 1). Cort-RFD rats had more than a twofold greater relative 
epididymal fat pad mass when compared with controls [placebo-treated rats fed a 
standard chow diet (placebo-SD); 9.81±1.65 versus 4.56±0.54 g/kg body mass, P<0.05, 
main effect of diet, P<0.01]. Epididymal fat pad mass was not significantly elevated in 
either cort-SD- or placebo-RFD-treated rats when compared with placebo-SD-treated rats 
(5.82±0.28 versus 5.27±0.57 g/kg, P=0.06). Mesenteric fat mass was also visibly more 
abundant in cort-RFD-treated rats than the other three groups (observational results). 
Corticosterone treatment resulted in reduced relative adrenal mass (extended results) and 
decreased thymus mass, as expected (observational results). Cort-RFD rats, in particular, 
had increased liver and pancreatic mass (all P<0.05). Absolute muscle mass was lower in 
all corticosterone-treated animals (extended resuilts ), although relative mass of the soleus 
and plantaris was unchanged. Cort-RFD rats had lower relative epitrochlearis muscle 
mass compared with the placebo-SD group (Table 1; P<0.01). 
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Cort-HFD results in hyperglycemia, hyperinsulinemia, insulin resistance and 
reduced insulin tolerance 
Cort-HFD animals demonstrated dramatically elevated fasted blood glucose levels 
(i.e. fasting hyperglycemia) compared with all other groups (I4.0±l.9 mmol/l in cort-
HFD compared with 4.2±0.2 mmol/l in the placebo-SD group; P<0.05; Fig. lA). Neither 
the cort-SD nor placebo-HFD groups demonstrated fasting hyperglycemia. Moreover, 
following an oral glucose gavage on day 13, onlly cort-HFD animals had sustained 
hyperglycemia throughout the I20 minutes of the glucose tolerance test (P<0.05; Fig. 
IA). By contrast, the cort-SD group had mildly elevated blood glucose levels, compared 
with placebo-SD, but only at 30 and 60 minutes post oral glucose gavage (P<0.05; Fig. 
IA). The placebo-HFD group failed to demonstrate elevated glucose levels at any time 
during the glucose tolerance test, as expected based on the short timeframe of treatment. 
Fasted insulin level in the cort-HFD group was elevated ....,threefold compared with all 
other groups (P<0.05; Fig. IB). No differences in fasting insulin concentrations were 
found among the cort-SD, placebo-SD and placebo-HFD groups. 
The homeostasis model assessment for insulin resistance (HOMA-IR) was used to 
determine insulin resistance on the basis of fasted insulin and glucose levels. The cort-SD 
group had a twofold higher HOMA-IR than the placebo-SD group, whereas the cort-HFD 
group had a I5-fold increase compared with placebo-SD animals (P<0.05; Fig. IC). The 
HOMA-~ index, commonly used as an index of J3-cell function, showed cort-SD animals 
to have an ....,twofold increase in ~-cell function relative to the placebo-SD group, whereas 
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the cort-HFD group demonstrated reduced HOMA-~ levels relative to all other groups 
(P<0.05 compared with the cort-SD group). Moreover, cort-HFD animals had a 20% 
decrease in HOMA-IR levels and no differences were found in placebo-HFD compared 
with placebo-SD animals (P<0.05; Fig. lD). 
An insulin tolerance test was also carried out in all treatment groups on day 15 to 
further characterize whole body insulin sensitivity. As expected, cort-HFD animals had 
higher plasma glucose levels prior to and after the insulin injection, compared with all 
other treatment groups (P<0.05; Fig. lE). The c:ort-HFD group also demonstrated a 2.5-
fold higher glucose area under the curve (AUC) following insulin injection, illustrating 
impaired insulin sensitivity (P<0.05; Fig. lF). There were no differences found in glucose 
response to insulin injection among the other three groups. 
Cort-HFD treatment impairs normal corticosterone circadian rhythm, as well as 
increasing fasting insulin, leptin and triglycerides levels 
All treatment groups demonstrated a n01mal circadian rhythm of corticosterone 
secretion prior to pellet surgery, as measured by trough and peak corticosterone levels 
measured in the early evening (20:00 hours) and in the morning (08:00 hours) (Table 2). 
However, 7 days after pellet implantation, cort-:SD- and cort-HFD-treated animals both 
had significantly elevated corticosterone levels at the 08:00 hour measurement only 
(P<0.05; Table 2). On day 10, the cort-HFD group demonstrated more than a 17-fold rise 
in fasting plasma insulin, a >fivefold elevation in plasma leptin levels and >threefold 
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elevation in plasma triglyceride levels compared with placebo-SD animals (P<0.05; 
Table 2). 
Corticosterone treatment causes islet hyperplasia and increases ectopic fat 
deposition, effects that were further exacerbated with high-fat feeding 
To demonstrate altered islet morphology, pancreas sections were collected and 
stained with hemotoxylin and eosin. As shown, there were no observed differences 
between placebo-SD and placebo-RFD islet area (Fig. 2A). However, corticosterone 
treatment increased islet area, with the greatest increase observed in the cort-HFD group 
(Fig. 2A). In addition to elevations in visceral adiposity, Oil red 0 staining of liver and 
tibialis anterior muscle sections revealed increased ectopic lipid accumulation in both 
corticosterone-treated groups, effects that were ~~xacerbated with the HFD (Fig. 2B and 
C). HFD feeding alone caused a much less pronounced effect on ectopic lipid deposition. 
Cort-HFD significantly augments adipose tissue 11-PHSD-1 expression, whereas 
cort-SD treatment increases GC receptor exp1ression 
Cellular GC activity and the genomic effocts of GCs within tissues are largely 
determined by the presence of active and inactive hormone in the circulation as well as 
the cellular expression of the pre-receptor enzyme 11-PHSD-l and GR. As previously 
mentioned, 11-PHSD-l acts in various target tissues to convert inactive GCs (11-
dehydrocorticosterone) into their active form (corticosterone) (290). To determine the 
effects of corticosterone and HFD treatment on cellular mediators of GC action, we 
performed real-time PCR (RT-PCR) to analyze mRNA expression of GR and 11-PHSD-l 
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in visceral ( epididymal fat pads) and subcutaneous adipose tissue because we 
hypothesized that corticosterone treatment would increase the expression of 11-~HSD- l 
in visceral tissue but also exacerbate its effects with high-fat feeding. In epididymal fat 
depots, corticosterone treatment significantly increased 11-~HSD- l mRNA expression, 
regardless of diet type. By contrast, GR expression was only elevated in cort-SD 
compared with placebo-SD animals (P<0.05; Fig. 3A and B). In subcutaneous adipose 
depots, 11-~HSD- l mRNA expression was elevated twofold in both corticosterone-
treated groups; however, this increase was greatly augmented by the HFD (P<0.05; Fig. 
3C). Compared with the placebo-SD group, GR mRNA expression tended to be elevated 
in the cort-SD group and was significantly reduced in the placebo-RFD group (P<0.05; 
Fig. 3D). 
Discussion 
T2DM is a complex disease and the mechanisms for its development are probably 
varied. However, it is generally held that whole body insulin resistance is related to 
increased ectopic lipid accumulation in insulin-siensitive tissues ( 177) and that ~-cell 
dysfunction occurs via lipid and glucose toxicity of the islets (140, 141). One possible 
mediator of T2DM development is an elevation in circulating and/or tissue levels of GCs 
(142, 143). Indeed, exogenous GC treatment dramatically increases the odds ratio of 
developing T2DM in humans (145). The goal of the present study was to develop a new 
non-genetic model of GC-induced diabetes that is cost effective and rapidly inducible. 
The main finding of this study is that the simple combination of exogenous GCs with a 
HFD rapidly induces excessive ectopic fat deposition, hyperinsulinemia and/or insulin 
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resistance, and severe hyperglycemia in young Sprague-Dawley rats, effectively 
mimicking GC-induced diabetes mellitus. 
Strengths and limitations of the corticosterone- and HFD-induced diabetic model 
Rodent models of metabolic syndrome or diabetes should largely reflect the 
biochemical profile and pathogenesis that occurs clinically in humans with pre-diabetes 
or T2DM. The rodent model presented here, what we term as the 'rapid onset of diabetes' 
(ROD) model, clearly exaggerates the fundamental physiological parameters that are 
typically observed in individuals with T2DM who might have chronically elevated GC 
levels and who may consume an energy dense 'westernized' HFD. Here, we clearly 
demonstrate that the combination of elevated GCs and a HFD in otherwise healthy 
Sprague-Dawley rats induces a diabetic phenotype including glucose intolerance, insulin 
resistance, hyperglycemia and hyperinsulinemia as early as 1 week post intervention and 
produces a blood biochemical profile that is strikingly similar to T2DM individuals. 
Interestingly, HOMA-IR and HOMA-~ scores indicate extremely elevated levels of 
insulin resistance and ~-cell dysfunction in this model, despite major increases in ~-cell 
compensation, as measured by increased islet areas in the cort-HFD group. It is important 
to note that neither corticosterone alone nor HFD alone promoted hyperinsulinemia or 
hyperglycemia in this short timeframe of study, thereby suggesting that these two 
treatments (i.e. GCs and HFD) have a synergistic effect on diabetes development. 
Moreover, cort-HFD animals were found to have :increased levels of hepatic and muscle 
fat accumulation (Fig. 2B, C), which was not observed when corticosterone or a HFD 
was tested alone. Importantly, prolonged corticosterone treatment alone, in similarly aged 
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Sprague-Dawley rats over a period of 6-8 weeks, failed to promote any observable 
increases in fasting glucose or impaired glucose tolerance (our unpublished observations). 
Taken together, the exposure to elevated GCs, in combination with a HFD, rapidly 
induces an obvious T2DM phenotype in young Sprague-Dawley rats, which are 
otherwise very resistant to the development of hyperglycemia. 
One limitation of this model is that the procedure does require some surgical 
expertise, general anesthesia and possibly an increased risk for infection because of 
immune system suppression. An alternative to this procedure would be to provide these 
animals corticosterone in their drinking water, as has been previously established in a 
murine model of metabolic syndrome (295). However, the surgical implantation of 
corticosterone provides a more steady state drug exposure that more effectively abolishes 
the diurnal GC rhythm, compared with providing it in the drinking water, because animal 
water consumption tends to be primarily in the early evening (295). 
We acknowledge that our model does affoct the immune system and the 
endogenous hypothalamic-pituitary-adrenal (HPA) axis, because ROD animals display 
decreases in thymus and adrenal weights. However, these results have been shown in 
various other models of corticosterone administration, i.e. spiking rodent drinking water 
with high amounts of corticosterone (295). We also realize that immune suppression is 
not characteristic of the diabetic phenotype (type 1 or type 2), nor is the endogenous HPA 
axis down-regulated, unless diabetic individuals are on exogenous GCs. 
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The physiological relevance of the amount of corticosterone that was 
administered to the animals in our study also warrants discussion. Because the 
corticosteroid-treated animals in this study received -20 mg/day/kg body weight (-6.25 
mg/day in rats that weighed -0.3 kg), we estimate that our treatment might be fivefold 
higher in corticosterone dose (assuming that there was no loss in drug potency with the 
procedure used to manufacture the pellets) than in humans treated with exogenous GCs 
that are known to increase the risk of diabetes development (300) . It was decided that, 
for the purpose of this study, we wished to treat the animals with the 'most tolerable 
dose' of corticosterone as a proof of principle to rapidly induce hyperglycemia and 
hyperinsulinemia. 
Prevalence of GC-induced diabetes in humans 
The prevalence of GC-induced diabetes i.n clinical populations, or in individuals 
exposed to chronic stress, is not clear. According to Lansang and Hustak (145), GC-
induced hyperglycemia might be quite common. In humans with rheumatoid arthritis who 
are receiving corticosteroid therapy,,..., 10% develop diabetes in the first 2 years of drug 
commencement (300). In a case control report, the incidence of initiating an oral 
hypoglycemic agent or exogenous insulin (i.e. indicative of diabetes development) 
increased dramatically with GC treatment and was positively correlated with the amount 
of drug that the patients were receiving. More specifically, a striking tenfold increased 
risk (i.e. 10.34 odds ratio compared with no treatment) was calculated for patients 
receiving a hydrocortisone-equivalent dose of=120 mg/day (293). Moreover, studies of a 
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single intravenous dexamethasone injection of just 10 mg, which is equivalent to - 260 
mg ofhydrocortisone (145), causes sustained hyperglycemia within -4 hours in healthy 
humans (301, 302). Taken together, it is clear that exogenous GCs in modest to high 
doses promote hyperglycemia in otherwise healthy humans. 
Effects of corticosterone treatment on food intake, body mass and body composition 
Elevations in GC levels have widely bee:n cited as promoting hyperphagia, 
particularly the increased consumption of energy dense 'comfort' foods (292, 303). 
Despite increased food intake, at least expressed relative to body mass, the 
corticosterone-treated animals in this study clearly demonstrate significantly lower body 
weight (Table 1). Although the mechanism for attenuated growth is unclear, GCs are well 
known to reduce overall body mass and body length, probably by promoting muscle 
proteolysis and by lowering the growth hormone (GH)--IGF-1 axis in young growing 
mammals (110). Indeed, Dong et al. demonstrated that attenuation in body weight gain 
with elevations in GCs is associated with a reduction in overall protein synthesis but not 
with reduced energy intake (304). More specifically, GCs are thought to reduce skeletal 
muscle protein synthesis and elevate proteolysis specifically in muscles containing a high 
proportion of fast twitch type II fibers (305). In support of this, the cort-HFD-treated 
animals in this study showed a significant reduction in epitrochlearis (primarily 
composed of type II fibers) but not in soleus (primarily type I) muscle mass, suggesting 
that this treatment attenuates growth primarily in glycolytic muscle fibers. The observed 
muscle atrophy coincides with evidence from individuals with T2DM who experience 
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reduced muscle strength and atrophy particularly when glycemic control is poor (306-
308). 
As expected, we found that body mass gain was dramatically attenuated with 
corticosterone treatment but, surprisingly, a HFD did not increase body mass in 
corticosterone-treated animals. It is well established that the development of T2DM from 
a state of pre-diabetes is often associated with re:ductions in body mass, perhaps because a 
large number of calories are lost to glycosuria. In contrast to our observations that 
increased corticosterone exposure attenuates body mass gains in rodents, Karatsoreos et 
al. (295) showed that C57 /BL6 mice exposed to high amounts of corticosterone (100 
µg/ml) in their drinking water for 4 weeks had elevated body mass gains, despite initial 
reductions in mass, compared with placebo treatment (295). However, C57 /BL6 mice are 
genetically engineered to rapidly develop insulin resistance when they are metabolically 
challenged (309, 310) and the study by Karatsort:os et al. (295) used mature mice that 
were well past their adolescent growth phase when the GC-induced inhibition of the GH-
IGF-1 axis would have less influence on body mass gains. It is also crucial to note that, 
although the C57 /BL6 mice that were provided corticosterone in their drinking water did 
develop insulin resistance, they did not develop hyperglycemia (i.e. T2DM). Thus, the 
body mass gain in that study might have been more dramatic than what was observed in 
our study because the cort-HFD animals would have had substantial caloric loss due to 
glycosuria. 
One of the hallmarks of the development of metabolic syndrome and T2DM is the 
elevation in ectopic lipid accumulation in non-subcutaneous adipose stores (increased 
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central adiposity, muscle and liver lipid accumulation). In this new ROD model, we 
observed dramatic increases in ectopic lipid deposition with corticosterone treatment, 
particularly in those animals fed a HFD (Table 1 ). Corticosterone is known to stimulate 
an increase in fat accumulation within central adipose stores because of an increased 
number of adipocytes as well as via adipose cell hypertrophy (110, 311 ). Increased 
visceral adiposity is characterized as an important factor in the development ofT2DM in 
human subjects (312, 313). Similarly, cort-HFD-treated rats did have increases in visceral 
adiposity, which might have played a role in the progression of their insulin resistance. 
Indeed, intracellular lipid accumulations in endocrine pancreas, liver and skeletal muscle 
cells have all been previously shown to contribute to the pathogenesis of impaired insulin 
secretion and insulin resistance (304, 314). In support of the notion that ectopic fat 
accumulation promoted the diabetes phenotype, ROD animals exhibited significant 
increases in ectopic fat deposition in the liver and muscle compared with all other 
animals (Fig. 2), which coincided with their deteriorated insulin sensitivity. Numerous 
studies have demonstrated the link between ectopic fat deposition and insulin resistance 
in persons with overt T2DM (315, 316). Future studies are needed, however, to determine 
whether the increase in lipid end products associated with increased ectopic fat deposition 
is a driving force behind the development ofT2DM in this rodent model, as has been 
proposed in humans with excessive liver and muscle lipid deposition (317). 
Glucose tolerance and insulin sensitivity 
Compared with all other treatment groups, cort-HFD rats demonstrated 
deteriorating glycemic control and severe insulin :resistance, as measured by both oral 
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glucose and insulin tolerance tests (Fig. 1). Cort-HFD animals exhibited a threefold 
elevation in plasma glucose concentration and a. 1 7-fold increase in insulin level 
compared with placebo-SD animals. Moreover, following oral gavage of glucose, cort-
HFD animals had sustained elevations in glucose and insulin concentrations, thereby 
demonstrating similar characteristics to individuals with T2DM (318, 319). Measurement 
of HOMA-IR revealed almost a 70-fold increase in whole body insulin resistance in cort-
HFD rats compared with the placebo-SD and placebo-HFD groups. Moreover, higher 
HOMA-~ index values in cort-SD animals indicate a higher pancreatic ~-cell function 
compared with placebo-treated animals. Importantly, however, the HOMA-~ value was 
significantly lower in cort-HFD-treated animals compared with cort-SD animals despite 
the finding that cort-HFD animals had larger islet areas than all other groups (Fig. 1). 
These results suggest that the combination of elevated corticosterone with a HFD might 
initially increase ~-cell compensation, possibly as a result of elevated insulin resistance, 
but that these ~-cells have insufficient capacity to secrete enough insulin to normalize 
glycemia in response to oral glucose stimulation. In other words, although cort-HFD 
animals have increased islet areas and elevated insulin concentrations (in both the basal 
and stimulated states) compared with all other groups, these animals remain extremely 
glucose intolerant because of insufficient insulin signaling within various insulin target 
tissues. 
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Intracellular GC activation and other plasma markers of insulin resistance or 
T2DM 
Our ROD model exhibits hyperglucocorticoidemia, exaggerated GC tissue 
reactivation and increased diabetes-related blood markers, all of which are present in 
humans and rodents with overt T2DM. Indeed, our cort-HFD animals show elevations in 
plasma GC levels beyond those observed with corticosterone treatment alone (Table 2), 
thereby suggesting that a HFD might exaggerate hyperglucocorticoidemia. Importantly, 
hyperglucocorticoidemia is frequently observed in both humans and rodent models of 
diabetes (63, 288, 320, 321). It has been previously proposed that heightened levels of 
plasma GCs in animals exhibiting metabolic syndrome might be a result of increased 11-
~HSD-1 activity in liver, muscle and adipose tissue (322). From our data, we can 
conclude that our corticosterone-treated animals have an increase in 11-~HSD-1 activity 
within adipose tissue (Fig. 3). This finding is more exaggerated in corticosterone-treated 
animals given a HFD, which might help to explain the higher circulating levels of 
corticosterone. 
Finally, it is important to note that the ROD model has other metabolic 
similarities to diabetes development, including hyperleptinemia and hyperlipidemia. 
Leptin is secreted by the adipocytes in response to increased adiposity and is thought to 
play a role in the development of peripheral insulin resistance and perhaps in the 
progression ofT2DM, although the role of this adipokine in disease development is 
controversial (323). We confirm here that elevation in plasma leptin levels occurs in 
corticosterone-treated animals and that these increases are dramatically enhanced by a 
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HFD (Table 2). Moreover, ROD animals experience hypertriglyceridemia similar to 
rodent models of and individuals with T2DM (287, 324), perhaps due to increased fat 
intake and/or dramatic increases in insulin resistance caused by corticosterone and high-
fat feeding. Further research is required, however, to establish the mechanisms of 
hyperglycemia development in this model (e.g. defective hepatic and muscle insulin 
signaling, glucose turnover and/or ~-cell function). 
Conclusion 
In conclusion, the present study demonstrates a new cost effective rapidly 
inducible rodent model of GC-induced T2DM, which has a similar anthropometric, 
biochemical and pathogenic profile as patients with severe insulin resistance or metabolic 
disease. This ROD model can be considered a new important tool for determining the 
complex multi-organ and multi-tissue connections between elevated GC levels and the 
development of metabolic syndrome and T2DM. 
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Table 1. Body composition and caloric intake of placebo- and corticosterone-treated rats. 
Placebo-SD Placebo-
HFD 
Gross body 358.86±5.57 350.84±4.52 
mass (g) 
Caloric 
Intake 0.28±0.01 0.42±0.01# (kcal/kg body 
mass* day) 
Left Adrenal 
mass (g/kg 0.10±0.01 0.10±0.01 
body mass) 
Epitrochlearis 
mass (g/kg 0.14±0.01 0.15±0.01 
body mass) 
Soleus mass 
(g/kg body 0.42±0.01 0.40±0.02 
mass) 
Epididymal 
fat pad mass 4.56±0.54 5.82±0.28 (g/kg body 
mass) 
Liver mass 
(g/kg body 39.90±1.44 36.16±1.21 
mass) 
Pancreas 
mass (g/kg 2.48±0.13 2.61±0.08 
body mass) 
Cort-SD Cort-HFD 
265.87±7.40# 226.12±9.05# 
0.33±0.01 # 0.61±0.02# 
0.03±0.01 0.05±0.06 
0.18±0.01 0.09±0.02# 
0.42±0.02 0.49±0.06 
5.27±0.57 9.81±1.65# 
58.35±3.8.3t 68.62±3.2ot 
3.92±0.46 3.40±0.52 
Main 
Effect 
Main Interaction 
Effect 
oif Cort of Diet 
p<0.001 p<0.01 ip<0.05 
p<0.001 p<0.001 p<0.001 
p<0.001 
p<0.01 p<0.01 
p<()).05 p<0.01 P=0.06 
p<0.001 -- p<0.05 
p<0.01 
Note: *indicates significance from Placebo-SD (p<0.05). 1he t indicates significance from the respective 
placebo group (p<0.05). The# indicates significance versus all other treatment groups (p<0.05) All values 
are means± SEM, n=7-10. 
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Table 2. Plasma composition of corticosterone (ng/ml), fasted insulin (ng/ml), leptin 
(pg/ml), triglycerides (mM) and non-esterified fatty acids (NEFAs) (mM) in Placebo-SD, 
cort-SD, Placebo-RFD and cort-HFD animal groups. 
Placebo-SD Placebo-
HFD 
Cort-Sn Cort-HFD Main 
Effect of 
Maih Interaction 
Effect of 
Cort Diet 
Peak 
corticosterone 270.3±51.3 303.2±140.7 295.2±74.4 585.6±126.9 
(ng/ml) 
Trough 
corticosterone 45.6±12.8 19.8±3.8 310.0±60.3# 595.9±122.0# p<0.001 p<0.05 
(ng/ml) 
Insulin 0.27±0.05 0.50±0.32 0.63±0.29 4.65±0.36# p<0.001 p<0.001 p<0.001 (ng/ml) 
Leptin 
(ng/ml) 1.20±0.19 3.08±0.55 4.59±0.72 6.23±0.42 
p<0.001 p<0.001 
Triglycerides 0.13±0.01 0.19±0.02 0.24±0.04 0.40±0.13 p<0.05 p<0.05 (mM) 
NEFAs(mM) 0.92±0.01 0.79±0.16 0.62±0.05 0.62±0.06 
Note: The* indicates statistical significance from Placebo group (p<0.05). The# indicates significance 
versus all other treatment groups (p<0.05). All values are :l:SEM. N=5-6 per group. 
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Figure Captions 
Figure. 1. Corticosterone treatment increases glucose intolerance and insulin sensitivity. 
(A) Glucose concentrations (mmol/l) were measured every 30 minutes post oral glucose 
load (1.5 g/kg). (B) Insulin concentrations (ng/ml) during the oral glucose tolerance test 
(OGTT). (C) HOMA-IR, as calculated by the formula: [insulin (µU/ml) x glucose 
(mmol/l)]/22.5. (D) HOMA-~, as calculated by the formula: [20 x insulin (µ 
units/1)]/[glucose (mmol/1)- 3.5]. This calculation indicates the functional response of the 
pancreatic ~-cells to a bolus of glucose. A higher HOMA-~ value suggests a greater 
response of the pcells to glucose, indicating higher P-cell function. (E) Glucose 
concentrations during the insulin tolerance test. (F) Insulin resistance, as measured by the 
AUC for glucose levels following the insulin tolerance test. All values are means ± 
s.e.m., n=5-6. *, Statistical significance from all other treatment groups, P<0.05. #, 
significance from cort-SD, P<0.05, using a two-way ANOV A. t, cort-SD significantly 
different from placebo-SD, P<0.05. 
Figure. 2. Histochemistry staining analysis. (A) Pancreatic islet hemotoxylin and eosin 
staining, indicating pancreas islet areas. (B) Liver Oil Red 0 staining, indicating liver 
total lipid content. (C) Tibialis anterior Oil Red 0 staining, indicating muscle total lipid 
content in placebo-SD, cort-SD, placebo-RFD and cort-HFD animals (20x 
magnifications). 
Figure. 3. Tissue determination of corticosterone action in adipose tissue. (A) Relative 
11-PHSD-l and (B) GR mRNA expression in epididymal fat deposits. (C) 11-PHSD-1 
and (D) GR mRNA expression in subcutaneous fat deposits in placebo-SD, cort-SD, 
placebo-RFD and cort-HFD rats. All protein was standardized to ~-actin expression. 
n=3-5. *, P<0.05 from placebo-SD; #, significance from cort-SD. All values are± s.e.m. 
Figure. 4. Treatment protocol timeline. Animals were given 7 days of habituation before 
pellet surgeries were performed (day 0). Also on this same day, plasma corticosterone 
levels as well as blood glucose levels were sampled (i.e. basal measurements). On day 7, 
corticosterone and blood glucose measurements were repeated and animals were fasted 
overnight on the night of day 11. Animals were then given an oral glucose tolerance test 
(OGTT) on day 12 and were subsequently allowed a 2-day wash-out period before 
another plasma corticosterone and blood glucose sample was taken (evening of day ]4). 
Animals were then fasted on the night of day 15 and finally subjected to an insulin 
tolerance test (ITT) on day 16. 
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Figure 2. 
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MANUSCRIPT-#2 Chapter 3 
The Effects of GCs and HFD on Islet Adaptations in the Sprague-Dawley Rat 
Rationale for Manuscript #2 
Manuscript # 1 demonstrated that elevated GCs, by implantation of corticosterone 
pellets and a HFD (60% total calories from fat} induced a rapid-onset T2DM phenotype 
in otherwise healthy young male Sprague-Dawley rats. Our treatment showed that 2 
weeks of treatment induced fasting hyperglycemia, hyperinsulinemia, severe peripheral 
insulin resistance, increased visceral adiposity, hepatic steatosis, and muscle lipid 
deposition. This study described the effects on whole body physiology with elevations in 
GCs and HFD that evidently overwhelmed pancreatic ~-cell compensation capacity 
leaving animals overtly diabetic. Chronic elevations in GCs are known to destroy glucose 
homeostasis, but the literature is undecided as to the role that short-term increases in GCs 
play on islet function. Some studies suggest that acute GC treatment in vivo increases 
insulin resistance, ~-cell mass, and secretion thereby up-regulating islet compensation 
mechanisms in rodents (2, 154). Whereas other studies suggest that in vitro 
administration of GCs deteriorates ~-cell function and decreases insulin secretion (3, 
161 ). In addition, lipid accumulation has been shown to directly impair islet function 
thereby decreasing insulin secretion (177, 180). Therefore, as increased GCs and lipid 
concentrations have both been linked to islet dysf\Jnction, the goal of our second 
manuscript was designed to enhance our understanding of in vivo and ex vivo islet 
adaptations to elevations of GCs and HFD by use of our ROD model in young rats. 
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Abstract 
Corticosterone (CORT) and other glucocorticoids cause peripheral insulin 
resistance and compensatory increases in ~-cell mass. A prolonged high-fat diet (HFD) 
induces insulin resistance and impairs ~-cell insulin secretion. This study examined islet 
adaptive capacity in rats treated with CORT and a HFD. Male Sprague-Dawley rats (age 
,...., 6 weeks) were given exogenous CORT (400 mg/rat) or wax (placebo) implants and 
placed on a HFD (60% calories from fat) or standard diet (SD) for 2 weeks (N=lO per 
group). CORT-RFD rats developed fasting hyperglycemia (> 11 mM) and 
hyperinsulinemia (,...., 5-fold higher than controls) and were 15-fold more insulin resistant 
than placebo-SD rats by the end of ,....,2 weeks (Homeostatic Model Assessment for Insulin 
Resistance [HOMA-IR] levels, 15.08±1.64 vs. l.0±0.12, P<0.05). Pancreatic ~-cell 
function, as measured by HOMA-~, was lower :in the CORT-HFD group as compared to 
the CORT-SD group (1.64±0.22 vs. 3.72±0.64, P<0.001) as well as acute insulin 
response (0.25±0.22 vs. 1.68±0.41, P<0.05). Moreover, ~- and a-cell mass were 2.6- and 
1.6-fold higher, respectively, in CORT-HFD animals compared to controls (both P<0.05). 
CORT treatment increased p-protein kinase Ca content in SD but in not HFD-fed rats, 
suggesting that a HFD may lower insulin secretory capacity via impaired glucose sensing. 
Isolated islets from CORT-HFD animals secreted more insulin in both low and high 
glucose conditions; however, total insulin content was relatively depleted after glucose 
challenge. Thus, CORT and HFD, synergistically not independently, act to promote 
severe insulin resistance, which overwhelms islet adaptive capacity, thereby resulting in 
overt hyperglycemia. 
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Introduction 
Exogenous glucocorticoids (GCs) can have acute beneficial outcomes for the 
treatment of some inflammatory conditions (325), however they are associated with 
widespread metabolic effects that have the potential to deteriorate glucose homeostasis. 
Acutely, GCs lower skeletal muscle glucose transport (151) and increase hepatic glucose 
production (326). Chronically, GCs promote increases in visceral adiposity and excess 
ectopic lipid deposition (110). Not surprisingly, therefore, prolonged GC treatment is 
associated with an elevated risk for the development of type 2 diabetes (T2DM) in 
humans, although the exact prevalence of GC-induced diabetes in humans is unknown 
(145). Synthetic GC treatment, such as those given prednisolone treatment, for 2 days 
(327), 2 weeks (156), as well as 3 months (146), demonstrates impaired first-phase 
insulin response and action. Thus, GCs can indilrectly pose major stress on pancreatic islet 
function by dramatically increasing insulin secretory demand (15). Whether GCs cause 
any direct effects on islet function remains unclear; however, some evidence suggests 
both enhanced (153, 155) and impaired (161, 166) insulin secretion depending on the 
duration of exposure and experimental models used (3, 162, 165, 166). Short-term GC 
treatment (1-6 h) to isolated islets from lean rodents has been shown to blunt the first-
phase and delay the second-phase insulin response thereby reducing the islet insulin 
response to glucose challenge (3, 161). However, long-term GC exposure (-2 wk of 
dexamethasone treatment in rats) is associated with increased insulin release with glucose 
challenge in vitro (167). Together, these results display the vast conflicting observations 
with respect to GC exposure and islet function. 
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In addition to peripheral insulin resistance, GC therapy induces elevations in free 
fatty acids (FF As) along with increased food consumption and the preference for energy-
dense foods (110). Elevations in lipids have long been known to induce ~-cell 
dysfunction in vivo and in vitro-a phenomenon known as lipotoxicity (177) whereby 
chronically high levels of FF As lead to a decrease in insulin secretion along with lower 
insulin gene expression (180). However, in vivo rodent models of high-fat diet (HFD) 
have not consistently demonstrated impairments of ~-cell function (140). 
Although GCs and FF As are often elevated with obesity, pre-diabetes, and 
diabetes, rarely have the independent and synergistic effects of these environments been 
studied in combination on islet function. Recently, we developed a rodent model of GC-
induced diabetes in young male Sprague-Dawley rats, showing that a diabetic phenotype 
can be rapidly induced when animals are exposed to elevations in exogenous 
corticosterone (CORT), the active GC in rodents:, and a HFD (328). The aim ofthis study 
was to examine the in vivo and ex vivo islet adaptations that result from this model of 
diabetes and test the hypothesis that elevated GC exposure in combination with a HFD 
exceeds the adaptive capacity of the islets to maintain glucose homeostasis. We 
demonstrate here that short-term (- 2 wk) administration of CORT and a HFD results in 
hyperglycemia despite increases in ~-cell mass, largely because of severe whole-body 
insulin resistance and impaired islet glucose sensitivity. 
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Methods 
Ethics statement 
All experiments were approved by the York University Animal Care Committee 
in accordance with the Canadian Council for Animal Care guidelines. 
Animal characteristics, surgical procedures, and design 
Male Sprague-Dawley rats (225-250 g, 6 wk post weaned; Charles River 
Laboratories, St. Constant, Quebec, Canada) were divided into 4 treatment groups (N=lO 
per group). Each rat 
received subcutaneous implantation of either CORT pellets (4 x 100 mg; C2505; Sigma, 
Oakville, Canada) or wax pellets, as previously described (328), so that 4 groups existed: 
wax pellet treatment fed a standard diet (placebo-SD; controls); CORT pellet treatment 
fed a standard chow diet (CORT-SD); wax pellet treatment fed a HFD (placebo-RFD); 
and CORT pellet treatment fed a high-fat diet (CORT-HFD). All animals were 
individually housed (lights on 12 h: lights off 12-h cycle) after 1 week of acclimatization 
and given their respective diets immediately following surgery. CORT was sampled on 
the evening of the sixth day after pellet implantation via tail nick from each rat at 2000 h 
and again 12 h later (0800 h). These samples were later analyzed for CORT levels using a 
RIA kit (MP Biomedical, Solon, Ohio). Blood glucose values were also measured on day 
6 (fed state) via a handheld blood glucose meter (Bayer, Contour, 
New York). 
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Diet specifications 
Standard diet (SD) (Purina Lab diet, 50Jl2, St Louis, Missouri) or a HFD 
(TD.06414; Harlan Laboratories, Madison, Wisconsin) was provided ad libitum 
following recovery from pellet implant surgeries. The HFD consisted of 5.1 kcal/g and 
the SD consisted of 3.4 kcal/g. Total fat content (60% of total calories) of the HFD was 
composed of 3 7% saturated fats, 4 7% monounsaturated fats, and 16% polyunsaturated 
fats. 
Plasma analyses 
Animals were administered an oral glucose tolerance test (OGTT; 1.5 g/kg body 
mass) on day 12 and an insulin tolerance test (ITT) on day 16 by i.p. insulin injection, as 
previously described (328). Capillary blood glucose concentration was measured by a 
handheld glucometer and blood samples from tail nick were collected in EDT A-coated 
microvette tubes, and plasma was subsequently analyzed for insulin (~SKR020; Crystal 
Chem, Downers Grove, Illinois) and FFA levels (NEFA kit, HR Series NEFA-HR; Wako 
Chemicals, Richmond, Virginia). Glucose and insulin area under the curve (AUC) were 
measured by each individual's fasting glucose and insulin levels. For technical and 
experimental reasons, the day of termination ranged from 2 to 5 days after the ITT to 
allow for subsequent islet isolation studies and trunk blood was collected for hormone 
analysis. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) was 
calculated based on the following equation: Glucose (mM) X Insulin(µ units x L)/22.5. 
Homeostatic Model Assessment for P-cells (HOMA-P) was calculated based on the 
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following equation: 20 X Insulin(µ units x L)/ Glucose (mM) 3.5, according to Kiraly et 
al (144). 
Assessment of islet morphology 
Immunohistochemistry 
The entire pancreas was extracted upon euthanization and immersed in 10% 
buffered Formalin or 4% paraformaldehyde (Sigma) for up to 48 hours. Tissues were 
washed in 70% ethanol, embedded in paraffin, and later serial sectioned onto slides. A 
random selection of slides from each group was dewaxed in xylene, dehydrated in 
ethanol, and washed in PBS. Antigen unmasking/epitope retrieval was performed by 
high-pressurized heat in a 10 mM solution of sodium citrate buffer, pH 6.0. Slides were 
incubated in a protein blocking solution (Signet) and then probed for insulin (1 :500, 
guinea pig; Dako, Burlington, Ontario, Canada) and glucagon (1 :200, rabbit, Cell 
Signaling, no. 2760, Boston, Massachusetts; New England Biolabs, Whitby, Ontario, 
Canada) and proliferating cell nuclear antigen (PCNA) (1 :4000, mouse; Cell Signaling 
no. 2586). After an overnight incubation at 4°C, slides were immunostained with a 
secondary antibody ofbiotinylated goat antiguim:a pig (Vector LabsBAlOOO, Burlington, 
Ontario, Canada at 1 :500 dilutions), antirabbit (Vector LabsBA 7000at 1 :500 dilutions), 
and antimouse (Vector Labs BA9200 at 1 :500 dilutions) for insulin, glucagon, and 
PCNA, respectively. A labeling reagent (Ultrastrt:ptavidin horseradish peroxidase, 
Convance Signet SIG-32242-95, Princeton,New Jersey) and diaminobenzadine (Sigma) 
were applied to slides until brown staining was visible. Slides were counterstained in 
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hematoxylin (Sigma, Canada). Representative slides of insulin and gfocagon were used 
for measurements of P- and a-cell mass, islet areas, P-cell number, and P- and a-cell size. 
Terminal transferase-mediated dUTP-digoxigenin nick end-labeling (TUNEL) staining 
protocols were performed by the University Health Network group at Toronto General 
Hospital. 
Quantification of P-cell mass, islet area, a-celll size, and number of P-cells per islet 
Estimated P-cell mass per animal was measured as the product of the total cross-
sectional area of insulin-positive stained P-cells divided by total tissue area and 
multiplied by mass of the isolated pancreas (mg} at euthanization. On average, 1000 to 
1500 islets were analyzed per group at 20 x magnification. Tissue areas were objectively 
quantified, using a positive pixel count algorithm, representing the insulin-positive areas 
with slide scanner software (Aperio Scanscope CS, Vista, California). The sum of the 
positive and strong positive pixel areas for each pancreas section was chosen as the best 
representation of positive insulin stained areas. 
All islets were individually circled around the positively insulin-stained cells and 
were regarded as the total insulin-positive stained. areas using a positive pixel count 
algorithm as previously described. The number of islets per squared millimetre was 
determined by adding the number of counted islets per slide and then dividing by the total 
tissue stained area. Islet areas (µm2) were found by adding together the total islet areas 
and dividing by the total number of islets per slide:. To quantify the size of the individual 
P-cells per islet area, all distinct nuclei surrounded by insulin-positive stained areas were 
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counted as a P-cell within each islet. Then the insulin-stained area on each slide (sum of 
P-cell area, µm2) was divided by the total number of P-cells counted on each slide to 
determine P-cell size. This analysis also allowed calculation of the number of P-cells per 
average islet by taking total islet areas and dividing by previously determined P-cell size. 
All of these methods were modified protocols from previously published reports by 
Kiraly et al (144) and Bates et al (329). Measurements of PCNA quantification, a-cell 
mass, area, size, and number of a-cell were quantified in a manner similar to insulin-
positive staining. 
Islet isolations and Western analysis 
Another set of identically treated animals ( 5-6 per group) were killed 18 to 21 
days after the start of treatment to examine ex vivo islet function and a similar protocol 
was used with modifications (330, 331). Collagenase solution (20 mL; 4.6 mg per 10 mL 
ofRPMI 1640 without glucose and glutathione [W'isent], 10 mM HEPES, 1 % penicillin-
streptomycin, glucose [50% dextrose]) was used to digest the pancreas for 20 minutes in 
a 3 7°C water bath with periodic agitation. RPMI buffer with 7% fetal bovine serum 
(FBS) was added to the digested pancreas and then shaken vigorously. Vials were 
centrifuged for 4 minutes at 1600 g at 4°C. The supernatant was discarded and RPMI 
with 7% FBS was added and gently shaken to dissolve the pellet. The new mixture was 
filtered through a mesh fabric (500 µm2 pore size) into a new conical tube. This new 
mixture was centrifuged for 4 minutes at 1200 g at 4 °C. The remaining pellet was 
suspended in Histopaque-1077 (H8889; Sigma, Canada) and topped off with a layer of 
RPMI without FBS. The mixture was centrifuged 25 minutes at 2700 g at 4°C. The 
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mixture was poured into a new conical tube and Kreb's buffer (125mMNaCl, 4.7mMKCl, 
1.2 mM, 5 mMNaHC03, 2.5mMCaC12, 2.4mMMgS04, lOmM HEPES, 0.5% BSA, pH 
7.4). The mixture was centrifuged 4 minutes at 1l400 g at 4°C. The remaining pellet was 
dissolved in Kreb's buffer and islets were selected and cultured in filtered RPMI buffer 
overnight (24 h) at 3 7°C, 5% C02 unless islets were used for western analysis at which 
point they were collected and stored at 80°C until further analysis. Fifty micrograms of 
protein were run on SDS-P AGE and proteins were transferred to a polyvinyldifluoride 
membrane and blocked in 10% powered milk and Tris-buffered saline with Tween20 for 
2 hours. Primary antibodies were protein kinase C (PKC; 5578, Cell Signaling at 1 :500 
dilution), phosphorylated-PKCa (sc-12356; Santa Cruz at 1: 1000 dilution), 11 ~­
hydroxysteroid dehydrogenase type 1 (11-HSDl, ab39364; Abeam at 1:500 dilution) and 
~-actin (ab6276; Abeam at 1 :20 000 dilution) were probed overnight at 4°C until the 
following morning when secondary antibodies w~~re added to membranes of either 
biotinylated antimouse or antirabbit (at 1: 10 000 dilution) were incubated for 1 hour at 
room temperature and then washed and imaged. Membranes that were probed with p-
PKC antibody were then stripped, blocked, and reprobed with PKC antibody overnight 
and incubated in secondary antibodies for 1 hour, washed, and then imaged. Images were 
detected on a Kodak In vivo FX Pro imager and molecular imaging software (Carestream 
Image MI SE, version S.0.2.3.0, Rochester, New York) was used to quantify protein 
content. 
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Glucose-stimulated insulin secretion (GSIS) and insulin content measurements 
Islets were separated into a 12-well culture plate (6-10 islets/well in 3 batches) 
and given a pre-incubation period for 30 minutes in Kreb's buffer 0.1 mM glucose 0.1 % 
BSA dissolved in Kreb's buffer. Media were flushed and islets were given fresh Kreb's 
buffer with 2.8 mM glucose 0.1% BSA for 1 hour at 37°C, 5% C02. Media were changed 
to Kreb's buffer with 16.7 mM glucose 0.1 % BSA for 1 hour at 37°C, 5% C02. 
Immediately following each incubation period:, media collected were spun at 5000 rpm at 
4°C for 10 minutes and frozen at 20°C for further analysis. Islets were placed in lmL 
cold lysis buffer (acid-ethanol solution), sonicated (15 s ), and centrifuged at 14 500 rpm 
at 4 °C for 10 minutes. Supernatant was collected and stored at 20°C until further analysis 
of insulin content. Insulin was measured using an RIA kit (Millipore, Billerica, 
Massachusetts). 
Statistical analyses 
All data are represented as mean± SE, with a criterion of P<0.05 and P<0.001, 
and were assessed using one-way and two-way ANOVAs as means of statistical 
significance except for determination of pellet mass differences between CORT treatment 
groups and acute insulin response (AIR) between placebo-SD and CORT-RFD where an 
unpaired Student's t test was used. Individual differences were evaluated using Tukey's 
HSD post hoc test (Statistica 6.0 software), with adjustments made for multiple 
comparisons. In each figure different letters denote statistical significance between 
groups. All fold differences are expressed as relative to the placebo-SD group. 
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Results 
Exogenous CORT increases plasma CORT and abolishes diurnal rhythm 
After 2 weeks of pellet implantation (at the time of euthanization), there were no 
significant differences found in the pellet mass excised from CORT-SD and CORT-HFD 
animals (Table 1), thereby suggesting that CORT absorption was not influenced by 
dietary treatment. CORT levels were higher at peak (2000 h) than at trough (0800 h) in 
placebo-treated animals 2 weeks after pellet implantation (Table 1). In contrast, CORT-
treated animals had elevated basal CORT values that were indistinguishable from peak 
concentrations. Left and right adrenals were,...., 50% smaller in CORT-treated animals 
compared to the two placebo groups, confirming that the exogenous CORT promoted 
feedback inhibition of ACTH release (P<0.05, Table 1). CORT treatment decreases lean 
mass, increases adipose tissue mass, and promotes hyperglycemia. All groups were 
similar in body mass prior to treatment (day 0). Six days following CORT implantations, 
CORT treated animals were smaller in mass compared to placebo-treated animals 
(P<0.05, Table 2). Relative food intake was increased in CORT-HFD animals compared 
to placebo-RFD at day 6 (P<0.05, Table 2). HFD resulted in greater epididymal fat pad 
mass compared to placebo-SD animals, with the greatest increase observed in the CORT-
HFD group (P<0.05, Table 2). Both CORT-treated groups had elevated fed blood glucose 
levels relative to the placebo groups on day 6 (main effect of treatment, P<0.05). Non-
esterified fatty acids were elevated in all treatment groups compared to placebo-SD, but 
were highest in the CORT-HFD group (P<0.05:, Table 2). 
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Severe glucose intolerance and hyperinsulintemia were induced with CORT-HFD 
treatment 
Fasting blood glucose levels were the highest in CORT-HFD animals, whereas all 
other treatment groups had similar fasting glucose levels (P<0.05, Figure IA). Glucose 
AUC during an OGTTwas also highest in CORT-HFD animals compared to all other 
groups (P<0.05; Figure IA'). Fasting insulin levels were highest in CORT-HFD animals 
compared to all other treatment groups (P<0.05; Figure IB). Insulin AUC was higher in 
CORT-SD than in the controls and CORT-HFD animals (P<0.05; Figure IB'). AIR is 
thought to be an early defect in the course of diabetes development and this response can 
be estimated as the change in insulin levels dur:ing the first I 5 minutes following oral 
glucose gavage in rats (I9I). CORT-HFD animals demonstrated lower AIR compared to 
CORT-SD and placebo-SD and placebo-RFD groups (P<0.05, Figure IC). Figure ID 
demonstrates the relationship between fasting glycemia and insulin levels in each of the 
treatment groups, indicating that higher glucose concentrations were associated with 
increased insulin levels (r2=0.42, P<0.05). This regression is based on all groups plotted 
on the same graph; independently the linear regressions are as follows: placebo-SD, 
r
2
=0.005, CORT-SD, r2=0.003, placebo-RFD, r2=0.04, and CORT-HFD, r2=0.02 (not 
statistically significant, independently). HOMA-IR index indicated that CORT-HFD 
animals were,...., 15-fold more insulin resistant than placebo-SD and,...., 4-fold more insulin 
resistant than CORT-SD rats (Figure 2A; P<0.05). HOMA-B, a measure of B-cell 
function, was elevated in the CORT-SD group by 3.5-fold compared to the placebo-SD 
group (Figure 2B, P<0.05). In contrast, the CORT-HFD group had a 2-fold lower 
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HOMA-P compared to the CORT-SD, suggesting the addition of a HFD reduced P-cell 
function. Following an i.p. insulin injection to assess insulin sensitivity, the CORT-HFD 
group continued to have elevated blood glucose levels compared to all other groups 
(P<0.05, Figure 2C). CORT-HFD animal's maintained 2-fold higher glucose AUC levels 
than all other treatment groups (Figure 2C'). 
CORT and HFD induce islet hyperplasia and hypertrophy 
Islet morphology was investigated by insulin, glucagon, TUNEL, and PCNA-
positive staining (Figure 3, A-P). Compared to placebo-SD rats, both HFD- and CORT-
treated rats had a lower degree of apoptosis as measured by TUNEL staining (placebo-
SD, 0.16 ± 0.18; CORT-SD, 0.064 ± 0.08; plac,ebo-HFD, 0.1±0.1; CORT-HFD, 0.03 ± 
0.03 divide values by 103; (Figure 3, I-L). PCNA, a marker of cell replication and islet 
proliferation (332) , was up-regulated in all CORT-treated animals relative to placebo 
groups, thus demonstrating increased-cell proliferation (placebo-SD, 100.0 ±9.l; CORT-
SD, 288.5 ± 9.8; placebo-RFD, 74.6 ± 21.5; CORT-HFD, 337 ± 116.2; Figure 3, M-P). 
Insulin-positive staining measured as P-cell mass revealed a 2.6-fold greater mass in the 
CORT-HFD group compared to placebo-SD controls (Figure 4A; P <0.05), whereas 
CORT-SD treatment resulted in a 1.8-fold increase in p-cell mass. To determine if 
increased P-cell mass was a reflection of changes in islet morphology, the number of 
islets per squared millimeter of analyzed tissue was measured and found to increase with 
CORT-HFD treatment compared to all treatment groups (Figure 4B; P<0.05). CORT 
treatment resulted in larger islet area with a greater number of smaller P-cells as 
compared to placebo controls (Figure 4, C, D, and F; P<0.001). Islets were also grouped 
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into various size groupings to demonstrate the differences in islet size distributions 
(Figure 4E). CORT treatment resulted in,...., 20% fewer islets in the smallest size group 
(<5000 µm2) and,...., 15% more islets in the largest size group (15 000 + µm2) compared to 
placebo-treated animals, regardless of diet. Plasma glucagon levels were elevated in 
CORT-RFD animals compared to placebo-SD (P<0.05; Figure 5A). In addition, the 
CORT-HFD group had the largest a-cell mass and size (µm2) compared to all other 
treatment groups (Figure 5, Band C; P<0.05), indicating a-cell hypertrophy. 
CORT treatment increases P-cell secretory capacity 
It has been previously reported that PKCa. plays an essential role in the insulin 
secretory process and its dysfunction may contribute to hyperglycemia in GC-treated 
rodents (2). Protein content of total PKCa. normalized to ~-actin was more highly 
expressed in islets treated with CORT regardless of diet (Figure 6A; P<0.05), suggesting 
that CORT treatment increases total PKCa. expn~ssion, perhaps as a result of increased~­
cell proliferation. Protein content for p-PKCa. normalized to ~-actin was up-regulated in 
the islets derived from CORT-SD, but not in CORT-HFD, rats compared to the islets 
from the placebo-SD rats (Figure 6B; P<0.05). 
CORT treatment increases islet llp-hydroxysteroid dehydrogenase type 1 (llP-
HSDl) expression 
The activity of tissue-specific 11~-HSDl manipulates the level of active CORT in 
various organs in the body (290). Moreover, this enzyme has been shown to decrease 
GSIS in pancreatic murine and human islets (333), potentially contributing to diabetes 
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development (176). Therefore, we assessed the protein content of 11~-HSDl to 
determine a functional relationship between insulin secretion and active GC regeneration 
in the islets. The protein content of 11~-HSDl was up-regulated in the islets from CORT-
treated animals compared to placebo treated groups, regardless of diet (Figure 7; P<0.05). 
CORT-RFD isolated islets exhibit enhanced insulin responses to glucose 
To determine ex vivo ~-cell function, islets were isolated from all treatment 
groups, stabilized in culture, and then subjectedl to low and high concentrations of glucose 
(2.8 and 16.7 mM). CORT-HFD islets released more insulin than the islets from all other 
groups in both glucose conditions (Figure 8A; P<0.05), although the fold change in 
insulin secretion from the low-glucose to the high-glucose media was lowest in the 
placebo-HFD and CORT-HFD islets (Figure 8A'). Total insulin content was measured 
after the islets were exposed to high levels of glucose in all treatment groups. CORT-
HFD islets expressed the lowest levels of insulin content compared to all other treatment 
groups (Figure 8B; P<0.05), possibly indicating a greater depletion of insulin in response 
to high glucose in the media. 
Discussion 
Exogenous GCs cause insulin resistance and may promote diabetes development 
(334). A HFD in conjunction with exogenous GCs may increase diabetes risk, although 
few studies have investigated the amalgamation of these treatments. In this study, we 
show that the combination of CORT and a HFD results in severe insulin resistance with 
~-cell proliferation that promotes fasting hyperinsulinemia, but this adaptation is 
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insufficient to maintain glucose homeostasis, particularly in response to an oral glucose 
challenge. We also show that, at least in the short term, ~-cell apoptosis is not increased 
with CORT and a HFD, but impairment in ~-cell glucose sensing in vivo, likely as a 
result of chronic hyperglycemia and profound xnsulin resistance that overwhelms insulin 
secretory capacity. Although a number of previous studies have investigated the 
physiological adaptations to HFD (reviewed in Ref. (140)) and exogenous CORT 
treatment alone (2, 153, 161, 166, 335, 336), we are aware of only one other study that 
has combined the two to examine potential synergistic effects on islet function and 
diabetes development (191). In that investigation, dexamethasone ("' 100 µg kg-1 body 
weight dai1; 5 d) and a HFD acted synergistically to induce glucose intolerance by 
impairing GSIS in vivo, similar to our findings (Figure 1). Moreover, short-term GC 
treatment (1-6 h) to isolated islets from lean rodents has been shown to blunt the first-
phase and delay the second phase insulin response (3, 161). In contrast to these in vivo 
and ex vivo findings, previous studies conducted in various rodent models have 
demonstrated that prolonged GC exposure (equal to or longer than 5 d) increases GSIS 
(151, 153, 167, 191). Interestingly, and similar to our observations, GCs administered to 
healthy men cause impairments in several ~-celll insulin secretory pathways and has been 
shown to inhibit the normal insulin response (156). Moreover, first-degree relatives of 
patients with T2DM who are treated with corticosteroids develop severe insulin 
resistance and may develop impaired glucose tolerance, depending on their islet function 
(170). Thus we conclude that in our model there is detriment to ~-cell function by placing 
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severe demands on insulin requirements in a fasted state and a blunted capacity to 
respond to glucose challenge. 
As expected, based on our previous study (328), we found that exogenous GCs 
promote hyperinsulinemia, in both the fasted and the fed state (OGTT) (Figure lA and 
Table 2), but that the addition of a RFD markedly increases glucose intolerance and 
prevents the appropriate insulin response to a glucose challenge (Figure 1,A'and B'). In a 
previously mentioned study (191), dexamethasone and a RFD precipitated glucose 
intolerance in rats by impairing the negative feedback loop between insulin sensitivity 
and secretion. Similarly, our study demonstrates the rapid onset of overt diabetes that 
occurs within 1 to 2 weeks and with no evidence of ~-cell mass decompensation but with 
obvious impairments in insulin responsiveness to oral glucose challenge (Figure lB'). 
Indeed, CORT-RFD animals demonstrate impaired first-phase insulin response during 
glucose challenge as measured by the acute insulin response (Figure 1 C), suggestive of 
impaired glucose sensitivity in vivo. On the other hand, it is unlikely 2 weeks of CORT-
RFD treatment resulted in complete destruction of ~-cell insulin secretion and more 
likely that the rise in hyperglycemia/hyperinsulinemia was driven by increased peripheral 
insulin resistance. 
Separately, both elevated CORT and a HFD increase peripheral and islet insulin 
resistance (140, 152), reduce insulin-mediated glucose disposal, and lower muscle 
glycogen synthesis (337, 338). We found a mode:st association between fasted glucose 
and insulin levels (r2=0.42, Figure lD), thereby suggesting that severe hepatic insulin 
resistance induces fasting hyperglycemia in CORT-RFD animals, as documented 
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previously (339). Indeed, this model of short-te:rm CORT treatment induced a,..., 5-fold 
increase in HOMA-IR compared to controls and the addition of a HFD exacerbated 
insulin resistance by,..., 15-fold compared to controls (Figure 2A). Therefore, the 
combination of the two treatments appears to be the driving force for elevated fasting 
glucose and insulin levels. To determine if CORT and HFD treatment affect P-cell 
function, a HOMA-P index was used. CORT-SD treated animals had improved P-cell 
function compared to all other treatment groups but the addition of HFD decreased P-cell 
function relative to CORT-SD animals, such that values were similar to what was 
observed in the placebo-treated groups (Figure 2B). One interpretation is that CORT-
HFD treated rats had normal ~-cell function, but were in an environment of severe insulin 
resistance that requires enhanced function. In addition to impairments in hepatic insulin 
sensitivity and possibly P-cell function, our model demonstrates decreases in skeletal 
muscle insulin-mediated glucose uptake, as evidenced by poor glucose responsiveness to 
exogenous insulin challenge (Figure 2C and C'). Together, these results show that 
elevations in CORT and HFD induce severe peripheral insulin resistance, reflected by 
direct and indirect effects on the liver, skeletal muscle, and P-cell function, which 
represents characteristics similar to those with Cushing's syndrome or with GC-induced 
diabetes (151, 170). 
A HFD given to rodents has been shown to up-regulate islet mass due to an 
increase in compensatory P- and a-cell mass ( 49). However, prolonged elevation in FF As 
results in ~-cell death (340) and can cause the accumulation of ceramides that impair 
insulin processing (i.e., irregular folding of the insulin peptide) (180) and transcription 
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(185). However, we found no evidence that HFD and CORT caused increased ~-cell 
death, at least in the short term (Figure 3, 1-L), but that this treatment significantly 
increases islet areas through increased~- and a··cell mass (Figure 3, A-H). PCNA 
staining was significantly up-regulated in the CORT-treated animals, suggestive that 
proliferation was increased in response to the insulin resistance (Figure 3, M-P). 
However, despite the fact that there is clear evidence of islet adaptation to CORT-HFD 
treatment, these islets are still unable to maintain euglycemia, even in the fasted state. 
Very few studies have examined the effocts of HFD and/or short-term CORT 
treatment on glucagon secretion. Interestingly, fasting plasma glucagon increases after 
dexamethasone treatment in insulin-resistant first-degree relatives of patients with T2DM 
(170). We demonstrate here that circulating plasma glucagon levels are increased with 
CORT and HFD (Figure SA), along with increases in a-cell mass (Figure 5, B and C), 
which likely further exacerbates hyperglycemia. We found that a-cell mass is up-
regulated in CORT-RFD-treated rats primarily as a result of increased a-cell hypertrophy, 
as there was no change found in a-cell number, but the treatment induced increased a-cell 
size. Early stages of diabetes are associated with a-cell dysfunction as glucagon is 
secreted at abnormally high levels during an oral glucose challenge (171) and a-cell mass 
increases linearly with a rise in peripheral insulin resistance (172). Although the 
mechanisms for increased a-cell mass with CORT treatment are unknown, it may be an 
additional diabetogenic feature of the combination of exogenous CORT and HFD 
treatment. 
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There are several crucial elements involved in the insulin secretory system (341 ), 
such as PKC, which is an important regulatory enzyme involved in insulin secretion by 
activating the movement of ~-cell insulin granules for exocytosis (342-345). GC 
administration in rats, results in an up-regulation of the PKC activation pathway, induced 
by increased Ca +2 release from intracellular stores, thereby leading to increased insulin 
secretion (2). Similar to previous findings by Rafacho et al (2), we demonstrate here that 
GCs in combination with a SD increases both total PKC expression and islet p-PKCa 
content (Figure 6). However, unique to our study, we show that the addition of HFD with 
CORT administration decreases islet p-PKCa content compared to CORT-SD animals. 
As previously described (346), chronic high glucose impairs normal PKC 
phosphorylation, thought to induce islet desensitization, thereby limiting insulin 
secretion. Furthermore, a study in the GK rat, which spontaneously develops impaired ~ 
cell function, suggests impairments in PKC activation (347). Thus, we speculate that at 
least a part of the impaired insulin response in the AIR of CORT-HFD animals may result 
because of reduced PKC activation, partly due to sustained hyperglycemia, although it 
should be noted that PKC regulation is not the only potential mechanism involved in 
insulin secretion and therefore other key regulatory proteins may be at play. 
Elevated tissue GC excess, driven by increased levels of the intracellular GC 
regenerating enzyme 11~-HSD1 in adipose tissue:, liver, and skeletal muscle, is 
implicated in the development of insulin resistance (108). Elevated 11~-HSDl activity 
and/or expression is also found in pancreatic islets of obese/diabetic rodents (173) as well 
as lean mice treated with GCs (155), but the functional consequence of this increase is 
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unclear. It is proposed that the increase in GC reactivation caused by elevated 1 lP-HSDl 
activity suppress insulin secretion (173), thereby promoting diabetes development. 
Recently, however, the use of a P-cell specific 11P-HSD1 over expression model suggests 
that elevations in this pre-receptor enzyme actually improves insulin release mechanisms 
and protects against RFD-induced diabetes (175). In this study, we found that CORT 
treatment increases 1 lP-HSDl protein content in islets, independent of diet (Figure 7). 
These results are supported by previous work, showing that islets cultivated in the 
inactive GC (11-dehydrocorticosterone) results in a rapid doubling in 1 lP-HSDl protein 
(176) and provides further evidence that elevations in this enzyme may be a 
compensatory mechanism supporting insulin hypersecretion (155, 175). 
Elevated fatty acid exposure ( 48 h) leads: to the reduction of GSIS in vitro (348); 
however, in vivo GSIS reports are relatively inconsistent and may be due to variations on 
insulin sensitivity within individual islets (140) . Short-term CORT treatment has been 
shown to enhance insulin release in vivo (2) by up-regulating IRS-2 signaling pathway 
(154, 349). We exposed isolated islets to low- (2.8 mM) and high-glucose (16.7 mM) 
concentrations and found that islets derived from CORT-HFD animals had greater GSIS 
compared to all other groups (Figure 8A). This may be explained, however, by the greater 
P-cell mass in the CORT-treated animals. Moreover, CORT-HFD islets that were 
subjected to high glucose exposure ex vivo demonstrated lower total insulin storage 
compared to all other groups (Figure 8B) and this was likely due to increased insulin 
secretion during the glucose challenge. In addition, it should be noted that although 
CORT-HFD islets have higher insulin secretion in high glucose media, their relative fold 
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increase over that observed in the low glucose media is less than that observed in SD 
groups (Figure 8A'). These findings on isolated islets suggest that, although CORT-HFD-
treated animals are able to secrete high amounts of insulin in response to glucose in vivo, 
that ex vivo they do suggest some forms of islet desensitization to changes in glucose 
concentrations. 
Conclusions 
In summary, short-term exposure to CORT and a HFD play a synergistic role in 
the development of insulin resistance, ~-cell mass compensation, and relative fasting 
hyperinsulinemia. However, in vivo, insulin responsiveness is blunted following oral 
glucose load in CORT-HFD treated animals despite the increase in B-cell mass. These 
disturbances are associated with increases in circulating glucagon levels and islet 11 B-
HSD 1 protein expression. In contrast, ex vivo, islets derived from CORT-HFD animals 
exhibit an up-regulated absolute insulin response:, although the fold change from low-
glucose exposure is lower. Taken together, these results demonstrate that the combination 
of exogenous CORT treatment in conjunction with a HFD induces severe 
hyperinsulinemia/hyperglycemia as a result of whole-body insulin resistance, 
hyperglucagonemia, and an inappropriate responsiveness of ~-cells to glucose challenge. 
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Table 1. Plasma corticosterone levels (ng/ml), adrenal gland mass (mg/BW) and pellet weights 
(mg) after 2 weeks of treatment. 
Placebo-SD CORT-SD Placeb0'-HFD C(l)RT-HFD 
Pellet Mass NIA 76.42 :±: 3.1 NIA 6i7.52 ± 3.9 
Loss1 
AM PM AM PM AM PM AM 
Corticosterone 219±33 496±44** 637±54* 659±40* 208±44 606±53** 703±71* 
Left Right Left Right Left Right Left 
Adrenal mass 0.09±0.005 0.09±0.004 0.04±0.007# 0.03±0.01# 0.1±0.01 0.1±0.012 0.04±0.003# 
1Value shown is the estimated amount of CORT dissolved over 2 weeks. 
Note: *indicates statistical significance from placebo-SD (controls) during corresponding time points that 
corticosterone levels were measured (p<0.05). **indicates statistical significance between AM and PM 
corresponding corticosterone levels within each treatment group (p<0.05). #indicates statistical significance 
of corresponding left and right adrenals from controls. BW=Body Weight. All values are mean± SE. 
Table 2. Animal body mass (g), average food consumption (kcal/g of BW)1, epididymal 
fat pad mass (g/BW), pancreas (g/BW), fed blood glucose (mM), non-esterified fatty 
acids (NEFAs, mM) at day 0 and day 6 after pellet implantation in controls (placebo-SD), 
CORT-SD, placebo-HFD and CORT-HFD rats. 
Placebo-SD CORT-SD Placebo-HFD CORT-HFD 
Da~ 0 6 0 6 0 6 0 6 
Body Mass 314±4.12 362±4.18 316±4.55 270±7.65*,# 313±2.82 366±2.82 310±3.74 271±7.62*,# 
Food NIA 0.42±0.0 NIA 0.52±0.03* NIA 0.35±0.01 * NIA 0.46±0.02*,# 
Consumed1 
Epididymal 
fat pad NIA 8.5±0.45 NIA 12.67±1. 12(• NIA 13.96±1. 76* NIA 22.45±1.76* ,$,# 
mass 
Pancreas NIA 3.15±0.37 NIA 4.15±0.45 NIA 3.27±0.34 NIA 3.59±0.55 
mass 
Fed blood 5.7±0.6 5.6±0.5 5.9±0.2 15.7±2.6*,# 5.8±0.3 6.0±0.1 5.8±0.2 19.2±1.7*,# 
glucose 
NEFA NIA 0.84±0.19 NIA 2.07±0.21* NIA 1.45±0.35* NIA 3.33±0.25*,S,# levels 
Note: The* indicates significance from placebo-SD (controls) on the same day (p<0.05). The$ indicates 
significance between CORT-SD and CORT-HFD. The# indicates significance from placebo-RFD. 
BW=Body Weight. 1Average food consumption measurements were taken every two days and the data 
represented in the table is that of a 24 hour period. All values are mean ± SE. 
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PM 
784±43* 
Right 
0.04±0.004# 
Figure Captions 
Fig. 1. Blood glucose levels (mM) (A) and plasma insulin levels (ng/mL) (B) after an oral 
glucose gavage. Glucose AUC (A=) and insulin AUC (B=) during an OGTT expressed in 
arbitrary units. N=7-10 for each group. AIR between basal and 15 minutes relative to 
placebo-SD (C) and fasting insulin (ng/ml) vs fasting blood glucose (mM) were anal!yzed 
by linear regression (r2=0.42) (D). N= 5-7 for each group. In all bar graphs, bars that do 
not share the same letters are statistically significant from each other (P<0.05; at test was 
used to measure significance between placebo·-SD and CORT-HFD in C). All values are 
means± SE. 
Fig. 2. Measurements of insulin resistance, ~-cell function, and insulin sensitivity. 
HOMA-IR index indicates whole-body insulin resistance (A) and HOMA-~ index 
indicates ~-cell function (D). Insulin sensitivity during an ip administered insulin 
tolerance test. Glucose (mM) levels after insulin injection (C) and glucose AUC (C=). 
N=9-10 for each group. In all graphs, bars that do not share the same letters are 
statistically significant from each other (P<0.05). All values are means± SE. Note that 
the closed triangles in C are obscured by the closed squares. 
Fig. 3. Images of islet morphology indicating insulin (A-D), glucagon (E-H), TUNEL 
(1-L), and PCNA (M-P) positive staining .. Arrows indicate apoptotic cells that are 
TUNEL positive. All images are 20 x magnification. 
Fig. 4. Insulin-positive staining indicates ~-ceH mass (A), number of islets per pancreas 
area (mm2) (B), islet area (µm2) (C), number of ~-cells per islet (D), percentage of islets 
per size grouping (µm2) (E), and ~-cell size (~tm2) (F). N= 6-7 per group. In all graphs, 
bars that do not share the same letters are statistically significant from each other (graph 
A-C and E, P<0.05, graph D and F, P<0.001). *,statistical significance where P<0.05. #, 
statistical significance where P<0.001 (E). All values are means± SE. 
Fig. 5. Fed plasma glucagon levels (A). Glucagon-positive staining indicates a-cell mass 
(B), a-cell size (µm2) (C). N=6 per group. In all graphs, bars that do not share the same 
letters are statistically significant from each other (P<0.05, graph A, P<0.001 ). All values 
are means ± SE. 
Fig. 6. Relative total PKCa content in isolate:d islets (A). Relative p-PKCa content in 
isolated islets (B). N=4-5 per group. All protein content was normalized to ~-actin 
content. In all graphs, bars that do not share the same letters are statistically significant 
from each other (P<0.05). All values are means± SE. 
Fig. 7. Relative 11~-HSDl protein content in isolated islets. All protein content was 
normalized to ~-actin content. N=4-6 per group. Bars that do not share the same letters 
are statistically significant from each other (P<0.05). All values are means± SE. 
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Fig. 8. Isolated islet GSIS, in 2.8 and 16.7 mM glucose (ng/mL/isle1t/h) (A). Fold change 
in insulin secretion from 2.8 mM (A'). Total insulin content (ng/ml) corrected by nu:tnber 
of islets from each treatment group (B). N=5-6 per group. In all graphs, bars that do not 
share the same letters are statistically significant from each other (P<0.05). All valuds are 
means± SE. 
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Figurel. Supplemental figure for mantuscript #1 demonstrating diurnal 
corticosterone levels in rats treated with wax (placebo) or corticosterone (200 or 400 
mg) pellet implants for a 14 day period (pilot data). Plasma corticosterone 
concentrations were measured at peak (8 PM) and trough (8 AM) in placebo-treated 
(wax), and in 200 mg corticosterone-treated or 400 mg corticosterone-treated rats. 400 
mg of corticosterone presented sustained abolishment of diurnal corticosterone pattern 
compared to 200 mg of corticosterone treatment. Therefore, this amount of corticosterone 
was selected as a means of ROD development. N=3 for each group. Values are means ± 
SE. 
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MANUSCRIPT-#3 Chapter 4 
Regular Exercise and Rapid-onset Diabetes Development in the Sprague-Dawley R..at 
Rationale for Manuscript #3 
Both manuscript # 1 and #2 highlighted the detrimental effects of elevated GCs 
concomitantly with HFD on whole-body physiology and islet adaptive capacity. 
Previously our laboratory has demonstrated that long-term regular exercise via voluntary 
wheel running restores alterations in HP A activation (220). Regular exercise has long 
been known to improve glucose tolerance and islet glucose sensitivity in healthy humans. 
Moreover, exercise has been shown to improve hyperglycemia/hyperinsulinemia and P-
cell dysfunction in ZDF rats by lowering hypercortisolemia (63, 144, 150). Regular 
exercise can reverse T2DM-like symptoms (255), however little is known about the effect 
of voluntary exercise on chronically elevated GCs concurrently with high-fat feeding. To 
date, there are very few studies investigating the effect of exercise and GC-induced 
T2DM. One study suggests that 8 weeks of exercise training via treadmill running 
attenuated dexamethasone-induced hyperglycemia, insulin resistance and muscular 
glycogen depletion (263). Therefore, our goal for manuscript #3 was to study the effects 
of volitional exercise on GC and RFD-induced diabetes. We hypothesized that voluntary 
wheel running ( 4 weeks) would improve glucose intolerance, whole-body insulin 
resistance, impaired islet glucose responsiveness in our model of ROD. 
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Abstract 
We have established a rapid-onset diabetic rodent model, induced by elevations in 
the stress hormone corticosterone (CORT) and a high-fat diet (HFD). Together, these 
treatments induce severe impaired insulin action and islet glucose responsiveness. 
Regular exercise alleviates insulin insensitivity and restores ~-cell function. We 
examined the effect of voluntary exercise (EX) on diabetes development in CORT and 
HFD treated male Sprague-Dawley rats(,...., 6 weeks old). Animals were acclimatized to 
running wheels for 2 weeks, then given either wax (placebo) or CORT pellets, a HFD and 
split into 4 groups; placebo-SED or -EX and CORT-SED or -EX. After an additional 2 
weeks of running combined with treatment, CORT-EX animals had reduced visceral 
adiposity, improved muscle composition and oxidative capacity compared to CORT-SED 
animals (p<0.05). CORT-EX animals had improved fasting glucose (14.3±1.6 vs. 
18.8±0.9 mM) and acute insulin response to glucose challenge(,...., 2-fold) compar~d to 
CORT-SED animals (p<0.05). CORT-EX animals had improved ~-cell function(,...., 2.5-
fold) and peripheral insulin sensitivity compared to CORT-SED animals (p<0.05). 
Glucose challenge administered to islets ex vivo showed that CORT-EX islets lower 
insulin secretion to levels almost comparable to placebo-SED islets. We conclude that EX 
improves overall body composition (but not body mass) and metabolic profile of animals 
administered CORT and HFD by reducing glucose intolerance, insulin insensitivity, 
impaired islet responsiveness and improving muscle oxidative capacity. These results 
suggest that the detrimental effects of elevations in GCs and circulating fatty acids may 
be lessened with regular exercise, even in situations of hypercortisolemia. 
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Introduction 
The stress response triggers the hypothalamic-pituitary-adrenal (HP A) axis 
resulting in the downstream secretion of glucocorticoids (GCs). This signal helps to 
mobilize fuel substrates needed to meet the metabolic demands of the body. In the short-
term, activation of GCs is ideal in situations of physical activity however, prolonged 
stimulation of the HPA axis can present major physiological consequences to the body. 
Chronic elevation in GCs, as seen in patients with Cushing's syndrome, can induce many 
metabolic disturbances such as increased visceral adiposity (110), peripheral insulin 
resistance (135), non-alcoholic fatty liver disease (339), and impaired islet function (350), 
all of which are major risk factors that augment the possibility of the development of type 
2 diabetes (T2DM) (145). Rodent (63, 144) andl human (145, 351, 352) studies of T2DM 
also demonstrate elevated HP A axis activity suggesting links between raised GC 
concentrations and disease progression. 
Rodent models ofT2DM such as the ZDF rat, which spontaneously develops 
hyperglycemia/hyperinsulinemia at,...., 12 weeks of age, help to study links between HPA 
axis activity and diabetes development. Our previous research shows that elevations in 
HP A axis activity precedes symptoms of diabetes, as ZDF rats develop hypercortisolemia 
at,...., 3 weeks into the experimental protocol (63, 144) while hyperglycemia and glucose 
intolerance is not evident,...., week 7. These ZDF model studies provide strong evidence 
that there is an association with the initial elevation of GCs and the onset of diabetes. 
It is important to note that not all activators of HP A axis can promote adverse 
metabolic effects. Physical activity, by definition, is considered a physiological 'stressor' 
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that can disrupt the homeostatic balance of energy dynamics within the body (353). If 
exercise is not performed regularly, physical inactivity can be a major contributor to the 
development of many cardio-metabolic diseases, especially T2DM (28, 247-249, 354). 
Endurance exercise is an excellent stimulator of the HPA axis in rodents (197, 219, 220, 
355) and in humans (64, 356, 357) and this subsequent GC secretion is relatable to 
exercise intensity (358). However, volitional exercise such as wheel running in healthy 
rodents does not continually increase HP A activity as GCs return to basal levels just 
weeks after initiation (200, 220, 355). In addition, lower GCs are found in ZDF rats 
within 5 weeks of non-volitional swimming exercise (63, 144, 213) and as early as 3 
weeks with voluntary wheel running (63, 150) compared to inactive controls. These 
studies in ZDF rats and exercise also show many positive effects on diabetes prevention 
that demonstrate how exercise can restore glycemic control, preserve ~-cell mass (144), 
improve ~-cell dysfunction and increase islet insulin stores (150). Although exercise in its 
various forms can reverse T2DM-like symptoms in part by lowering circulating GCs, 
little is known about the effect of voluntary exercise on a model of chronically elevated 
GCs, such as Cushing' s syndrome. In fact, there are no studies to date specifically 
investigating any type of exercise and Cushing' s syndrome. These studies are imperative 
as it is unclear whether exercise improves insulin sensitivity and glucose homeostasis by 
lowering circulating GCs as is seen with volitional or non-volitional exercise in ZDF rats. 
Or rather if exercise works independently of circulating GCs to improve muscle insulin 
action and pancreatic islet function. 
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Recently, our laboratory has developed an animal model of rapid-onset diabetes 
induced through elevated levels of corticosterone, (CORT, active GC in rodents) and a 
high fat diet (60% calories from fat) (RFD) (328, 350). We have established that 
elevations in CORT and a RFD result in severe hyperglycemia and hyperglucagonemia, 
despite hyperinsulinemia and increased ~-cell mass, largely due to extreme whole-body 
insulin insensitivity and impaired islet glucose responsiveness. Voluntary exercise is 
known to normalize glucose tolerance and islet glucose sensitivity (15) through up-
regulated mechanisms of skeletal muscle glucose uptake, i.e. GLUT4 translocation (28, 
151, 359), oxidative capacity (360) and pancreatic islet function (150). Therefore, we 
hypothesize that voluntary exercise will alleviate hyperglycemia, insulin resistance and 
preserve ~-cell function in our model of elevated GCs and RFD. The aim of our study is 
to investigate the role of volitional exercise on 1 )l whole-body glucose homeostasis, 2) 
islet responsiveness and glucose sensitivity, 3) adaptive peripheral tissue function, i.e. 
islet insulin secretion and skeletal muscle oxidative capacity, in our model of elevated 
levels of CORT and RFD. 
Methods 
Animals: Approximately 40 male Spragm:-Dawley rats (Charles River 
Laboratories, initial mass of 225-250 g, six weeks post-weaned) were individually housed 
(lights on 12 h: lights off 12 h cycle) after one week of acclimatization to room 
temperature (22-23°C) and humidity (50-60%) controlled facilities. Animals were 
divided into four experimental groups that consisted of two sets of sedentary (SED) and 
two sets of exercise-trained (EX) animals. 
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Experimental Design: After the acclimation period each exercising animal was placed 
into a standard rodent cage and given 24 h access to a standard running wheel (Harvard 
Apparatus). Each wheel was equipped with a magnet and sensor that was wired to an 
electronic counter. Wheel revolutions were cow1ted each time the magnet passed the 
sensor and the numbers on the counters were recorded and reset to zero daily. The wheel 
revolutions were multiplied by the wheel circumference (106 cm) to accurately calculate 
the running distance of each animal (previously reported in (220)). SED animals were 
housed in similarly sized cages as EX animals but without access to a running wheel. 
During the two weeks of wheel introduction, animals were given standard rodent chow 
(Purina) and water ad libitum. 
Pellet Surgeries: Upon surgery day (day 14), each rat received a subcutaneous 
implantation of either corticosterone (CORT) pelllets (4 x 100 mg; Sigma, Burlington, 
Ontario, Canada, Cat# C2505) or wax (placebo) pellets, as previously described (328). 
Immediately following surgery all rats were placed into sterile cages without running 
wheels for 24 h to recover and were given ad libi'tum access to a high-fat diet (HFD). 
This diet consisted of 60% of the total calories from fat and 5.1 kcal per gram (Dl2492, 
Research diets); this diet was maintained to the end of the experimental protocol and all 
animals received the same diet. The final four experimental groups consisted of two sets 
of EX animals; one group received wax pellets (placebo-EX) and the other group 
received CORT pellets (CORT-EX) and two sets of SED animals; one group received 
wax pellets (placebo-SED) and the other group received CORT pellets (CORT-SED). 
This study was carried out in accordance with the recommendations of the Canadian 
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Council for Animal Care guidelines and was approved by the York University Animal 
Care Committee. 
CORT sampling: On day 21 at approximately 0800 h blood samples were 
collected from each animal via saphenous vein for CORT concentration measurements. A 
small area of hair on the lateral upper hindlimb was removed with an electric razor and 
wiped with a thin layer of petroleum jelly. Once the saphenous vein was located, a sterile 
25-gauge needle was used to puncture the vein and whole blood was collected in lithium-
heparin coated microvette capillary tubes (Sarst{:dt, Montreal, Quebec, Canada, Cat# 
16.443.100) and centrifuged at 12,000 rpm for 5 minutes, transferred into polyethylene 
tubes and stored at -80°C until further analysis of CORT concentrations using a 
radioimmunoassay kit (MP Biomedical, Solon, OH, USA). Fed blood glucose 
concentrations (mM) were measured on day 21 using a single drop of blood (2 µl) with a 
handheld glucometer (Bayer Contour, Rochester:, NY, USA), after blood was collected 
for CORT measurements. This sampling was repeated on day 28 so that CORT 
concentrations could be assessed two weeks after pellets were implanted. 
Oral glucose and intraperitoneal insulin tolerance test: As previously described 
in (328) animals were fasted overnight (16 h) and were administered an oral glucose 
tolerance test (OGTT, 1.5 g/kg body mass) on dlay 26. Each animal's basal blood glucose 
(fasting, time 0) was measured via saphenous vein using a glucometer and collected for 
later analysis of plasma insulin concentrations via ELISA 96-well kit (Crystal Chem, 
Downers Grove, IL, USA, Cat# 90060). Blood glucose was also measured and recorded 
for time 5, 15, 30, 60, 90 and 120 minutes post oral gavage. Blood was collected to 
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measure plasma insulin for time 15, 30, 60 and 120 minutes post oral gavage. An insulin 
tolerance test (ITT) was performed on day 30 a:ft:er an overnight fast by intraperitoneal 
insulin injection, (previously reported in (328)). For these tests, blood glucose 
concentrations were measured with a glucometer at time 0, 5, 10, 20 and 30 minutes post 
insulin injection. Non-esterified fatty acids (NEFAs) concentrations were measured from 
fasted plasma collections (NEFA kit, HR Series NEFA-HR, Wako Chemicals, Richmond, 
VA, USA). Glucose and insulin area under the curve (AUC) was measured relative to the 
lowest fasting glucose and insulin levels of a placebo-SED animal. The acute insulin 
response (AIR) was determined between the difference in basal plasma insulin (fasting 
insulin levels) and 15 minutes following the oraJl glucose gavage (previously reported in 
(191, 350). This measurement represents the secretion of insulin in response to an 
exogenous glucose load. Homeostatic Model Assessment for ~-cells (HOMA-~) as 
previously reported in (328, 350) was calculated based on the following equation: 20 x 
Insulin(µ units·L)/Glucose (mM)-3.5 (361). 
Glucose stimulated insulin secretion (GSJS) experiments: All animals were killed 
by decapitation on days 31-3 5 of the experimental protocol and islet isolations were 
carried out as previously reported methods (350) that were originally modified from (330, 
331). Collagenase pancreas digestion was followed by Histopaque-1077 (H8889, Sigma, 
Canada) pellet suspension followed by re-suspension in KREB's buffer (125 mM NaCl, 
4.7 mM KCl, 1.2 mM, 5 mM NaHC03,2.5 mM CaCh,2.4 mM MgS04, 10 mM Hepes, 
0.5% BSA, pH-7.4). Islets were hand selected and cultured in filtered RPMI buffer 
(Wisent) overnight (24 h) at 37°C, 5% C02. Islets were separated into a 12-well culture 
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plate (6-10 islets/well in 3 batches) and given a 30 minute pre-incubation period as 
previously described (350). Islets were given fresh KREB's buffer with 2.8 mM glucose 
+ 0.1% BSA for 1 hoilr at 37°C, 5% C02• Media was changed to KREB's buffer with 
16.7 mM glucose+ 0.1% BSA for 1 hour at 37°C, 5% C02. Immediately following each 
incubation period, media was collected, centrifuged and stored at -20°C for further 
analysis. At the termination of experiments, islets were placed in 1 ml cold lysis buffer 
(acid-ethanol solution), sonicated (15 s), and centrifuged at 14, 500 rpm at 4 °C for 10 
minutes. Supernatant was collected and stored at -20°C until further analysis of insulin 
content. All insulin secretion data was normalized to total insulin content. Insulin was 
measured using radioimmunoassay kit (Millipore, Billerica, MA, USA). 
Histology: Liver and skeletal muscle tissue from euthanized animals were frozen 
in liquid nitrogen, cryosectioned (10 µm thick) and stained with Oil Red 0 (ORO) for 
neutral lipid content as previously described (299). Liver sections were fixed with 3.7% 
formaldehyde for 1 hat room temperature while an ORO solution composed of 0.5 g 
ORO powder (Sigma-Aldrich, Canada) and 1 OOml of 60% triethyl phosphate (Sigma-
Aldrich, Canada) was mixed and filtered. Following fixation in 3.7% formaldehyde, 
slides were immersed in filtered ORO solution for 30 minutes at room temperature. 
Slides immediately underwent five washes with ddH20, were allowed to dry for 10 
minutes and were sealed with Permount (Sigma-Aldrich, Canada). Liver images were 
acquired at 20 x magnification using a Nikon Eclipse 90i microscope (Nikon, Canada) 
and Q-imaging MicroPublisher 3.3 RTV camera with Q-capture Software. To identify 
skeletal muscle fiber type a metachromatic myosin A TPase stain was performed on cross 
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sections of the tibialis anterior muscle using a modified protocol (362). Sections were 
pre-incubated in an acidic buffer (pH = 4.25) to differentially inhibit myosin ATPases 
within the different fiber types. In this protocol, type I fibers appear dark blue, type Ila 
appear very light blue and type Ilb and Ilx are not apparent from each other and are thus 
classified as Ilb/x. These fibers appear bluish-purple. A representative image of the 
tibialis anterior for each group was acquired for analysis. Succinate dehydrogenase 
(SDH) activity was then assessed using histocht~mical analysis and expressed in relative 
optical density to placebo-SED ( 4 7). The same muscle regions of the tibialis anterior that 
were used for fiber typing were used for SDH activity determination. Serial sections were 
used to directly compare levels of SDH in each fiber, to each fiber type. SDH activity 
was assessed with Adobe Photoshop CS6, converted to greyscale and reported as the 
average optical density ( 60 fibers were counted per muscle section). The greyscale is 
evaluated on a range of completely black (0) to white (255). All images were acquired 
with a Nikon Eclipse 90i microscope and Q-Imaging MicroPublisher with Q-Capture 
software. 
Statistical Analysis: All data are represented as means ± SE, with a criterion of 
p<0.05 and p<0.001 and were assessed using two-way ANOVAs as a means of statistical 
significance. Individual differences were calculated using Tukey's post-hoc test unless 
stated in figure captions as using Duncan's post-hoc test (Statistica 6.0 software). Bars 
that do not share the same letters are statistical significance from one another. 
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Results 
Body mass. All animals had similar body mass prior to pellet surgery (day 14, ,..., 
350 g). Both placebo-treated groups gained mass after pellet surgery from day 14 to 24 
(Fig. 2A). However, on experimental termination day (day 31-35) placebo-SED animals 
tended to weigh more than placebo-EX animals (472.7±14.4 vs. 438.7±31.5 g). Similar to 
previously reported findings, CORT groups lost body mass after pellet surgery compared 
to placebo animals (328, 339, 350) (p<0.01, Fig. 2A). No differences were found in 
relative body mass between CORT-EX and-SED animals on day 24; however, CORT-
EX animals had heavier absolute body mass than CORT-SED animals at the termination 
of treatment (333.5±16.2 vs. 265.9±13.0 g, p<0.05). 
Running Distances. On average CORT-treated runners ran longer distances than 
placebo runners (6541.7±467 vs. 3308.4±260 m:, p<0.05, Fig. 2B). No differences were 
found between running distances prior to pellet surgeries and after 10 days of treatment 
(day 14 vs. day 24) within either placebo or CORT-treated groups (p>0.05). Running 
distances on each treatment day were plotted relative to running distances prior to surgery 
and no differences were found in either placebo or CORT-treated groups (Fig. 2C). This 
indicates that running distances prior to pellet surgery were not altered by pellet 
treatment, suggesting neither treatment had a significant effect on the animals' ability or 
desire to run, regardless of the individual being a short distance runner or a long distance 
runner. 
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Food intake and body composition. Relative food intake tended to be slightly 
higher in placebo-EX animals than placebo-SED although no significant differences were 
found (p>0.05, Table 1). Also no differences in relative food intake were found between 
CORT-SED and -EX animals but there was a main effect of pellet treatment across 
groups as CORT-treated animals had higher relative food intake than placebo-treated 
animals (p<0.05). Visceral adiposity as measured by relative epididymal fat depots was 
lower in CORT-EX compared to CORT-SED group (p<0.05, Table 1). There were no 
differences found between placebo-SED and -EX groups in visceral adiposity. Relative 
liver mass was up-regulated with CORT treatment compared to placebo-treated animals 
(p<0.05) but no differences were found with the addition of exercise in placebo or 
CORT-treated animals (Table 1). Relative gastrocnemius mass was lower with CORT-
SED treatment compared to placebo-treated animals (p<0.05) and tended to be higher 
with CORT-EX treatment. No differences were found with relative tibialis anterior mass 
between any treatment groups. Relative soleus mass, a measurement of red oxidative 
muscle mass was higher in CORT-SED animals compared to CORT-EX animals and 
placebo-SED animals (p<0.05, Table 1 ). Relative epitrochlearis mass, a measurement of 
white glycolytic muscle mass was significantly lower in CORT-SED animals compared 
to placebo-SED animals. The exercise intervention greatly increased relative 
epitrochlearis mass in CORT-EX animals compared to CORT-SED animals (p<0.01, 
Table 1). 
ORO and SDH staining. ORO staining of liver sections was used to quantify fat 
accumulation in all treatment groups. CORT-treated animals had increased red staining 
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compared to placebo-treated animals, indicating more lipid accumulation in the liver. 
There were no differences in liver fat accumulation between CORT-SED and-EX groups 
as well between placebo-SED and -EX groups. To determine any effects of training after 
4 weeks of voluntary wheel running, the tibialis anterior of each animal was stained for 
SDH activity (Fig. 3E-H). SDH is an oxidative complex bound to the inner mitochondrial 
membrane of skeletal muscle cells and is responsible for oxidizing succinate to fumarate 
in the citric acid cycle (363). Strong SDH staining correlates with increased mitochondria 
and higher muscle fiber oxidative potential. Placebo- and CORT-EX muscle types had 
elevated oxidative capacity compared to placebo- and CORT-SED muscle (p<0.001, Fig. 
31). In type I and Ila muscle sections CORT-SED had lower oxidative capacity than all 
treatment groups (p<0.05, Fig. 31). In type Ilb/x muscle CORT-SED tended to have lower 
oxidative capacity than placebo-SED animals. 
Plasma CORT, fasting NEFAs, glucose and insulin concentrations. CORT levels 
measured at 0800 hon day 21 were highest in CORT-SED and -EX groups compared to 
placebo-SED and -EX groups (p<0.05, Table 2). Placebo-SED animals had the lowest 
CORT levels compared to all other animal groups (p<0.05). CORT levels measured at 
0800 hon day 28 were also highest in CORT-treated animal groups compared to placebo-
SED but not significant from each other (CORT-SED vs. CORT-EX). On day 28, CORT 
levels in placebo-EX animals were higher than placebo-SED animals, similar to CORT-
SED and lower than CORT-EX (p<0.05, Table 2). Fasted NEFA levels were highest in 
CORT-treated animals compared to placebo animals (p<0.05, Table 2). CORT-EX 
animals tended to have lower fasting NEFAs than CORT-SED animals and placebo-SED 
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animals tended to have higher fasting NEFAs than placebo-EX animals. Fasting blood 
glucose levels prior to oral glucose challenge were,...., 4-fold higher in CORT-SED 
animals than placebo-SED (p<0.05). CORT-EX animals had lower fasting blood glucose 
levels compared to CORT-SED although concentrations were still higher when compared 
to placebo-treated groups (p<0.05, Table 2). CORT-SED animals had,...., 5.4-fold increase 
in fasting plasma insulin levels compared to placebo-SED. CORT-EX animals had,..., 8-
fold increase in fasting plasma insulin levels compared to placebo-EX animals (p<0.05, 
Table 2). CORT-EX animals tended to have higher fasting plasma insulin levels than 
CORT-SED animals but values were not statistically significant (p>0.05). 
Oral glucose tolerance challenge. CORT-SED animals had markedly elevated 
blood glucose levels before and during the oral glucose tolerance challenge compared to 
all treatment groups (p<0.05, Fig. 4A). Voluntary wheel running in CORT animals 
reduced glucose intolerance compared to SED animals (p<0.05) however, CORT-EX 
animals still expressed higher glucose intolerance than the placebo groups (p<0.001, Fig. 
4A'). Plasma insulin concentrations were highest in CORT-EX animals before and during 
the oral glucose tolerance challenge compared to all treatment groups (p<0.001, Fig. 4B). 
CORT-SED animals also had increased levels of plasma insulin during the oral glucose 
challenge that remained above the placebo-treated animals but were lower than the 
CORT-EX animals (p<0.01, Fig. 4B'). AIR was measured to determine the islet 
sensitivity to exogenous glucose (Fig. 4C). CORT-SED animals had the lowest AIR to 
glucose, indicating impaired islet responsiveness (p<0.05). Voluntary wheel running in 
both placebo- and CORT-treated groups greatly increased AIR by,..., 2-fold above 
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placebo-SED animals (p<0.05). To determine the influence of basal blood glucose levels 
on plasma insulin concentrations in each treatment group both parameters were plotted 
(Fig. 4D). The r2 with all groups included was 0.47 and there was a significant linear 
regression (p<0.0001) meaning that higher fasted blood glucose concentrations were 
correlated with higher insulin levels. CORT-EX and CORT-SED animals had the highest 
glucose and insulin levels. Blood glucose and plasma insulin values in the placebo 
animals did not deviate from each other and clustered around 3.5-5.5 mM of glucose and 
less than 4 ng/ml of insulin. 
In vivo P-cell function. HOMA-~ was used to calculate basal ~-cell function 
where higher HOMA-~ scores indicate greater ~-cell function. Voluntary wheel running 
improved ~-cell function in CORT animals by,..., 2.5-fold compared to CORT-SED 
groups (p<0.05, Fig. 5A). It also increased ~-cell function in placebo-EX animals 
compared to placebo-SED animals (p<0.05). No differences in HOMA-~ levels were 
found between CORT-SED and placebo-SED groups (p>0.05). An insulin tolerance test 
was conducted to measure insulin sensitivity primarily in the skeletal muscle (Fig. SB). 
CORT-SED animals had the highest glucose AUC levels compared to all treatment 
groups (p<0.001, Fig. 5B'). Voluntary wheel running reduced glucose AUC in CORT-
EX animals indicating improved peripheral insulin sensitivity (p<0.05) presumably 
mediated through improved glucose uptake in the skeletal muscle. 
Running distance vs. blood glucose, plasma insulin and CORT To determine if 
fasting blood glucose, plasma insulin and CORT had an effect on running distance, each 
value from each EX animal group was plotted and a linear regression was used to 
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measure significance (Fig. 6). No significant correlations were found between placebo-
and CORT-EX groups and their running distances versus fasting blood glucose (r2=0.083, 
p>0.05), plasma insulin (r2=0.023, p>0.05), and plasma CORT (r2=0.003, p>0.05). 
Ex vivo GSIS. Islets were harvested from each animal upon euthanization (Day 
31-35) and challenged with low (2.8) and high (16.7) glucose (mM) media. In low 
glucose media, CORT-SED islets had higher relative GSIS than placebo-SED and -EX 
groups (p<0.05, Fig. 7). CORT-EX tended to have higher relative GSIS levels in low 
glucose media compared to placebo-SED and -EX groups. High glucose media 
significantly increased relative GSIS concentrations in all treatment groups compared to 
low glucose media. CORT-SED had the highest relative GSIS compared to placebo-SED 
and -EX all other treatment groups, whereas CORT-EX had higher relative GSIS than 
placebo-SED and-EX, but lower GSIS than CORT-SED. 
Discussion 
Voluntary wheel running initially activates the HP A axis while prolonged wheel 
access reduces GC elevation in healthy rodents. It is not known whether chronic 
voluntary exercise has the ability to reduce the detrimental effects of elevated GCs in 
rodents. For the first time, we demonstrate in our model of elevated GCs and HFD that 
voluntary exercise (,...., 4 weeks) is able to alleviate symptoms of diabetes such as increased 
visceral adiposity, glucose intolerance, insulin insensitivity, and impaired islet glucose 
responsiveness. We validate these findings by showing that CORT-EX animals have 
lower glucose AUC, better acute insulin responsiveness, higher HOMA-~ scores and 
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improved insulin sensitivity than CORT-SED animals. These novel findings suggest that 
even in situations of chronically elevated GCs, regular exercise is able to promote 
healthier metabolic function. To date no studies have been published on the role of 
voluntary exercise and exogenous elevations in GCs. These results suggest that 
individual's suffering from hypercortisolemia, i.e. Cushing's syndrome, may benefit from 
regular exercise to help alleviate hyperglycemia:, excess fat accumulation, decreased 
muscle oxidative capacity and impairments in islet function. 
Generally, GCs decrease body mass, although it appears to be dependent upon 
animal model/type, dosing and duration of treatment (153, 295, 364-367). In this study 
and in previously published works (328, 350), we demonstrate that treatment with CORT 
induces (,...., 50%) a reduction in body mass compared to placebo-treated animals, 
regardless of diet treatment and increased food :in.take. Traditionally, voluntary wheel 
running in healthy animals demonstrates lower body mass gain (197, 220, 367, 367) as 
well as in obesity compromised rodent models (368, 369). However, in our study 
voluntary exercise did not prevent body mass loss in CORT-treated animals as both 
CORT-SED and-EX-treated groups had similar body masses throughout 10 days of 
treatment (Fig. 2A). These findings are similar to other studies in rats that show no 
differences in body mass loss with elevations in GCs and exercise, regardless of training 
regime, i.e. voluntary versus trained (263, 367, 367, 370). Some studies suggest that 
lower body mass shown in GC-induced models is a result of reduced food intake (263). 
However, we find that CORT-treated animals, regardless of being SED or EX, consume 
more Calories than the placebo-treated animals (r~ 1.5-fold change, Table 1 ). These 
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results are similar to previous findings suggesting that chronic GC treatment strongly 
influences eating behavior centres in the brain, especially increasing preferences for 
foods with high-fat content, that override the anorexigenic effects of insulin (124). 
Therefore, regardless of food consumption CORT treatment significantly decreases body 
mass and voluntary exercise does not correct this adaptation. 
Cushing' s syndrome results in a variety of clinical symptoms that include: 
hypertension, low bone mass, hyperglycemia, depression, and muscle atrophy as well as 
abdominal obesity, which can lead to further complications (135, 371). GCs help to 
regulate adipose tissue by promoting mechanisms of differentiation and distribution but 
in excess GCs can induce severe fat accumulation through hypertrophy and hyperplasia 
in the adipocytes (110). In our model of elevated GCs and HFD, there is an excessive 
accumulation of visceral fat that is - 1.5-fold higher in CORT-SED than placebo-treated 
animals (Table 1), which parallels other previous work (133, 328, 371, 372). Exercise is 
known to help reduce body mass gain, specifically fat mass gain (373-375) even in 
instances ofHFD (375, 376). In the present study, we demonstrate that voluntary wheel 
running is sufficient to attenuate visceral fat accumulation in animals treated with CORT 
and HFD. These results are similar to previous published work (377); however our study 
findings are novel as voluntary exercise exhibited changes in visceral adiposity even with 
elevations in CORT .and the addition ofHFD. 
GCs induce body mass loss, which is usually accompanied by muscle atrophy 
(365). GCs specifically target type lib fibers in the skeletal muscle; however, to date the 
mechanisms remain unknown (3 78). GCs also induce negative protein balance through 
146 
increased protein degradation and decreased protein synthesis (3 79), both potentially 
leading to an overall decrease in muscle contractility. In our present study, we 
demonstrate that CORT and HFD lead to lower epitrochlearis and gastrocnemius muscle 
mass. In contrast to other studies that have found dexamethasone-induced muscle loss 
with treadmill or uphill exercise (263, 370) we show that voluntary exercise was able to 
reverse muscle mass loss in gastrocnemius and further increase epitrochlearis muscle 
mass above placebo-SED animals. We suggest differences found in muscle mass are due 
to the nature of the exercise protocols. Treadmill exercise, although an excellent exercise 
stimulus is only performed in rats for 1 hour a day at ,...., 20m/min (3 70) whereas voluntary 
wheel running is accessible to the animals 24 h a day and some animals are able to run. 
distances > 10 km. As such, it is likely that voluntary exercise is a more potent stimulator 
of preserving muscle mass than treadmill or uphill exercise in situations of 
hypercortisolemia. In addition, the soleus muscle did not decrease with CORT-SED 
treatment but instead increased in mass compared to the other treatment groups, a finding 
unique to our study. This mass increase has been a continued observation in our model 
and the mechanisms remain unknown. We sugg{:st that since GCs primarily target white 
muscle tissue the soleus muscle could be preserved as it consists mostly of red muscle 
tissue. 
GCs advance muscle atrophy by targeting fast-twitch, glycolytic muscles (380) 
and consequentially causing reduced muscle oxidative capacity (381). Here, we also find 
lower muscular oxidative capacity with CORT-SED treatment in type I and II fibers 
compared to placebo-SED fibers (Fig. 3I). We hypothesized that voluntary exercise 
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would increase muscle oxidative capacity as voluntary exercise for 10 weeks stimulates 
increased muscle oxidative capacity in Wistar··Kyoto rats with the metabolic syndrome 
(360). Similarly, we find that voluntary exercise: promotes improved muscle oxidative 
capacity in all fiber types of the placebo-EX animals. Moreover, CORT-EX animals have 
similar oxidative capacity to the placebo-EX animals demonstrating that the lower 
oxidative capacity observed with CORT-SED is reversed with voluntary exercise. 
Therefore, we conclude that voluntary exercise is an adequate stimulus to improve 
skeletal muscle oxidative capacity even in situations of elevated GCs and HFD. 
Animal models ofT2DM, such as ZDF rats, have elevated levels of CORT prior 
to the onset of impaired glucose metabolism and abnormal glycemic control (63, 213). 
Exercise training and adaptations to psychological stress reduce elevations in GCs and 
lowers the risk ofT2DM development in ZDF rats (144, 382). In this study and 
previously published work (328, 350) we show that elevated GCs induce severe glucose 
intolerance, hyperinsulinemia, impaired AIR, insulin resistance and ~-cell function. Here, 
we show that (,..., 4 weeks) daily voluntary wheel running was a sufficient amount of 
exercise to attenuate glucose intolerance and improve insulin response to exogenous 
glucose challenge (Fig. 4 ). Similar results have be:en found in exercise-trained humans 
where exercise improved glucose intolerance and insulin sensitivity just 10 days after 
being sedentary (247); exercise training also improved glucose intolerance induced from 
10 days of dexamethasone treatment (263). In comparison to other published work on 
dexamethasone and treadmill exercise (263), we found that CORT-EX animals had 
elevated fasted and stimulated insulin levels during the glucose challenge compared to au 
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other treatment groups (Fig. 4B). These results are similar to those of Kiraly et al., 2008 
(144), who showed increased fasting insulin at 11 weeks of a swim training intervention 
in ZDF rats compared to sedentary and lean controls as well as elevated P-cell mass, 
through increased cell proliferation (hypertrophy and hyperplasia) (144). Elevated plasma 
insulin levels were also found in exercised ZDF rats post glucose challenge compared to 
inactive controls (150). We show that voluntary exercise in both the placebo- and CORT-
treated animals' results in a rise in AIR compared to both placebo- and CORT-SED 
animals (Fig. 4C). It is possible that elevated P-cell mass in both EX groups may 
contribute to elevated insulin response; however it was not measured in this study. We 
also show here that there is a correlation between fasted insulin and glucose levels when 
data is plotted together (Fig. 4D), indicating that higher glucose levels were associated 
with higher fasting insulin levels. However, CORT-EX animals have higher fasted insulin 
levels than CORT-SED animals, possibly indicating that CORT-EX animals have 
elevated islet compensation for higher glucose levels and therefore, may explain, in part, 
why these animals have attenuated glucose intolerance. Taken together, these data 
suggests that voluntary exercise results in more circulating insulin, but also in a more 
profound insulin response to exogenous glucose that is otherwise blunted with physical 
inactivity. 
We have shown that CORT-SED treatment impairs the P-cell response to 
elevations in glucose (350). In the present study we show that P-cell function improves 
with exercise training in both placebo- and CORT-treated animals compared to their 
respective SED groups (Fig. 5A). These results are similar to ZDF rats (144) but no 
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studies have shown these effects in models of sustained elevation in exogenous GCs 
concomitantly with a HFD. Insulin sensitivity was severely abrogated in CORT-SED 
animals compared to placebo animals however voluntary exercise attenuated this 
response (Fig. SB and B'). Exercise training improves insulin sensitivity in humans 
through the up-regulation of insulin action in the: skeletal muscle (383). Voluntary 
exercise did lower insulin insensitivity in CORT-treated animals; however it did not 
normalize insulin sensitivity to that of the controls. Perhaps a longer exercise intervention 
would have promoted better exercise-induced insulin action at the level of the skeletal 
muscle. 
Endurance training regardless of exercist~ protocol (swimming, voluntary, 
treadmill) results in reduced insulin release in isolated healthy rodent islets (222, 224, 
226, 230, 384) and more specifically in the ~-cell itself (225). Our findings suggest 
similar results, where placebo-EX animals tended to have lower GSIS (Fig. 7) compared 
to placebo-SED islets. As previously mentioned exercise training improves ~-cell mass, 
through proliferation and increased ~-cell neogenesis (144). In addition, voluntary wheel 
running (6 weeks) shows improvements in GSIS in ZDF rat islets as well as prevents 
complete depletion of insulin stores within the islet (150). Our study is the first to show 
that with voluntary exercise lowers relative GSIS in CORT-treated animals, although did 
not normalize to levels of placebo-SD or -EX. Our results were different to those found in 
active ZDF rats, in that GSIS was elevated in high glucose and palmitate media compared 
to inactive ZDF rat islets (150). These results differ as ZDF animals may have larger 
compensatory ~-cell mass causing higher insulin levels. These differences could be the 
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result of different disease models and we conclude that abnormally elevated GSIS is 
attenuated with exercise training, as insulin requirement may be lower than CORT-SED 
islets. 
Recently, we have shown that elevated short-term CORT in conjunction with a 
HFD induces severe hyperglycemia, hyperinsulinemia, along with impaired insulin 
response and glucose sensitivity despite increases in ~-cell mass. In the present study, we 
were able to demonstrate that voluntary wheel running, concurrently with CORT and a 
HFD was sufficient to lower visceral adiposity, glucose intolerance, improve insulin 
response, muscle composition and oxidative capacity as well as increase ~-cell function. 
These results are interesting and novel as it is not clear in the literature whether exercise 
is able to attenuate symptoms ofT2DM independent oflower GC sensitivity. Our study 
shows that voluntary exercise attenuates symptoms ofT2DM induced by elevated CORT 
and HFD and provides evidence that exercise can influence tissues independently from 
hypercortisolemia. Exercise intervention may be an ideal form of rehabilitation in 
individuals with hypercortisolemia or Cushing' s syndrome as these individuals suffer 
from hyperglycemia, insulin insensitivity, muscular atrophy and increased central 
obesity. Therefore, they may benefit from the positive effects of regular exercise that help 
to control or attenuate symptoms, which could put them at a higher risk for diabetes 
development. 
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Table 1. Food intake and body composition. 
Placebo CORT 
---- --
~m:ID m~ ~~IID ~~ 
- - - ----- --- ------ -- ~- - -------.---- -------------
Food mtake 0.25±0.02 0.30±0.02 0.45±0.01 ' ' 0.44±0.02 
lJi[Jfd]~ rnnG Il 'Y JffiM JQP TI 11 JQ)~~ Il oC0815 ~o ®3-1 U u, ~ r oi~ol1:: n A~~ 
Liver 37.4±1.6 37.7±1.6 69.7±2.4 ' ' 69.3±6.8 
Tibialis Anterior 1.5±0.048 1.6±0.208 1.35±0.058 1.50±0.18 
~ @A)(Q)~},{Q)o@Ilffi ©aiB~~oJltiliJ 1 @o~@__2{Q)o@](ij ©~o~h@l~G 
I I Epitrochlearis 0.14±0.01 0.17±0.02 0.11±0.01 0.20±0.03 
Note: Values are means± SE in kcal/g of BM/day for food intake and g/kg for tissue 
mass. Different letters beside each value indicate the mean was statistically significant 
from other groups that do not share the same letter. All analysis was carried out by a two-
way ANOVA with a Tukey's post-hoc, where p<0.05. n=7-12. 
Table 2. CORT, fasted NEF As, glucose and insulin concentrations. 
Placebo CORT 
------
~m:ID ~~ ~11IID I~~ 
Day21 CORT 66.0±17.1 271.3±42.9 566.2±65.6 548.2±45.0 
~@~ iBa®MIDj\8 StTiilliID~ill Il~o~1©oCW~ niBJ3i2 Tio@ I 
Fasted lnsulm 1.24±0.3 1.1±0.5 6.8±0.6 I I 8.9±1.2 
All values are means± SE in ng/ml for CORT and insulin. Values are in mM for glucose 
and NEF As. Different letters beside each value indicate the mean was statistically 
significant from other groups that do not share the same letter. All analysis was carried 
out by a two-way ANOVA with a Tukey's post-hoc, where p<0.05. n=7-12. 
152 
Figure Captions 
Fig.1. Schematic of experimental design. On day 0, all animals were individually housed 
and divided into one of four groups; placebo-EX, CORT-EX, placebo-SED and CORT-
SED (EX, exercise and SED, sedentary). At this time, all EX animals were introduced to 
running wheels in their cages and allowed 2 weeks to acclimate to the experimental 
conditions. On day 14 either wax or CORT pellets were subcutaneously implanted .into 
the animals according to the assigned experimental group and all animals were given a 
HFD (60%) ad libitum. Seven days after pellet surgeries (- 0800 h) blood samples were 
taken to measure plasma CORT and blood glucose levels. On day 25 animals were fasted 
overnight (- 16 h) and the following day (26) were administered an oral glucose 
tolerance test. On day 28 (- 0800 h) blood samples were taken again to measure plasma 
CORT and blood glucose levels. On the evening of day 29, animals were fasted and on 
day 30 animals were administered an insulin tolerance test. All animals were euthanized 
between days 31-35 of the experimental protocol. 
Fig.2. Body mass relative to pre-surgery body mass during pellet treatment (10 days) (A) 
and average daily running distances during pelkt treatment (B) and average daily running 
distances relative to pre-surgery running distances (C). CORT-treated animals 
experienced - 10-15% body loss throughout the pellet treatment period while placebo-
treated animals continuously gained mass (p<0.05). CORT-EX animals ran longer 
distances per day than placebo-EX animals (p<0.05) however CORT-EX animals ran 
more prior to surgery. No differences were found between CORT-EX and placebo-EX 
groups in running distances relative to pre-surgery running distances. Therefore, pellet 
implants had no impact on running distances. n=7-12. All values are means ± SE. 
Fig.3. Measurement of liver lipid accumulation and muscle oxidative capacity was 
completed through ORO (A-D) and SDH staining (E-H). SDH activity was measured as 
the mean optical density relative to the placebo-SED group, for each fiber type: I, Ila, and 
Ilb/x (I). CORT treatment increased liver lipid accumulation. Muscle oxidative capacity 
was increased in all placebo- and CORT-EX muscle types compared to placebo- and 
CORT-SED muscle. In type I and Ila muscle sections CORT-SED had lower oxidative 
capacity than placebo-SED animals. n=3-5 per group. In bar graphs, letters that are not 
the same are statistically significant from each other (p<0.05) using a two-way ANOVA 
with Duncan's post hoc test. All values are means± SE. 
Fig.4. Measurement of glucose tolerance (A and A'), insulin secretion (B and B') and 
insulin response (C and D). Blood glucose levels were greatly elevated with CORT-SED 
treatment compared to placebo treatment (p<0.001) but voluntary wheel running 
decreased glucose intolerance in CORT-treated animals (p<0.05). Plasma insulin levels 
post an oral glucose challenge were elevated with CORT treatment compared to placebo-
treated animals and exacerbated with the addition of wheel running (p<0.01). n=7-12 for 
all above graphs. Acute insulin response (AIR) between basal and 15 minutes post 
exogenous glucose challenge was elevated with EX (p<0.05) and reduced with SED-
treated animals (p<0.05). n=6-12. Higher fasting plasma insulin concentrations was 
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correlated with higher fasting blood glucose concentrations in both CORT-EX and SED 
groups (r2=0.47, p<0.0001). n=6-12. In all bar graphs, letters that are not the same are 
statistically significant from each other using a two-way ANOVA with Tukey's (A' and 
B') and Duncan's (C) post hoc tests. All values are means± SE except in D, where values 
are individual. 
Fig.5. Measurement of ~-cell function (A) and insulin sensitivity (B and B'). HOMA-~, 
an indicator of ~-cell function, was increased with voluntary wheel running in placebo 
and CORT-treated animal groups (p<0.05). Insulin sensitivity measured by the response 
to an insulin bolus was improved with voluntary wheel running in CORT-treated animals 
(p<0.05). n=7-12. In all bar graphs, letters that are not the same are statistically 
significant from each other using a two-way ANOV A with Duncan's (A) and Tukey's (B 
and B') post hoc tests. All values are means± SE. 
Fig.6. Running distances versus fasted blood glucose (A), plasma insulin (B) and plasma 
CORT (C). No significant correlations were found in any groups with running distat}ces 
and measured plasma parameters (p>0.05). n=7 for placebo-EX and 12 for CORT-EX. 
Linear regressions were performed to determine significance ((r2=.083 (A), r2=0.023 (B) 
and r2=0.0003 (C)). All values are plotted as individual values. 
Fig.7. Isolated islet glucose stimulated insulin secretion (GSIS), in low (2.8) and high 
(16.7) glucose (mM) media(% of total insulin content). CORT-SED treated group had 
higher insulin secretion in low and high glucose media compared to placebo-treated 
groups (p<0.05). Voluntary exercise normalized GSIS in CORT-treated animals 
(p<0.05). n=3-7 per group. The * indicates statistical significance from CORT-SED and 
the# indicates statistical significance from CORT-EX (p<0.05) using two-way ANOVA 
with Duncan's post hoc test. All values are means± SE. 
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Figure 5. 
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MANUSCRIPT-#4 
Glucocorticoid Receptor II Antagonists and Rapid-onset 
Diabetes in Sprague-Dawley Rats 
Rationale for Manuscript #4 
Chapter 5 
Manuscript #3 demonstrated that voluntary wheel running was sufficient to 
attenuate symptoms of ROD, such as increased visceral adiposity, hyperglycemia, 
hindered muscle oxidative capacity, impaired insulin response to exogenous glucose 
challenge, and ~-cell glucose insensitivity. However, not all symptoms of ROD were 
successfully restored with voluntary wheel running, i.e. normalized glucose control and 
peripheral insulin resistance. Therefore we were interested to determine if pharmacologic 
agents would be able to fully reverse the detrimental effects of ROD. Mifepristone 
(RU486) is a known non-selective GRII antagonist that inhibits the GRII, but not 
exclusively as it also inhibits the androgen and progesterone receptor (267). It is known 
to reverse symptoms of T2DM in individuals suffering from hypercortisolemia or with 
Cushing' s syndrome, but due to its occupancy with other nuclear receptors it can produce 
some on undesirable side effects (276). Recently there are several selective GRII 
compounds being tested to replace the use ofRU486, as they are thought to eliminate 
unwanted side effects. Therefore, the goal of manuscript #4 was to study the effects of 
selective GRII antagonists, such as C 113176 and C 108297, and non-selective 
antagonists, such as RU486 on ROD development. 
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Abstract 
Chronically elevated glucocorticoids (GCs) promote visceral fat mass 
accumulation, severe insulin resistance, hyperglycemia, skeletal muscle proteolysis and 
degradation to bone. Antagonism of the glucoc.orticoid receptor II (GRII) using 
Mifepristone (RU486) has been used to minimize these undesirable effects but at the 
expense of also blocking the progesterone receptor. A number of new selective GRII 
antagonists have recently been developed, but Hmited testing has been completed in 
animal models of hyperglucocorticoidemia. Therefore, two selective GRII antagonists 
(C 113176 and C 108297) were tested to determine their effects in a rodent model of GC-
induced rapid-onset diabetes (ROD). Male Sprague-Dawley rats (....., six weeks of age) 
were placed on a high-fat diet (60%), given pellets containing corticosterone (CORT) or 
wax (control) and divided into five treatment groups. Each group was treated with either 
an antagonist or vehicle for 14 days after surgery: CORT pellets (400 mg/rat)+ 
antagonists (80 mg/kg/day); CORT pellets+ drug vehicle; and wax pellets (control)+ 
drug vehicle. After 10 days of CORT treatment, body mass gain was increased with 
RU486 (by ....., 20% from baseline) and maintained with C 113176 administration, whereas 
rats given C108297 had similar body mass loss (~J 15%) to ROD animals. Fasting 
glycemia was elevated in the ROD animals (>20 mM), normalized completely in animals 
treated with RU486 (6.2±0.1 mM, p<0.05) and improved somewhat in animals treated 
with C108297 and Cl 13176 (14.0±1.6 and 8.8±1.6 mM, p<0.05 respectively). Glucose 
intolerance was normalized with RU486 and attenuated with Cl 13176 and C108297, 
whereas acute insulin response was only improved with RU486 and C 113176 treatment. 
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Also, peripheral insulin resistance was attenuated with Cl 13176 treatment along with 
improved ~-cell function while C 108297 antagonism only provided modest changes. In 
summary, Cl 13176 was an effective agent that minimized some GC-induced detrimental 
metabolic effects and may provide an alternative: to the non-selective GRII antagonist 
RU486. 
Introduction 
Glucocorticoids (GCs) are naturally occurring steroid-derived hormones that are 
essential for healthy whole-body metabolism and adaptation to stressful environments. 
The hypothalamic-pituitary-adrenal (HPA) axis is the main regulator of GC secretion 
(cortisol in humans and corticosterone in rodents), operating normally in a diurnal rhythm 
and in response to stressors to increase GC release (385). GCs bind to receptors including 
GRII that are found ubiquitously throughout the body. The mineralocorticoid receptor 
(MR) also binds GCs. As GCs have ten times the affinity for MR compared to GRII, MR 
activity is most relevant in basal, non-stressful conditions. Expression of MR is low in 
most tissues except for in the hippocampus, kidneys, adipose tissue and heart (386) .. Once 
the GRII is occupied by a ligand, the complex translocates to the nucleus where it acts as 
a transcription factor to activate or repress the expression of genes necessary for cell 
proliferation, inflammation, immune development, reproduction (325) and energy 
homeostasis (77, 337). 
Acute elevations in GCs are important for many biological functions, however, 
chronically high levels of GCs, such as those observed in patients suffering from 
Cushing's syndrome (135), result in unwanted metabolic disturbances such as reduced 
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growth (387), increased whole body insulin resistance (388), elevated fasting glucose 
levels (389) and possibly increased risk for type 2 diabetes mellitus (T2DM) development 
(138, 145, 146). Currently there are a large number ofrodent (22, 288, 289) and human 
(58, 266) studies suggesting that the rise in circulating and/or cellular levels of GCs are 
connected with diabetes onset. At the cellular level, the pre-receptor enzyme, 11 ~­
hydroxysteroid dehydrogenase type 1 (11~-HSDl) is responsible for conversion of 
inactive GCs into active GCs. This activity increases GC concentrations leading to the 
progression of tissue specific metabolic dysfunction (290) and, if left untreated, T2DM 
development (291). GRII antagonists have become an area of interest as they may 
eliminate unwanted metabolic effects of elevated GCs. 
Mifepristone (RU486) is a non-selective GRII antagonist that competitively 
blocks the GRII, the progesterone receptor (PR), but not the MR (267). This receptor 
antagonist has recently gained FDA approval (Korlym™, 2012) for the treatment of 
patients with hypercortisolemia or Cushing's syndrome with established hyperglycemia, 
since it has been shown clinically to improve glucose tolerance in these patients (268, 
269, 272). However, RU486 treatment requires consistent patient monitoring as it can 
result in various side effects such as endometrial hypertrophy, hypokalemia, and aborted 
pregnancy (267, 276). Currently, more specific antagonists selective for the GRII are 
being developed in the hope of eliminating the progesterone blocking properties of 
RU486 administration. A few studies of selective GRII antagonists have been conducted 
in rodent models ( 48, 278, 279). In these studies, selective GRII antagonists have been 
shown to play a role in the attenuation of detrimental GRII-dependent pathways in the 
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brain (278), whole-body steady state glucose metabolism ( 48), and body mass gain (279). 
However, no studies in this field have been conducted to investigate the role of selective 
GRII antagonists in a model of elevated GCs indicative of Cushing' s syndrome and 
diabetes development. 
Recently, we have developed a rodent model of rapid-onset diabetes (ROD) that 
involves the administration of increased levels of GCs by a slow release corticosterone 
pellet in combination with a high-fat diet (HFD) in young male Sprague-Dawley rats 
(328, 350). We are interested in the effects of GRJI antagonists on ROD and 
hypothesized that this therapeutic treatment will help to prevent ROD development. In 
this present study, we tested two selective GRII antagonists, C 113176 and C 108297, in 
comparison to the non-selective GRII antagonist, RU486, in our established rodent model 
of ROD. We show th~t a new selective GRII antagonist, Cl 13176, has beneficial effects 
in our model of ROD, attenuating the pathophysiological outcomes, including perturbed 
body mass, impaired glucose tolerance, reduced insulin release by pancreatic ~-cells and 
insulin resistance. 
Materials and Methods 
This study was carried out in accordance with the recommendations of the 
Canadian Council for Animal Care guidelines and was approved by the York University 
Animal Care Committee (Protocol # 2010-15(R2) ). All surgical procedures were 
performed under isoflurane anesthesia, and all efforts were made to minimize animal 
suffering. 
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Rodent Treatment and Experimental Design 
Three sets of 20 male Sprague Dawley rats (Charles River Laboratories, 225-250 
g, six weeks post-weaned) were individually housed (lights on 12 h: lights off 12 h cycle) 
after one week of acclimatization to the rodent facilities. Upon surgery day (day 0), each 
rat received a subcutaneous implantation of either corticosterone (CORT) pellets (4 x 100 
mg; Sigma, Canada, Cat# C2505) or wax (control) pellets, as previously described (328). 
Immediately following surgery all rats were given ad libitum access to a high-fat diet 
(HFD), 60% of the total calories from fat and 5.1 kcal per gram of pellet (Dl2492, 
Research diets); this diet was maintained to tht~ end of the experimental protocol. Rats 
recovered in sterile cages for two days and were then separated into five groups while 
being maintained on a HFD and were assigned. either vehicle or GRII antagonist 
treatment (RU486, Cl 13176 and C108297) at a dose of 80 mg/kg/day. The antagonist 
dose was chosen based on doses used in earlier studies ( 48). The following treatment 
groups were created; wax+ vehicle gavage controls (controls), CORT+vehicle (ROD), 
CORT+RU486 (RU486), CORT+C108297 (C108297), CORT+Cll3176 (C113176). All 
antagonists were first dissolved in DMSO which was further dissolved in a vehicle 
consisting of 0.5% HPMC + 0.1 % Tween 80 by approximately 30 seconds of sonication. 
ROD animals who were given only vehicle received 10% DMSO +vehicle instead of an 
antagonist compound. Antagonists and vehicles were administered with a syringe and 
oral gavage tube (lnstech, Plymouth, PA USA, Cat# FTP-18-75) twice daily, 
approximately 10 hours apart. Body mass and food intake were measured and recorded 
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daily for each rodent using an electronic sea.le (Mettler Toledo, Canada) and any changes 
in the rodents' health were noted and monitored. 
Blood Sampling 
Plasma CORT levels were sampled on the morning of the 7th and 14th day after 
pellet implantation at approximately 0800 h, using the animal's saphenous vein. Blood 
samples were collected in lithium-heparin coated microvette capillary tubes (Sarstedt, 
Des Grandes Prairies, Montreal, Quebec, Canada, Cat# 16.443.100) and centrifuged at 
12,000 rpm for 5 minutes so that the plasma could be collected into polyethylene tubes 
and stored at -80°C until further analysis. These samples were later analyzed for CORT 
levels using a radioimmunoassay kit (MP Biomedical, OH, USA). 
Fed blood glucose concentrations were measured on day seven using a handheld 
glucometer (Bayer, Contour, NY, USA). On day 11, animals were fasted overnight (16 
hours) and on day 12, animals were administered an oral glucose tolerance test (OGTT, 
1.5 g/kg body mass). An insulin tolerance test (ITT) was administered on day 16 after an 
overnight fast by intraperitoneal (i.p.) insulin injection, (previously reported in (328, 
350)). For these tests, all blood glucose conc~m.trations were also measured with a 
handheld glucometer and blood samples drawn from saphenous vein were collected in 
microvette tubes (Sarstedt). The animals' plasma was subsequently analyzed for insulin 
(Crystal Chem, IL, USA, Cat# 90060) using the high-range assay method and for non-
esterified fatty acids (NEFA) levels (HR Series NEFA-HR, Wako Chemicals). Glucose 
area under the curve (AUC) was measured relative to the fasting glucose levels of the 
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control animals, and insulin AUC was measured relative to each individual's fasting 
insulin levels. The acute insulin response (AIR) was determined by the difference 
between basal (fasting) insulin levels and insulin levels 15 minutes following the oral 
glucose gavage (previously reported in (191, 350)). This measurement represents the 
ability of the pancreatic ~-cells to respond to exogenous glucose load. 
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) was 
calculated as previously reported in (328) and is based on the following equation: 
Glucose (mM) x Insulin(µ units·L)/22.5 (361). This calculation represents basal glucose 
and insulin action on peripheral tissues, and primarily reflects the relationship between 
hepatic glucose output and insulin secretion (390). Homeostatic Model Assessment for~­
cells (HOMA-~) was calculated based on the following equation: 20 x Insulin(µ 
units-L)/Glucose (mM)-3.5 (361). This measurement represents basal pancreatic ~-cell 
function in response to basal glucose levels. 
For technical and experimental reasons, the day of termination ranged from 2-5 
days after the ITT to allow for subsequent tissue collection. Trunk blood was collected 
for further analysis. Tissues collected from animals euthanized via decapitation were as 
follows: liver, heart, epididymal fat pads, and skeletal muscles such as epitrochlearis, 
soleus, gastrocnemius and tibialis anterior. 
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Histology 
Liver and skeletal muscle tissue from euthanized animals were snap frozen, 
cryosectioned (10 µm thick) and stained with Oil Red 0 for neutral lipid content as 
previously described (299). Muscle and liver sections were fixed with 3. 7% 
formaldehyde for 1 hat room temperature while an Oil Red 0 solution composed of 0.5 g 
Oil Red 0 powder (Sigma-Aldrich, Canada) and 1 OOml of 60% triethyl phosphate 
(Sigma-Aldrich, Canada) was mixed and filtered. Following fixation in 3.7% 
formaldehyde, slides were immersed in filtered Oil Red 0 solution for 30 minutes at 
room temperature. Slides immediately underwent five washes with ddH20, were allowed 
to dry for 10 minutes and were sealed with Permount (Sigma-Aldrich, Canada). Skeletal 
muscle and liver images were acquired at 10 x and 20 x magnifications respectively using 
a Nikon Eclipse 90i microscope (Nikon, Canada) and Q-imaging MicroPublisher 3.3 
RTV camera with Q-capture Software. Intensity of Oil Red 0 staining of IMCL droplets 
on serial sections of the tibialis anterior was assessed with Adobe Photoshop CS6, 
converted to greyscale and reported as the average optical density ( 60 fibers were counted 
per muscle section). The greyscale is evaluated on a range of 0 (completely black) to 255 
(completely white). 
Western Blotting 
Western blot analysis was carried out according to previously published work 
(350, 391). In brief, 50 micrograms of protein lysate from epididymal fat protein was run 
on a 12% SDS-page gel and proteins were transferred to a PVDF membrane (Bio-Rad, 
Canada). Membranes were blocked in 10% powdered milk and Tris-buffered saline with 
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Tween 20 at room temperature for 1 hour. Membranes were then incubated overnight at 
4°C with polycolonal rabbit anti-11~-HSDl (1l :1000, Cat#10004303, Cayman Chemical 
Company, Ann Arbor, MI) and monoclonal mouse anti-a-tubulin (1 :40000, Cat#ab7291, 
Abeam, Toronto, ON). The following morning the membranes were washed with TBST 
and incubated with goat anti-mouse (1 :·10000, Cat#ab6789, Abeam) and goat anti-rabbit 
(1 :10000, Cat#ab6721, Abeam) secondary antibodies for 1 hour at room temperature. 
Membranes were then washed and imaged. Images were detected on a Kodak In vivo FX 
Pro imager and molecular imaging software (Carestream Image MI SE, version S.0.2.3.0, 
Rochester, New York) was used to quantify protein content. 
Glucose stimulated insulin secretion (GSIS) 
Islet isolations and ex vivo glucose challenges were carried out as previously 
reported (350). Collagenase pancreas digestion was followed by Histopaque-1077 
(H8889, Sigma, Canada) pellet suspension followed by re-suspension in KREB's buffer. 
Islets were handpicked and cultured in filtered RPMI buffer (Wisent) overnight (24 h) at 
37°C, 5% C02. Islets were separated into a 12-well culture plate (6-10 islets/well in 3 
batches) and given a 30 minute pre-incubation period as previously described (350). Islets 
were given fresh KREB's buffer with 2.8 mM glucose+ 0.1% BSA for 1 hour at 37°C, 
5% C02. Media was changed to KREB's buffer with 16.7 mM glucose+ 0.1 % BSA for 1 
hour at 3 7°C, 5% C02. Immediately following each incubation period, media was 
collected, centrifuged and stored at -20°C for further analysis. Insulin was measured 
using a radioimmunoassay kit (Millipore, Billerica, MA, USA). 
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Statistical Analysis 
All data are represented as a mean± SE, with a criterion of p<0.05 and were 
assessed using one-way ANOVAs as a means. of statistical significance. All individual 
differences were evaluated using Tukey's post-hoc test unless otherwise stated as a 
student's t-test (Statistica 6.0 software and Prism Graph Pad version 5.1). Results from 
post-hoc analyses were denoted on each figure bar using letters. If bars do not share the 
same letters then mean values were statistically significant between treatment groups. If 
bars share the same letter then mean values were found to not be statistically significant 
from each other. 
Results 
Body mass 
GC antagonist treatment commenced on day 2 of pellet treatment and body mass 
was measured every day relative to day 0 (pre-surgery) for 10 days. Animals weighed-
300-325 g prior to pellet surgery (Figure 1 shows the fold changes in mass over the 10 
day period). ROD treatment resulted in - 15% body mass loss relative to pre-surgery 
mass and - 50% body mass difference compar<::d to control animals 10 days after CORT 
treatment. In comparison, RU486 treatment increased body mass gain relative to ROD 
treated animals by day 4. Body mass continued to rise during the treatment period and 
ultimately resulted in - 20% mass gain over the 10 day period. Probably because of the 
initial mass lost from day 0 to 2, RU486 treatment did not fully reverse body mass loss in 
CORT treated animals when compared to controls (final mass on day 10: 352.7±5.9 g, vs. 
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397.6±6.1 g, in the RU486 treated animals and control animals respectively, p<0.05, 
Figure lB). Cl 13176 treatment recovered body mass to pre-surgery levels by day 8 (mass 
on day 10, 317.6±3.8 g), whereas C108297 treatment resulted in an overall mass loss of,..., 
15% (mass on day 10, 259.3±4.4 g), similar to the ROD animals (mass on day 10, 
266.5±3.l g, Figure lB). 
Corticosterone and food intake 
Normally, circulating CORT concentrations follow a diurnal pattern in rodents 
and fluctuate from high levels in early evening hours (i.e. peak, ,..., 2000 h) to low levels in 
early morning hours (i.e. basal,,..., 0800 h). In this study, blood was sampled on day 7 and 
on day 14 at ,..., 0800 h to determine basal CORT levels. Control animals had normal basal 
CORT levels on day 7 and day 14, values that were about 3-4-fold lower than all other 
treatment groups that received CORT pellets (p<0.05, Table 1). CORT pellet groups 
treated with ROD, RU486, Cl 13176 and Cl08297 all had similar basal CORT levels at 
day 7 and 14 (p>0.05, i.e. not significant, Table 1 ). 
Food intake was measured on day 10 of pellet treatment. ROD treated animals 
had an increase in absolute food intake compared to controls (p>0.05, Table 1 ). RU486 
treated animals had the highest absolute food intake compared to all other groups 
(p<0.05, Table 1). Animals that were treated with Cl 13176 or C108297 had similar 
absolute food intake to control animals (Table 1 ). Daily total kilocalorie intake relative to 
body mass was elevated in all CORT treated animals compared to controls (p<0.05) 
however, relative food intake was highest in ROD animals compared to all groups 
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(p<0.05). Relative food intake was similar between RU486, Cl 13176 and C108297 
groups. Therefore, antagonist treatment lowered relative food intake compared to ROD 
animals but did not normalize food intake compared to the controls. 
Hormone and blood analyses 
Fed blood glucose concentrations wen~ elevated in ROD animals compared to 
controls (p<0.05, Table 2). RU486 normalized fed blood glucose levels whereas C 113176 
and C108297 treated animals had similar levels compared to ROD treated animals (Table 
2). All animals were fasted on the night of day 11 for - 16 h. Fasting blood glucose 
concentrations, measured the following day, were highest in ROD animals by - 4-fold 
compared to controls (p<0.05, Table 2). RU486 treatment normalized fasted glucose 
levels compared to controls, while Cl 13176 treatment resulted in improved but not 
complete normalization of fasting blood glucose concentrations (Table 2). C 108297 
treated animals had significantly lower fasting lblood glucose levels compared to ROD 
animals, however they had fasting blood glucose levels that were also higher than 
controls and RU486 treated rats (p<0.05, Table 2). ROD, RU486, Cl 13176 and C108297 
treated rats had higher fasting insulin concentrations compared to controls (p<0.05, Table 
2). However, RU486 treatment resulted in lower fasting insulin levels compared to ROD 
animals, or rats treated with Cl 13176 or C108297 (p<0.05). Insulin AUC was measured 
during the OGTT to determine in vivo insulin response to exogenous glucose. ROD, 
Cl 13176 and C108297 treated animals had a similar AUC compared to control animals 
(p>0.05, Table 2). Interestingly, RU486 treatment resulted in a - 3-fold increase in 
insulin AUC compared to controls, and promoted the highest increase in insulin AUC 
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(p<0.05, Table 2). Fasting NEFAs were measured on day 12, as high levels of free fatty 
acids are associated with an increased risk of diabetes (392). ROD, Cl 13176 and 
C108297 treated rats demonstrated- 2-fold increase in fasting NEFAs compared to 
controls (p<0.05, Table 2). In contrast, RU486 normalized fasting NEF A concentrati1ons 
to levels found in control animals. 
Glucose tolerance and insulin response 
An OG TT was performed on all animals on day 12 after an overnight fast to 
determine glucose tolerance and insulin response to exogenous glucose challenge (Figure 
2A). The ROD group had the highest glucose concentrations throughout the OGTT 
challenge (Figure 2A) with a glucose AUC - 6-fold higher than controls (p<0.05, Figure 
2B). RU486 treatment normalized glucose tolerance, with results similar to those 
observed in the control group. Cl 13176 treatment resulted in an improvement in glucose 
tolerance compared to the results in the ROD group but values in the animals treated with 
Cl 13176 were still - 2-fold higher than those observed in the animals in the control 
group (p<0.05, Figure 2B). Treatment with Cl 08297 improved glucose tolerance 
compared to the ROD treated group, but glucose AUC was still - 4-fold higher than in 
control animals. Acute insulin response (AIR) was measured to determine insulin 
response at 15 minutes post oral glucose gavagc. ROD animals had reduced AIR 
compared to all other groups (p<0.05, Figure 2C). RU486 treatment resulted in - 3-fold 
increase in AIR compared to the values in the control group (p<0.05), and C 113176 
treatment resulted in similar AIR levels to those observed with RU486 treatment, with 
higher AIR compared to animals in the control group (Figure 2C). Animals treated with 
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C 108297 showed no differences compared to control animals or ROD treated animals 
(p>0.05). 
Insulin sensitivity, insulin resistance and P-cell function 
To determine peripheral insulin sensitivity primarily through skeletal muscle 
insulin action, an insulin tolerance test (ITT) was performed on all treatment groups. The 
ROD group had the highest fasting glucose concentrations and remained hyperglycemic 
(> 12 mM) 30 minutes post insulin bolus. RU486 treatment resulted in fully normalized 
insulin sensitivity, with glucose levels responding to insulin administration similarly to 
that observed in control animals. Cl 13176 and C108297 treated animals had 
improvements in fasting glucose (- 12 mM) and insulin sensitivity compared to ROD 
animals (Figure 3A), but treated animals did not have fully normalized insulin sensitivity. 
To determine insulin resistance as measured by liver insulin action, the HOMA-IR index 
was used. ROD animals were - 40-fold and- 30-fold more insulin resistant than control 
animals and RU486 treated groups (p<0.05, Figure 3B). RU486 treated animals were 
more insulin resistant than control animals (by-· 2-fold). However they were less insulin 
resistant than the ROD and the selective GRII antagonist treated groups. Cl 13176 and 
C 108297 treated animals showed attenuated increases in insulin resistance when 
compared to ROD animals., However these treatment groups remained more insulin 
resistant than control animals and RU486 treated animals (p<0.05, Figure 3B). The 
HOMA-P index was used to determine P-cell fw1ction; higher values indicate elevated P-
cell response to basal glucose concentrations. No differences were found between ROD 
animals and control treated animals. Both RU486 and Cl 13176 treatments improved P-
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cell function by~ 5-fold compared to all other groups (p<0.05, Figure 3C). Cl08297 
treatment did not significantly impact the HOMA-~ index. 
Body Composition 
Relative visceral fat mass was represented by the measured amount of isolated 
epididymal fat pad mass divided by body mass. All treatment groups had increased 
relative visceral fat mass compared to the control group (p<0.05, Table 3). No differences 
in fat mass were found between the groups treated with the antagonists. Liver mass was 
also increased in all treatment groups compared to controls (p<0.05) except for animals 
treated with RU486, in which liver mass was normalized (Table 3). Heart mass was 
increased with ROD and C 108297 treatment and normalized with RU486 treatment. 
Animals treated with Cl 13176 showed slight improvements compared to control animals 
(p<0.05, Table 3). It is known that CORT treatment specifically impairs white muscle 
growth (378). As expected, ROD animals had lower epitrochlearis mass compared to all 
other treatment groups (p<0.05). All groups that were administered an antagonist did not 
show changes in muscle mass relative to the animals in the control group (Table 3). The 
soleus muscle primarily consists of red, slow twitch muscle fibers and has been 
previously shown to increase with ROD treatn1<::nt (328), although the mechanisms for 
this change remain unknown. ROD animals demonstrated an increase in soleus muscle 
mass (p<0.05, Table 3) whereas RU486 treated animals only had a slight trend towards 
an increase in soleus muscle mass compared to control animals (p>0.05, Table 3). There 
were no differences between tibialis anterior muscle mass among the various treatment 
groups (Table 3). 
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Fat accumulation in muscle and liver 
Oil Red 0 staining of liver and tibialis anterior muscle sections was used to 
quantify fat accumulation in all treatment groups. ROD treatment increased red stain in 
muscle tissue and appearance of lipid droplets in liver tissue compared to controls. 
RU486 was the only antagonist that promoted normalized lipid accumulation in both the 
liver and type Ila muscle fibers relative to controls animals (115.76±10.12 vs. 
127.3±4.74, arbitrary units). The animals treated with the selective antagonists (Cl 13176 
and C108297) had similar ectopic lipid accumulation compared to ROD treated animals 
(144.52±3.17, 144.9±2.62, and 142.58±7.44 vs. 141.58±2.98, n=3-4). 
11P-HSD1 content in visceral fat 
At the tissue level, inactive GCs become activated by the action of the pre-
receptor enzyme 11~-HSDl, which acts to convert inactive GCs into active GCs. Recent 
studies have shown that inhibition of 11~-HSD1 activity helps to reverse metabolic 
pathological conditions such as T2DM (393). ROD treatment resulted in"" 4-fold increase 
in 11~-HSDl content in epididymal fat compared to controls (p<0.05, Figure 5). RU486 
normalized levels of 11~-HSDl content in epididymal fat. Cl 13176 and C108297 had 
similar levels of 11~-HSDl compared to ROD animals that were elevated compared to 
controls (p<0.05). Animals treated with Cl 13176 or C108297 had similar levels of 11 ~­
HSDl to the ROD treated group. 
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GSJS (Glucose stimulated insulin secretion) 
Pancreatic islets were isolated from all animals and insulin secretion was 
stimulated by an exogenous glucose challenge. ROD treatment resulted in an elevation in 
GSIS in both low (2.8 mM) and high (16.7 mM:) glucose media concentrations compaFed 
to controls (p<0.05, Figure 6). RU486 and C 113176 normalized GSIS in low and high 
glucose media concentrations compared to controls. C 108297 treatment resulted in 
similar levels as ROD treatment that had higher GSIS in high glucose media compared to 
control animals (p<0.05) with similar levels of GSIS compared to ROD treated islets. 
Discussion 
This study is the first to investigate the effectiveness of selective and non-
selective GRII antagonists in a rodent model of.ROD induced by GCs and HFD. We 
show that of the tested compounds, Cl 13176 treatment is the more effective selective 
GRII antagonist as it attenuates glucose intolerance, reinstates ~-cell function, and 
improves insulin sensitivity. The other selective antagonist tested in this study, Cl08297, 
also provides modest attenuation in hyperglycemia and peripheral insulin resistance and 
no changes to insulin response in vivo or ~-cell function in this ROD model. By 
comparison, however, the non-selective antagonist RU486 demonstrated superior 
effectiveness in this animal model of hyperglucocorticoidemia/diabetes, completely 
normalizing all abnormal features of growth and metabolism. Nonetheless, the new 
selective antagonist C 113176 may be of some therapeutic advantage for treatment of the 
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metabolic features of hyperglucocorticoidemia/cliabetes since it does not bind to the 
progesterone receptor. 
Elevated GCs induce a severe state of hypercatabolism that can lead to drastic 
metabolic complications, such as muscle wasting, low bone density and inhibited 
structural growth (135). GCs can also act in an anabolic fashion, promoting increased 
food intake and body fat deposition, especially in the abdominal region, thereby 
increasing an individual's risk for the development of diabetes (135). We have previously 
reported that ROD treatment decreases overall body mass (,.., 50%) but increases visceral 
adiposity compared to control animals (328). In the present study, we show that RU486 
treatment reverses body mass loss caused by ROD treatment, increasing body mass gain 
by,.., 20% compared to pre-surgery mass (Fig. lA and B). Previous results have shown 
that RU486 and C108297 treatment lower body mass gainin C57BL/6J mice consuming 
a HFD and given access to 11 % sucrose for 4 weeks ( 48). An obese phenotype is also 
alleviated with RU486 (271, 279, 394, 395) and C108297 (395) in other rodent and 
human models of disease. However, to our knowledge, C 113176 administration in 
animals with ROD has never before been reported. We demonstrate in this study that 
Cl 13176 antagonism restores pre-surgery body mass at day 8 of treatment and animals 
continue to maintain a healthy body mass until the termination of the study. In contrast, 
C 108297 treatment promoted mass loss similar to that observed in untreated ROD 
animals, a finding that could be considered detrimental in this particular animal model of 
severe cachexia. In other studies, C 108297 has been shown to decrease mass gain in 
C57BL/6J mice ( 48) as well as in rats treated with olanzapine, an anti-psychotic 
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medication associated with weight gain in rodents and humans (395). Body composition 
analysis was not reported in these studies to determine if the drug influenced lean or fat 
mass or both. Therefore, C 11317 6 antagonism might be an appropriate treatment for 
body mass management in humans with Cushing's syndrome because C108297 did not 
prevent body mass loss. 
RU486 has been used to treat patients with Cushing's syndrome (272). It is 
readily absorbed, has a half-life up to 48 hours, and has a greater binding affinity to GRII 
than GC agonists such as dexamethasone (3 to 4 times) and cortisol itself (18 times) (273-
275). The potent blockade of the GRII with RU486 administration interrupts GC 
negative feedback to the HP A axis, which could: have an effect on corticosterone levels. 
In our study, there were no differences in CORT AM levels between ROD and antagonist 
treated animals (Table 1). This finding is not surprising as our model of ROD administers 
exogenous GCs via CORT pellets at a level that already inhibits HPA axis negative 
feedback and reduces adrenal GC production (328). It can therefore be concluded that the 
results of the antagonists on whole-body metabolism are not due to differences in CORT 
levels as these were unchanged by the antagonists. It is known that increased levels of 
stress hormones not only promote hyperphagia (328) but also influence food choice 
decisions towards higher caloric foods (303). In this study, ROD treatment resulted in 
increased relative food intake compared to control animals and the GRII antagonist 
treated groups. Our study confirms that relative food intake is lower with the 
administration of GRII antagonists, as has been n~ported for RU486 treatment in rodents 
on a HFD (396) and in humans with Cushing's syndrome (271, 272). In addition, RU486 
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treatment in obese fa/fa rats with increased levels of circulating GCs, results in lower 
food intake (397) while no alterations in feeding are found in lean rats given the drug 
(398). Moreover, studies investigating the effects of selective GRII antagonists on weight 
gain show no differences in food intake in healthy rodents despite decreases in body mass 
gain (279). Taken together, these results suggest that GRII antagonism helps limit 
hyperphagia in Cushing' s syndrome and in diabetic animals. 
RU486 administration improves glycemic control and insulin sensitivity in 
rodents given HFD for 4 weeks ( 48) and lowers glycated hemoglobin levels in patients 
with Cushing's syndrome who often exhibit poor glycemic control (272). In our study, 
we show that RU486 administration resulted in normalized glycemic control, and that 
Cl 13176 had a greater influence on attenuating glucose intolerance than the other 
selective GRII antagonist tested (C108297) (Figure 2A and B). Moreover, both RU486 
and Cl 13176 treatment resulted in higher AIRs to oral glucose challenge compared to the 
other treatment groups thereby suggesting that enhanced P-cell function occurs with GRII 
antagonism (Figure 2C). Animals treated with C 108297 tended to have lower AIR 
compared to controls, suggesting poor P-cell sensitivity to exogenous glucose, similar to 
the effects seen in ROD animals. Treatment with RU486 also resulted in a significant 
increase in insulin AUC levels during the OGTT suggesting an elevated insulin response 
to_ exogenous glucose stimulation (Table 2). In accordance with these findings, we 
recently have shown that ROD treatment results in impaired islet glucose responsiveness 
in vivo and ex vivo, which likely exacerbates the poor glucose control caused by reduced 
insulin sensitivity (350). Importantly, this present study suggests that the non-selective 
184 
GRII antagonist RU486 reverses defective insulin responsiveness in vivo, which may 
help to explain the normal glucose control in these animals. In addition, ~-cell function in 
vivo is improved with both RU486 and C 11317 6 treatment but not with C 108297 
treatment (Figure 3C). There are very few studies to date that investigate the effects of 
RU486 on ~-cell function in vivo and to the best of our knowledge, this study is the first 
to report on ~-cell function in vivo with selective GRII antagonism. As such, it is possible 
to suggest that improvements to ~-cell function in vivo are through exclusive inhibition of 
GRII as seen with C 113176 administration. However, more investigations are required to 
fully understand the mechanisms of action with selective GRII antagonism. 
Elevated GCs in rodents induce peripheral tissue abnormalities that affect liver 
and skeletal muscle insulin sensitivity/signalling, thereby promoting hyperglycemia (111, 
339, 399). In our study, we show that RU486 normalizes whole body insulin sensitivity 
while C 113176 and C 108297 partially attenuated the condition (Figure 3A). The 
blockade of the GRII with RU486 helps to reduce peripheral insulin resistance in 
individuals with mild GC excess ( 400). Our study confirms these results, as insulin 
resistance was normalized with RU486 while attenuated with Cl 13176 and C108297 
administration (Figure 3B). Liver and skeletal muscle lipid accumulation is elevated in 
ROD treated animals, ultimately contributing to peripheral insulin resistance (328, 339). 
Interestingly, RU486 administration was able to lower both skeletal muscle and liver fat 
content, while no differences were measured between animals with ROD and animals 
treated with the selective GRII antagonists (Figme 4). Therefore, more studies are 
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required to investigate the mechanisms of action, especially with C 113176 
administration, on improving insulin resistance. 
Patients with Cushing's syndrome have an increased risk of obesity, which 
heightens their risk (60-80%) of developing diabetes as the disease progresses (138). 
Recent research shows that administration of RU486 results in normal body mass gain in 
rodents and in healthy men (271, 394). In addition, selective GRII antagonists such as 
Cl 12716 and Cl 13083 have been shown to help reverse olanzapine-induced mass gain in 
rats. (279). In our study we found that none of the GRII antagonists normalized the 
visceral adiposity that is readily observable in ROD treated animals (Table 3). We 
propose that it is likely that GRII antagonism. inhibits GC-induced lipolysis (110, 401) or 
off-target non-genomic effects that may indirectly increase GC tissue action ( 402), 
thereby promoting visceral adiposity. Moreove:r, increased 11~-HSDl activity in adipose 
tissue has been linked to obese and/or insulin resistant individuals (403). Our ROD model 
demonstrates increased 11~-HSD1 content in visceral fat compared to controls. RU486 
attenuates 11~-HSDl content (Figure 5), contradicting the idea that an increase in GC 
activity results in more visceral adiposity as RU486 treated animals had similar visceral 
adiposity to the ROD treated animals. Therefore, we propose that the increase in visceral 
adiposity with RU486 is due to the anti-lipolytic effects of increased insulin levels. 
Insulin is an anabolic hormone that down-regulates non-genomic actions of GCs 
(lipolysis) (110, 404) thereby promoting increased adiposity. Together these data suggest 
that although GRII antagonism does not lower visceral adiposity it may decrease lipolytic 
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GC action in the adipose tissue of RU486 treated rats, in part indicating a lesser risk of 
developing adiposity-induced abnormalities. 
Previously we have shown that ROD treatment results in increased islet 11 ~­
HSD 1 content as well as elevated GSIS in isolated islets (350). RU486 administration to 
insulin secreting cells in vitro reverses ~-cell dysfunction through improvements in 
insulin biosynthesis, release and content (164) as well as ~-cell [Ca2+]i response to 
glucose (165). Our study confirms these results as we show that RU486 and Cl 13176 
normalize GSIS compared to controls whereas C 108297 has similar GSIS compared to 
ROD animals (Figure 6). This is the first study to report the effects of selective GRII 
antagonists on ex vivo islet GSIS. We observe that Cl 13176 is an effective antagonist on 
GC action in the islet and it normalizes GSIS whereas C 108297 does not demonstrate the 
same result. More studies are required in vitro to replicate and further investigate the 
mechanisms of Cl 13176 action on GSIS. 
It is evident that GCs play a major role in whole body physiology (151) and 
reducing their action can help eliminate some unwanted effects. Although RU486 binds 
to the GRII with high affinity (0.3 nM) it also binds with high affinity to the progesterone 
receptor, resulting in endometrial wall thickening causing early disruption to pregnancy 
in females (reviewed in, (267)). Therefore, selective GRII antagonists have a major 
advantage over non-selective antagonists and presently there is a significant effort 
underway to find replacements for non-selective GRII blockers (277). More experiments 
need to be completed before the best antagonist is identified but in our study we 
consistently see that one compound, C 11317 6, attenuate diabetes symptoms. The 
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advantage of Cl 13176 is that it binds to the GRII with excellent affinity (0.28 nM) and 
does not bind significantly to ER, AR, PR or MR (data obtained through personal 
communications with Corcept Therapeutics Inc.). It has been found to be more potent 
than C108297 in functional TAT (tyrosine aminotransferase) in vitro assays that measure 
inhibition of dexamethasone induced activity in HepG2 cells and ratH4 cells (Corcept 
Therapeutics Inc.). For example, in HepG2 ceHs, the Ki values for C108297 and Cl 13176 
are 25 and 11 nM, and in rat H4 cells, the Ki values are 14 and 4 nM, respectively 
(Corcept Therapeutics Inc.). Compounds such as C108297 are described as having some 
beneficial effects in inhibiting GC action. However, C 108297 does not completely 
reverse adverse GC effects in our ROD model.. Perhaps, as previously described (278), 
this antagonist may actually work as a partial agonist, which could account for some of 
the results presented. 
This study describes the various metabolic and morphologic outcomes of 
administering selective and non-selective GRII antagonists to our rodent model of ROD. 
We show that in comparison to RU486, the compound C 11317 6 provides many 
therapeutic advantages over C108297 in ROD animals. Cl 13176 helps to attenuate 
fasting hyperglycemia, insulin resistance and improves AIR, and pancreatic ~-cell 
response. It may be a reasonable alternative me:dication to help patients suffering from 
Cushing's syndrome and other diseases associated with elevated GCs. Although Cl 13176 
did not completely normalize all complications of diabetes, it did provide clear benefits 
without any observable adverse effects. Thus, C 113176 may be a good alternative to the 
non-selective GRII antagonist RU486. 
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Table 1. Corticosterone concentrations, absolute and relative food intake. 
Control ROD RU486 C113176 C108297 
Day7 Day14 Day7 Day 14 Day7 Dayl4 Day7 Day 14 Day 7 Day 14 \ 
Day IO 
Corticosterone 169±503 61±303 623±38b 537±4lb 611±6lb 401±65b 711±63bc 637±58b 
L Day 10 DaylO Day 10 Day 10 
r--F_o_od~<~~ta_k_e~~~2_0_.9±~0_.6_a~~=--2_4_.0±~l-.2-b•~-~~~26_._3±_I_.o_b~~~~2-I_.l±_I_.3_a~~~~2-0_.3_±_I._6a~---. 
I 
· Food Intake 
. (kcal/g/BM) 0.23±0.4
8 0.40±0.0lc 0.40±0.02° 0.40±0.03c 
Note: BM= Body Mass. Different letters denote statistical significance, p<0.05, n=6-10. The * indicates 
that a significant difference was performed by a student's unpaired t-test. All values are mean± SE. 
Table 2. Fed and fasting glucose, insulin, insulin area under the curve (AUC) and non-
esterified fatty acids (NEF As) concentrations on day 12. 
Control ROD 
Fed Blood 
Glucose 6.6±0.28 20.6±1.4b 
(mM) 
~edBlood 
lucose 4.8±0.28 21.0±0.6b 
mMl 
Fasted 
Insulin 0.85±0.168 6.75±0.58b 
(!gL!!!!}~~~~~~~~~~~­[illS ulin AU C 
Fasted NEF As 
(mM) 
60.6±14.68 
0.45±0.038 
84.4±30.8ab 
l.08±0.07b 
RU486 C113176 C108297 
9.5±1.38 20.7±1.3b 23.6±2.3b 
6.2±0.l 8c 8.8±l.6c 14.0±l.6d 
3.64±0.15c 6.46±1.04b 5.22±0.73b 
l 74.0±37.6b 95 .0±49 .98b 94.5±4 l .48b 
0.49±0.058 l.10±0.15b 1.06±0.12b 
Note: Insulin area under the curve (AUC) was measured relative to individual basal insulin concentrations. 
Different letters denote statistical significance, p<0.05, n=6-10. All values are means± SE. 
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Table 3. Anthropometric data for epididymal fat pad, liver, heart, epitrochlearis, soleus 
and tibialis anterior mass (g/kg of body mass). 
Epitrochlearis 
(g/kg) 
Tibialis 
Anterior (g/kg) 
Control 
0.13±0.0la 
1.61±0.058 
ROD 
0.09±0.0lb 
1.51±0.088 
RU486 C113176 
0.13±0.0la 0.11±0.01 ab 
1.54±0.048 1.88±0.068 
Note: Different letters denote statistical significance, p<0.05, n=6-10. All values are means± SE. 
Cl08297 
0.1~±0.028 
1.55±0.078 
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Figure Captions 
Figure 1. C113176 treatment maintains body mass while RU486 increases body 
mass with ROD treatment. Animal body mass (g) were recorded every two days for 10 
days as a measure of fold change from day 0, pellet surgery (A). Animal body mass on 
day 10 were measured as a percent change of body mass from day 0 (B). The dotted line 
(100%) represents no change in body mass from day 0. Arrow indicates that 2 days after 
pellet surgeries respective antagonists or vehicle were administered at 80 mg/kg/day to 
each treatment group. Bars that do not share similar letters denote statistical significance, 
p<0.05, one-way ANOVA using Tukey's post-hoc test. n=7-10. All values are means± 
SE. 
Figure 2. Glucose intolerance and acute insulin response (AIR) is improved with 
RU486 and Cl13176 treatment. Fasting (basal, 0 minutes) and stimulated blood 
glucose (mM) were measured at 5, 15, 30, 60, 90 and 120 minutes post oral glucose 
gavage using a handheld glucometer (A). Glucose area under the curve (AUC) was 
calculated based on fasting blood glucose of control animals (B). To measure insulin 
capacity acute insulin response (AIR) was measured by the difference in insulin levels 
between fasting insulin and 15 minutes post glucose gavage (C). Negative values 
represent a decrease in insulin response, indicating impairment in insulin secretion. Bars 
that do not share similar letters denote statistical significance, p<0.05, one-way ANOVA 
using Tukey's post-hoc. A student's unpaired t-test was performed between controls and 
ROD, C108297 and Cl 13176 groups (C). n=7··10. All values are means± SE. 
Figure 3. Peripheral insulin sensitivity and fl-cell function is enhanced with RU486 
and Cl13176 administration. Fasting (basal, 0 minutes) and blood glucose levels (mM) 
were measured at 5, 10, 20 and 30 minutes post insulin i.p. injection using a handheld 
glucometer (A). HOMA-IR index was used to measure whole-body insulin resistance (B). 
HOMA-P index was used to measure pancreatic P-cell function (C). Bars that do not 
share similar letters denote statistical significance, p<0.05 one-way ANOVA using 
Tukey's post-hoc test. n=7-10. All values are means± SE. 
Figure 4. Fat accumulation is normalized with RU486 in skeletal muscle and liver 
cross sections. To determine fat content in skeletal muscle, tibialis anterior muscle was 
dissected and stained with a neutral lipid stain (Oil Red 0) (A-E). Cross sections of liver 
were also stained with Oil Red 0 to measure lipid content (F-J). 
Figure 5. llP-HSDl content in visceral fat is attenuated with RU486 treatment but 
not with C113176 or C108297 treatment. 1 lP-HSDl content was measured in 
epididymal fat pads to represent visceral adipose tissue and expressed relative to a.-
tubulin content. Bars that do not share similar letters denote statistical significance, 
p<0.05 one-way ANOV A using Tukey's post-hoc test. n=6. All values are means± SE. 
Figure 6. Glucose stimulated insulin secretion (GSIS) was normalized with RU486 
and Cl13176 treatment. GSIS in isolated islets was measured in low (2.8 mM) and high 
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r------ -
! 
(16.7 mM) glucose media for 1 hour incubations expressed as ng/ml/islet/hour. Bars that 
do not share similar letters denote statistical significance, p<0.05 one-way ANOVA using 
student's unpaired t-test. n=3-7. All values are means± SE. 
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design an effective rodent model of diabetes that produced a similar metabolic profile to 
humans with T2DM. Using young healthy male Sprague-Dawley rats, we developed a 
model of elevated GCs brought on by slow :release corticosterone ( 400 mg) and a HFD 
(60% of calories from fat) that induced rapid-·onset diabetes (ROD) within 1-2 weeks 
from the start of the treatment. Through administration of exogenous GCs, we 
ameliorated GCs diurnal pattern and continuously elevated GCs to peak levels at all 
times. We demonstrated that ROD induced a plethora of symptoms that included 
decreased body mass gains, despite increased levels of food intake, lower glycolytic 
muscle mass, increased visceral adiposity, hepatic steatosis, muscle lipid deposition, 
hyperglycemia, hyperinsulinemia, dyslipidemia, and severe insulin resistance. We also 
showed that visceral and subcutaneous fat depots from GC treated animals expressed 
relatively more 11~-HSDl mRNA expression than placebo animals, indicating increased 
adipose GC exposure, a mechanism contributing to whole-body impaired metabolic 
function. Interestingly, the ROD phenotype was not obtainable when elevated GCs and 
HFD were administered independently, and was only present when GCs and HFD were 
given simultaneously. Overall, manuscript #1 introduced a new cost effective and novel 
rodent model that paralleled similar symptoms experienced in individuals with T2DM. 
The study' s results provided insight into the idea that elevated GCs and HFD act together 
to cause severe insulin resistance that overwhelms islet adaptation. Furthermore, the 
development of this rodent model of disease facilitates future investigations of various 
therapeutic approaches (i.e., pharmacological and exercise therapies) that act to help 
reduce or reverse ROD development. Therefore, future successful therapeutic 
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interventions may be appropriately applied to help protect or prevent T2DM development 
in individuals. 
The findings from manuscript # 1 demonstrated that elevated GCs and HFD 
synergistically imposed severe insulin resistance that overwhelmed islet function, leading 
to overt hyperglycemia. Therefore, the focus of manuscript #2 was to specifically 
investigate the role of elevated GCs and HFD on pancreatic islet function to understand 
mechanisms of impaired islet compensation. GCs are known to interfere with the 
signalling pathways of various insulin secretagogues and insulin gene synthesis; 
however, the exact mechanisms are still not clear (151 ). GCs administered in vitro to 
rodent islets induce major islet and ~-cell dysfunction within a short period to time (1-6 
hours), dose depending (3, 161). In contrast, acute (5 days) and prolonged exogenous 
GCs (> 10 days) in vivo, in healthy rodents, with either dexamethasone or hydrocortisone 
(GC synthetic agonists) showed both unchanged and increased GSIS respectively (166, 
335, 405). Interestingly, prolonged(> 14 days) GC administration in healthy human 
subjects who were able to compensate for GC-induced insulin resistance in the short-
term, induced impairments in insulin secretion (146, 156). Similarly, prolonged 
elevations in lipids impair insulin secretion, but results may be dependent on an 
individual's existing/established insulin sensitivity (140). We demonstrate in manuscript 
#2 that exogenous GCs and HFD reduces islet glucose responsiveness in vivo, despite 
increases in ~-and a-cell areas and insulin secretion. Moreover, we showed that ROD 
treatment increased GC exposure directly in the islet, through elevated 11~-HSD1 
content, which is known to alter insulin secretion (155). Further, we showed that elevated 
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GC levels, along with dyslipidemia induced lower phosphorylation of PKC content, 
which suggests a mechanism in which GCs may impair GSIS in vivo. We found that 
ROD treated islets had less insulin storage capacity as well as a lower fold change in 
GSIS, indicating abnormal islet adaptive mechanisms that cause islet glucose 
insensitivity. Taken together, manuscript #2 highlighted the effect of ROD on islet 
function demonstrating that severe insulin resistance induced impaired islet 
responsiveness, despite increased islet compensation i.e. islet proliferation and 
hyperinsulinemia. Overall these results demonstrated that elevated GCs and the addition 
of a HFD induce appropriate islet adaptation, causing overt hyperglycemia. These results 
suggest that GCs and HFD work synergistically, not independently to cause islet 
impairments. Therefore, these risk factors should continue to be studied in tandem to 
further our understanding of T2DM development. 
Regular exercise such as voluntary wheel running is known to protect and prevent 
against the rise in insulin resistance and the metabolic syndrome ( 406). Exercise in early-
life has been shown to improve B-cell function and growth (232). Exercise can reverse 
T2DM-like symptoms (255), and our laboratory has demonstrated that exercise training, 
either swimming or wheel running, helps to lower GC excess in ZDF rats and reverse 
pathological symptoms of T2DM, by improving glycemic control and B-cell function (63, 
144, 150). There is little research that has inv1estigated the role of exercise in 
compromised metabolic conditions, such as situations of elevated GCs. Therefore, the 
focus of manuscript #3 was to examine the effects of regular exercise on our model of 
ROD. We found that ROD animals that wheel ran for~ 4 weeks had lowered glucose 
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intolerance, visceral adiposity, normalized glycolytic muscle loss, and muscle oxidative 
capacity. Furthermore, at the level of the pancreas, exercised ROD animals also displayed 
improved islet glucose responsiveness, ~-cell function, and better insulin sensitivity in 
vivo, whereas ex vivo they had a normalized GSIS. These results are important, as they 
are one of the first to demonstrate that regular exercise can help to Feverse detrimental 
effects of hypercortisolemia and dyslipidemia. In contrast to our hypothesis, we found no 
changes in body weight gain, whole-body insulin resistance or hepatic lipid accumulation 
with regular exercise and ROD, demonstrating that not all aspects of ROD were reversed 
or improved with regular exercise. These results show that more studies are necessary to 
further investigate the impact of exercise and ROD development. For example, a longer 
exercise protocol may be needed to observe complete prevention of ROD development, 
or it is possible that the level of GCs is too high for the exercise stimulus to overcome. 
Another therapeutic approach to the ROD model was to investigate the effects of 
pharmacological intervention. Recently RU486, which is a known non-selective GRII 
antagonist, is used to treat hypercortisolemia. This type of pharmacological therapy 
reverses symptoms of hyperglycemia, visceral adiposity, depression, and muscle wasting 
in individuals suffering from hypercortisolemia or Cushing's syndrome, but due to its 
occupancy with other nuclear receptors, such as the progesterone receptor, it can induce 
undesirable side effects (276). Recently, the development of selective GRII antagonists 
has diminished unwanted side effects, but there is little research reported on them. 
Therefore, the aims of manuscript #4 were as follows; 1) to investigate the effect of GRII 
antagonists had on ROD development, 2) to determine if selective GRII antagonists, such 
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as Cl 13176 and Cl08297, were more effective agents at reversing ROD development 
than non-selective antagonists, such as RU486. Impressively, RU486 treatment 
normalized the majority of ROD symptoms, such as body weight loss, impaired glucose 
tolerance, acute insulin response, insulin resistance, P-cell dysfunction, and hepatic and 
muscle lipid deposition. The other GRII antagonists did not completely reverse 
detrimental effects of ROD like RU486; however, Cl 13176 was able to maintain pre-
surgery body weight, attenuate hyperglycemia, insulin resistance, and improve acute 
insulin response, and P-cell function, whereas C 108297 only partially improved glycemic 
control and insulin resistance. Therefore, RU486 was found to be the most effective agent 
at normalizing the detrimental effects of ROD:, but selective GRII antagonists may still be 
an effective alternative to lowering and protecting against ROD development. 
Interestingly, no compound that was tested was able to reduce visceral adiposity with 
ROD treatment, but RU486 was able to lower GC excess, measured by l lP-HSDl 
content in epididymal fat depots. In conclusion, lowering GC exposure at the level of the 
adipose tissue, or other peripheral tissues for that matter, may be an effective way to fully 
obtain complete glucose and metabolic control, even in states of obesity. Therefore, 
metabolic dysfunction may not necessarily dev1~lop with increased adiposity, but in 
combination with elevated GCs it can be very detrimental to the body. 
Study Limitations 
There are several limitations that are highlighted in each study' s discussion; 
however, we have dec'ided to further examine some additional potential limitations that 
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warrant discussion. Our rodent model of ROD does induce severe glucose intolerance, 
insulin resistance and insulin insensitivitiy, which are classic symptoms of an individual 
with T2DM. We have identified that ROD animals demonstrate a diabetogenic 
phenotype; however, one characteristic that is not a typical symptom of T2DM is the loss 
in body weight gain due to reduced muscle mass. Some may argue that this is a classic 
symptom of Cushing's syndrome; however, not all Cushing's syndrome patients have 
T2DM. The ROD animals do share many symptoms with T2DM individuals, but they 
could also be categorized as a model of Cushing's syndrome. In addition, the CORT 
pellet treatment was given to rats at a very young age (6 weeks). It is possible that the 
effect we are observing in our model may be due to the fact that these animals have 
decreases in growth hormone and normal body maturation that has an overall affect on 
body weight gain and muscle mass. Therefore, future studies should be carried out to 
investigate these hypotheses. 
The use of voluntary wheel running as an exercise regime does not normalize all 
detrimental metabolic effects of ROD treatment. In fact, treadmill running may actually 
induce a sufficient amount of exercise intensity that may present better improvement to 
glucose intolerance in the ROD animals than volitional exercise. It is extremely difficult 
to identify the amount of exercise intensity dming a volitional exercise protocol. In 
addition, there are many differences between animals and their desire to run freely within 
their cages. For example, some rats run more than others and it is very hard to reverse or 
encourage this behaviour in low activity rats. Vv e found though our observational studies 
that rats that ran more had better glucose control than those who did not run at longer 
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distances. However, it is not possible to quantify the amount of exercise intensity of these 
rats unless video recordings were in place dming exercise protocols. Therefore, we only 
can measure the distances run by the rats and draw conclusions from these data. 
In manuscript #4 we did not utilize a dose response to determine our drug 
concentration administered to our ROD animals and instead we selected a dose that was 
previously published in the literature. Therefore, our conclusions in manuscript #4 
identify that the selective GRII antagonists only had partial beneficial effects to our ROD 
model, but perhaps a dose response of the GRII may provide further insight into the true 
effects of these antagonists. For example, a higher dose of C 11317 6 may conclude that 
this antagonist may provide more improvements to protect against ROD development 
than at the lower dose. Also, since our corticosterone pellet induced very high 
concentrations of corticosterone in the blood, that may not even be attainable in humans, 
the less potent antagonists such as Cl 13176 and C108297 compared to RU486 may be 
'out-competed' by the elevated GC levels, and therefore, appear to have lower efficacy. 
Therefore, our studies would benefit from studies investigating a dose response to GRII 
antagonists in ROD development. 
Future Directions 
There are several pathways that can be followed up with this research. It would be 
interesting to investigate the effect of prolonged treatment period. Our ROD model only 
lasts for a 2-week period, which can be considered an acute or short-term protocol. 
Therefore, it would be interesting to observe the effects of a four or six week treatment 
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period. Although this would probably require more technical manipulations to the 
original protocol because experiments that lasted for longer than 2 weeks during a dose 
response protocol had a lower amount of cotticosterone levels by 4 and 6 weeks. It is 
possible that the pellets did not absorb as well as they did at the beginning of the study 
and this may need further examination before an understanding of the best way to keep 
corticosterone levels in the elevated state. In addition, to a prolonged ROD treatment 
protocol, it would also be interesting to administer pellets to rats that were older than 6 
weeks of age. We are unsure whether our results are an effect of supraphysiological 
levels of corticosterone or if the rats are still very young when they receive the pellets and 
therefore it may exhibit more pronounced and detrimental phenotype. 
It would be interesting to follow ~-cell mass during this prolonged treatment 
period. We demonstrate that ~-cell mass is increased with ROD treatment without any 
increase in apoptosis. Therefore, it would be interesting to investigate whether or not ~­
cell mass continues to increase with prolonged treatment or whether it starts to decline 
after a certain point due to elevations in GCs or chronic GC administration. 
Another interesting follow-up study to the ROD model would be to observe the 
effects of replacing the HFD with a SD after a two-week treatment period. It is not known 
whether the animals would be able to recover from ROD and normalize glucose control 
or if they would remain in the same metabolic: detrimental state due to permanent effects 
of the ROD treatment. 
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Although we observe beneifical effects of regular exercise, it is still unclear 
whether exercise intensity plays a role in reducing ROD development. Therefore, future 
studies that compare the effects of treadmill and volitional exercise would provide further 
insight into the role of exercise and ROD development. In addition, we observe beneficial 
effects of regular exercise and pharmacological intervention via GRII antagonists 
separately in the ROD model. Therefore, it would be interesting to examine the effects of 
the combined treatment of regular exercise and the administration of GRII antagonists 
together. We hypothesize that the combination of both therapeutic interventions would 
normalize ROD development and prevent glucose metabolism deteriotation. 
Summary 
Collectively, all of these studies show how elevations in GCs and HFD, when 
administered in combination, can induce metabolic dysfunction and that a therapeutic 
approach, such as exercise and pharmacological intervention, can help to attenuate some 
of these symptoms. This work demonstrates that exogenous GCs and HFD can induce 
severe levels of peripheral insulin resistance that overwhelms islet function, resulting in 
hyperglycemia. We also examined the detrimental effects of our treatment and how it 
adversely affects normal islet capacity in response to increased metabolic demand. 
Furthermore, this thesis demonstrated the positive metabolic effects of regular exercise 
on hypercortisolemia and dyslipidemia. Regular exercise decreased visceral adiposity, 
lowered glucose intolerance, and insulin insensitivity. In addition, RU486 treatment 
normalized glucose control better than regular exercise on ROD development, despite 
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having no changes in visceral adiposity. Moreover, we were the first to demonstrate that 
selective GRII antagonists showed some positive improvements to the metabolic profile 
of the ROD animals; however, were not as effective as RU486 treatment. Taken together, 
this dissertation displays the detrimental effocts of elevated GCs and HFD in combination 
on whole-body physiology and islet function, and therapeutic strategies such as exercise 
and GRII antagonism are sufficient to prevent or even reverse development of ROD. 
Lastly, it is extremely important to continue our studies of the effects of GC 
therapy on glucose metabolism. There are several investigations that are just emerging in 
the litature that have identified an association between GC therapy use and poor glucose 
control. Therefore, it should be conveyed more clearly to patients and physicians that this 
type of treatment can greatly effect glucose and whole-body metabolism. An individual's 
diet and fat distrubition plays an important part in an individual's healthy metabolism and 
in combination with elevated administrated GCs can greatly impair glucose homeostasis 
therefore, patients should be closely monitored. 
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APPENDICES Chapter 7 
A. Extended Methods 
Immunohistochemistry Staining Protoc(i)l 
Materials List 
Xylene 
100, 95, 70% Ethanol 
H202- Z16763 
Methanol 
PBS 
Sodium citrate buffer 
Wax pen-mini pad pen 
Protein blocker 
Primary antibody 
Secondary antibody 
Avidin-Biotin (Vitamin B) 
DAB-Diaminobenzadene 
Microwave 
Hematoxylin 
Plastic trays- VWR-47751-792 
- Normal Serum Block SIG-31172-50--Covance signet antibodies 
- Nordic Ware #62104> $60.50 
Caspase 3-Dl 75 Rabbit Ab 
Cell Signalling #96615 
Dako Cytomation #A0564 
Labeling Reagent-SIG 322 4295 
Pink Level 2 USA HRP-enzyme conjugated avidin Biotin confer 
Staining apparatus-714 3 0-20-electron microscopy sciences 
Embedding cassettes-simport plastics 
WINLAB 20-Slide Racks> 71430-20 WINLAB 20-Slide Rack, Model LS-20 
each 46.00 
WINLAB 20-Slide Rack Carriers> 
Protein Blocker- SIG 31172-50 Covance Signet antibodies-Normal Serum Block 
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1. De-waxing 
a. Slides must be at room temperature 
b. 3 successive xylene baths 5 min each 
c. In between baths dab rack on paper towel to loose paraffin 
2. Rehydration 
a. 100% EtOH 2X 5 min each 
b. 95% EtOH lX 3 min 
c. 70% EtOH lX 3 min each 
3. Wash Slides 
a. Wash PBS lX 5 min. 
4. Inhibition of Endogenous Peroxidase Activity (3% H202 in PBS) 
a. Make 3% hydrogen peroxide in PBS (5ml 30% hydrogen peroxide in 45ml 
MEOH). Make fresh daily. 
b. Incubate slides in solution for 30 min at room temperature. 
c. Wash well in running tap H20 for 5min 
5. Protein Blocking (Covance Signet SIG-31172-50; to help decrease nonspecific 
staining) 
a. Treat sections with Protein Blocker (Blue bottle) for 30 min in humid 
chamber. 
6. Primary Antibody 
a. Shake off excess fluid (shake off protein blocker). 
b. Add 100-400 ul of primary antibody to each section. Negative controls are 
blocking solution only (in this case, PBS only) RECOMMENDED dilution 
for cleaved caspase-3 (cell signal #9661 is 1 :200). Try 1.33 in 200ul. 
c. Incubation should overnight in the fridge. 
8. Wash 
a. Wash in PBS 5X 3 min (moderate shaking). 
VERY IMPORTANT STEP! 
9. Secondary antibody (biotinylated) 
a. Add 100-400 ul of secondary antibody to each section. 
b. Incubate at room temperature for 30 min. 
RECOMMENDED dilution for BIOTINYLATED ANTI-GUINEA PIG (VECTOR BA-
1000) is 1 :500. 
10. Wash 
a. Remove secondary antibody by shaking/tapping your slides. 
b. Wash in PBS 4X 2 min. (moderate shaking). 
11. Labelling 
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a. Add 100-400 ul (1 drop) of labeling reagent (Pink Leve:l 2 USA-HRP 
(Ultrastreptavidin Horseradish peroxidase; Convance Signet SIG-32242-95)) 
to each section. 
b. Incubate for 30 min at room temperature in humid chamber. 
This step here makes the enzyme conjugated avidin-biotin complex for amplification of 
signal. 
12. Wash 
a. Remove labeling reagent by shaking/tapping your slides. 
b. Wash in PBS 4X 2 min. (gentle shaking). 
13. DAB (Diaminobenzaden Sigma-Aldrich D4293-50set; please wear gloves as this 
chemical is TOXIC and CARCINOGENIC) 
a. Prepare DAB by dissolving 1 pellet of DAB and 1 pellet of Urea Hydrogen 
peroxide in 5 mL of ddH20. Vortex for 1 min. 
b. Add 100-400 ul of DAB for variable amounts of time (as soon as you see 
brown on the slides). Should be around 1-3min. 
16. Wash 
a. Wash in running tap water (gentle'!!). 
DO NOT LET THE WATER HIT DIRECTLY ON THE SLIDES! 
1 7. Counterstain with Hematoxylin 
a. Immerse in Mayer's Hematoxylin (Sigma-aldrich MHS 1) for 5 sec 
b. Stop staining and wash in running tap water, 5-10 min. 
18. Dehydrate Sections 
a. 95% ethanol (2 changes): 10 sec. 
b. 100% ethanol (2 changes): 10 sec. 
c. Xylene (2 changes): 10 sec. 
19. Mount coverslips 
a. Remove slides from xylene on paper towel (Let drip little and do this in the 
fumehood unless you love the smell of xylene). 
b. Add Permount (two drops) adjacent to the sections. 
c. Lay down coverslip gently and try to get rid of any air bubbles. 
d. Use nail polish to seal the coverslip. 
e. Let dry. 
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Pancreas Profusion and Removal 
Materials Checklist for Pancreas Profusion and Removal 
Solution List 
Forceps 
30ml Syringe with 23g needle 
PESO tubing (45° angle from one end) 
Scissors 
Hemostats 
Suture (with and without needle) 
EtOH 
Gauze/Tissue 
Ice 
Conicals (50ml) 
Water Bath at 3 7°C 
Ketamine/HEP-SA 
Insulin Needle 
All Solutions must be kept on ice 
1. Collagenase (Sigma-C6885-1 g) 
4.5-5mg of collagenase (estimate depending on collagenase activity- Start with 
4.6mg) per 20mL RPMI without FBS. Each rat needs about 15mL collagenase. 
2. RPMI without FBS (Fetal Bovine Serum) (good for 2 weeks after preparation) 
RPMil 640-glutathione-glucose 500mL 
lOmM HEPES l.19-1.2g 
1 % Penicillin 5mL 
Glucose (50% dextrose) 250mg (0.5mL) 
3. RPMI with FBS (good for 2 weeks after preparation) 
RPMI 640-glutathione-glucose 
lOmMHEPES 
1 % Penicillin 
7%FBS 
Glucose (50% dextrose) 
Directions for solutions 2 & 3: 
Mix all 
500mL 
1..19-l.2g 
5mL 
37.5mL 
250mg (0.5mL) 
pH Solution (-7.4) with lON NaOH 
Filter solution for in vitro culture 
4. KREB's Buffer (500ml ofH20) 
212 
125rnM NaCl- 3.6525g 
4.7mM KCl- 0.1750g 
l.2mM KH2P04-0.0816g 
5 rnM NaHC03- 0.21 Og 
2.5 mM CaC12- 0.1385g 
2.4 mM MgS04- 0.144g 
10 rnM Hepes- 1.19g 
0.1 % BSA- 0.5g 
5. Krebs+ lOrnM HEPES +Glucose+ BSA= pH 7.4 
KREBS+ lOrnM HEPES 500mL 
Glucose (50% dextrose) 250mg (0.5mL) 
BSA 500mg 
(98% electrophoresis Sigma A 7906) 
6. Insulin Extraction Media 
Procedure: 
12mM in 70% ETOH 
0.18mol/L in 70% ETOH 
l .Sml in 98.5 ml of 70% ETOH 
1. Rats are anesthetized 
2. Abdominal fur is shaved off 
3. Alcohol is used to sterilize the shaved area 
4. The abdomen is cut open with scissors 
5. The aorta is cut in the abdomen and the blood is removed by gauze or tissue 
6. The duodenum end of the common bile duct (the other end being underneath the 
liver) is tied off 
7. An incision is made into the common bile duct right below the bifurcation 
8. PE50 tubing is inserted into the hole towards down and -15mL of collagenase 
solution is injected into the pancreas within 2-2.5minutes 
9. The pancreas is removed (entangle tht: duodenum, then the large intestine; do not 
cut off the spleen till you remove the whole pancreas). 
10. The pancreas is put into 50mL ice cold conical (it is about 5-lOmL) 
Islet Isolation Method 
1. The pancreas is incubated for 20minutes at 37°C with agitation (speed 5 shaking) 
in water bath 
2. Fill to 40mL of RPMI with FBS followed by vigorous shaking for 1 Osec 
3. The mixture is centrifuged at 1600rpm for 4 minutes at 4 °C 
4. The supernatant is discarded and 20rnL ofRMPI with FBS is added 
5. The mixture is gently shaken to mix the pellet and filtered 
6. The filtrate is collected into a new conical 
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7. The conical and the filter are washed with 20mL RMPI with FBS and the filtrate 
is put into the same new conical final volume 40mL 
8. The mixture is centrifuged at 1200rpm for 4minutes at 4°C 
9. The supernatant is discarded 
10. lOmL ofHistopaque-1077 is added to 1he pellet 
11. The mixture is gently shaken or mixed with 1 OmL pipette to dissolve the pellet 
12. lOmL RMPI without FBS is added gently to the tubing using lOmL pipette (add 
onto the side of the conical) so that 2 layers are seen 
13. The mixture is centrifuged at 2700rpm for 23minutes at 4°C (this step may have 
to be repeated if there is a lot of crap in the islets) 
14. The mixture is poured into a new conical and KREB's solution is added up to 
45mL. (Do this step in the fume hood) 
15. The mixture is centrifuged at 1400rpm for 3minutes at 4°C 
16. The supernatant is discarded 
17. The pellet is suspended in lOmL KREB's, pipette well and poured in culture 
dishes. 
18. Another lOmL KREB's is added to the conical washed and back to the same 
culture dish. 
19. The plates are then incubated for 1 hour at 3 7°C in incubator 
For insulin secretion: 
Solution: Different glucose concentrations for islet incubation and secretion 
For every 0.5L of KREBS (WITHOUT Glucose)+ lOmM HEPES, add 05.g BSA (A) 
Then add glucose per lOOmL of (A) as follows: 
252mg glucose: 2.8mM (same as solution 4) (Glucose 180.16) 
495.5mg glucose: 5.5mM 
999.8mg glucose: 11.lmM 
2.252g glucose: 25mM 
Each rat will require 12 test tubes (triplicate of each concentration): 
To 3 tubes, add lmL of 2.8mN[ 
To 3 tubes, add lmL of 5.SrriM 
To 3 tubes, add lmL of 11.lmM 
To 3 tubes, add lmL of25mM-To 12 welled plates 
1. ,..., 10 islets of medium size are sucked up with a P70 pipette and added to each 
tube (or plate) of different glucose concentrations 
2. The tubes are incubated in an incubator at 37°C 5% C02 and 95% 02 for 
2hours 
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3. Plates were removed from the incubator and placed in the fridge for 
l 5minutes to stop insulin secretion and 500ul of media was collected and put 
into -20°C freezer until further anaXysis. 
4. An additional 10 islets x3 were isolated from same animal and were extracted 
in (12mM HCL in 70% ETOH) overnight and then spun down in 
microcentrifuge for lOmin at 7.0 rpm. Supernatant was collected and then put 
into the -20°C freezer. 
Leftover islets7 Collected for Western Analysis 
1. Collect islets in Eppendorf tubes 
2. Spin at 7000rpm for 30sec to get islet pellets 
3. Discard supernatant 
4. Add lmL PBS 
5. Spin and discard ALL LIQUID 
6. Snap freeze with liquid nitrogen and store at -80°C 
Islet Isolations Protocol 
After islets have been isolated and re-suspended into KREB'S Buffer keep on ice 
1. Pick up islets using a syringe needle or pipette and a dissecting microscope 
2. Transfer islets with a little acinar and debris as possible to petri dish (1000cm2) 
with KREB's buffer 
3. Once all islets have been isolated then discard original petri dish and pick islets 
again and place into 35mm dish with 2ml ofKREB's buffer 
4. Once all islets have been transferred then remove supernatant (not all of it, do not 
want to dry islets out) 
5. Wash with lml ofRPMI with FBS and glucose buffer 
6. Remove supernatant 
7. Wash 1 ml ofRPMI with FBS and glucose buffer 
8. Add a final 2 ml of RPMI with FBS and glucose buffer and let islets rest in 
incubator over night 
Glucose Stimulated Insulin Secretion (GSIS) 
1. Remove 35mm plate from incubator and examine islets 
2. Remove RPMI buffer and wash 2 x with KREB-Low glucose (LG) 
3. Incubate islets in low glucose for 30minutes 
4. Remove supernatant and incubate~ 10 islets for 1 hour in LG (lml) in 12 well 
plate 
5. Remove 500ul of supernatant from each well of the plate and add to eppendorf 
tube. Spin tube for 1,200 rpm for 5minutes and transfer to new tube and freeze -20 
until further analysis 
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6. Wash each well x 2 with KREB-HG and add lml KREB-HG and leave plate in 
incubator for 1 hour 
7. Remove 500ul of supernatant and spin for 1,200rpm for 5 minutes and transfer to 
new eppendorftube and transfer to a new tube and freeze at -20 until further 
analysis 
8. Wash remaining islets with PBS in dish x 2 
9. Remove most of supernatant and add lysis ethanol buffer (lml). Pick up islets in 
each well and transfer to eppendorf tube. 
10. Sonicate sample for 15seconds x 2 and spin at 12,000 rpm x 5 minutes at 4°C. 
11. Transfer sample to new eppendorf tube and put into freezer until further analysis 
Note: If you require more time after islet isolation until GSIS experiments then replace 
~ 1 ml of RPMI each day to avoid contamination 
If isolating islets for protein concentrations then do not spin down at a high speed. Only 
1,200rpm for 5 minutes and then wash in PBS. 
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NEFA Protocol (96 Well Microplate) 
1. Prep materials: All samples (diluted if nece:ssary) approx 1 OOml distilled water, NEF A 
standard solution, colour Reagent A and B mixed and ready to use. 
2. Make the standards: 
•Place 5 µL ofDW in the top left well. 
• Run the standard solutions in triplicates, at 2.5 µL, 5 µL and 10 µL 
3. Pipette 5 µL of samples (in duplicates) into the remaining wells 
4. Pipette 200 µL of colour reagent A to every well 
•Mix well (approximately 30 seconds) and then incubate at 37 °c for 5 minutes 
5. Measure the absorbance of each well at 550 nm 
• Referred to as absorb 1. This serves as a baseline reading to compare the second 
absorbance reading (taken later) 
6. Pipette 100 µL of colour reagent B to every well 
• Mix well and then incubate at 3 7 °c for 5 minutes 
7. Measure the absorbance of each well (550 nm) 
• Referred to as absorb 2 
Example: 
1 2 
A Blank lOj.1._L 
B 2.5 µL lOj.1._L 
c 2.5 µL S_p_ 1 
D 2.5 µL S_p_ 1 
E 5 H_L S.£2 
F 5j.i._L S_E_ 2 
G 5 µL S_p_ 3 
H 10 µL S_p_ 3 
Excel Work 
3 4 
Sp4 
S_p_ 4 
Etc ... 
Note: In order to transfer the data from (insert computer program name here) into excel, 
select File - Export. Excel should come up, then select plates (tab on sub menu, top left 
of spreadsheet area) and click on the name of your plate, default M550. 
Making the standard curve 
1. Calculate the final absorbance: Absorb 2 -- Absorb 1 for each well. 
2. Subtract all final absorbance from the final absorbance of the blank (well 1) to obtain 
an adjusted absorbance 
3. Take an average of the adjusted final absorbance for each concentration and plot the 
data on a graph (absorbance vs concentration). Obtain a regression equation (r2 > 0.98) 
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4. Calculate the calculated concentration by plugging in the standard absorbance into the 
regression equation and solving for x. 
Calculating the sample concentrations 
1. Calculate the final and adjusted absorbance for each sample and take an average (same 
procedure as with the standards) 
2. Calculate the concentration (in mEq/L) by plugging in the absorbance values into the 
regression equation (as y) and solving for x. 
3. To obtain the concentration in mmol/L, divide the concentration in mEq/L by the 5 µL 
standard concentration. 
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ORO Stainiing Protocol 
(Modified from Koopman et al. 2001) 
Preparation 
1. Glass jars (enough for side samples, and x2 for staining, then place in freezer day of) 
2. Beakers-2x ddH20, 2x ORO, 1 fixation 
3. ORO stock 
4. Formaldehyde fixation 
5. Put ORO stock in 37°C water bath 
ORO stock solution 
500mgORO 
1 OOml 60% triethyl-phosphate (or 40ml ddH20 + 60ml 100% triethyl-phosphate) 
Mix while on heat 
Staining 
1. Mix ORO solution 12ml stock ORO+ 8ml ddH20 (x4 for --18 slides, always a 3:2 
ratio) 
2. Stir while on low heat 
3. Double filter ORO solution in 37°C incubator with circular filter paper 
Formaldehyde fixation 
3ml 3 7% formaldehyde + 27ml ddH20 
1. Determine slides to be used, serial (every other, use ones in between for fiber typing), 
with fiber type that worked. 
2. Place slides in glass jars while in freezer. 
3. Bring the jars with slides out of freezer and allow to defrost together. 
5. Pour formaldehyde solution into jar (pour on the side and not directly into the slides), 
formaldehyde fixation for 60 minutes. 
6. Prepare a beaker of ddH20. 
7. When formaldehyde fixation is complete, wash slides in ddH20 with 3 dips into the 
beaker. 
8. Dab dry and place in empty jar. 
9. Pour filtered ORO into the side of the jar, stain for 30min. 
10. Prepare a beaker of ddH20. 
11. When ORO stain is complete, wash the slides in ddH20 by dipping three times into 
beaker. 
12. Dab and allow slides to dry (standing up to prevent drops settling on section). 
13. Place a drop of crystal mount (small white bottle) on slide, no bubbles, and allow it to 
run over section - allow drying standing up. 
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Muscle Fiber Type Staining 
(modified from Ogilvie & Feeback. Stain Technology, 65:231-241, 1990) 
Solutions 
1. Toluidine Blue Stain (0.1 % solution) - stock 
• 0.250 g Toluidine Blue 
• 250 ml ddH20 
2. CaCl Rinse (1 % solution) - fresh every time 
• 4 g CaCl Dihydrate 
• 400 ml ddH20 
3. Tris Rinse -fresh every time 
• 270 ml ddH20 
• 4.356 g Trisma Base [Tris (hydroxymethyl) Aminomethane] 
• 0.936 g CaCl Dihydrate 
pH to 7.8 with HCl-prior to adjustment pH is ....,10.53 
top volume to 360 ml with ddH20 
4. Incubation Medium-fresh every time: 
• 120 ml ddH20 
• 0.632 g Glycine 
• 0.672 g CaC12 Anhydrous 
• 0.608 NaCl 
• 3.04 ml of 0.1 g/ml NaOH (add about 2 pellets, add last) 
pH should be ...., 10 .67 - pH to 9 .4 with H Cl ... use concentrated and step down to 
diluted HCl if necessary - better to leave pH ....,9 .60 because adding ATP lowers 
pH 
top up volume to 160 ml with ddH20 
add 0.32 of ATP just before use; readjust pH to 9.40 with HCl or NaOH 
(1/2=0. l 6g). 
5. Pre-Incubation Medium - fresh every time 
• 120 ml ddH20 
• 0.748 Potassium Acetate 
• 0.416 g Ca~l2 Dihydrate 
pH prior to adjustment should be ....,7.69- lower to 4.45 with Glacial Acetic Acid 
- take ...,half of the solution and then lower the pH of the other half to 
approximately 4.30- 4.32 ***these pH's work well with mouse muscle, 
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however the original article develops this technique on human muscle and 
suggests a pH of 4.50 for pre-incubation. 
Protocol 
1. run slides in duplicate/triplicate; one set in each pre-incubation medium. Incubate 
for4 min 
2. 3 Tris rinses at 2 min each. Add ATP to incubation medium and correct pH during 
these rinses 
3. incubatin medium for 25 min in the 37oC water bath 
4. 3 CaCl rinses (pour in, swish-swish pour out, don't want the slides sitting in Ca 
for too long) 
5. prepare beakers of Toluidine Blue, 2x dldH20, 95% ethanol, 100% ethanol and 
glass jars of citri-solv. 
6. stain slides for 15-20 seconds in Toluidine Blue solution (dip slide into beaker of 
stain). 
7. rinse slides in ddH20 to remove excess TB solution (-5 seconds/dips). 
8. dehydrate sections with 5 dips ni 95% ethanol; 5 dips in 100% ethanol. 
9. clear the slides in 2 changes of citri-sol for 5 min each 
10. allow slides to dry; mount cover slips with permount (no bubbles, place a drop 
beside section and push over with coveir slip). 
Important Notes 
Make solutions accurately - pH and concentrations are critical. Success is not guranteed 
but sloppy solutions 
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Succinate Dehydrogenase (SDH) Stain 
Protocol modified from: http://neuromuscular.wustl.edu/pathol/histol/sdh.htm, 
http://www.nottingham.ac.uk/pathology/protocols/sdh.html 
Solutions 
1. Phosphate buffer (lOOmM, pH 7.6) 
-Solution A (l.36g KH2P04/100ml): 12ml 
-Solution B (l .42g Na2HP04/1 OOml): 88ml 
2. Nitroblue tetrazolium (NBT) stock - freeze into 2ml aliquots 
-Phosphate buffer: 1 OOml 
-KCN [SIGMA 207810]: 6.5mg (CAS 151-50-8) 
-EDTA: 185mg 
-Nitroblue tetrazolium [SIGMA N6876]: lOOmg 
3. Succinate stock (500mM sodium succi.nate)- ideally, make fresh 
-sodium succinate [SIGMA S2378]: 2.7g 
-ddH20: 20ml 
4. Incubation medium - mix just before: use, keep out of strong light 
-NBT stock: 2ml 
-Succinate stock: 0.2ml 
-Phenazine methosulphate [SIGMA P9625]: 0.7mg (one small crystal) 
Sections 
Fresh or pre-cut frozen sections, 8-1 Oµm thick 
Incubation Protocol 
1. Incubation time varies by species/tissue 
-rat TA/soleus@room temp,..., 5min (less than mouse). 
-mouse TA/gastrocnemius@room temp,..., 10 min 
2. Use a pipette to cover section with incubation medium, and immediately cover. 
3. Incubate then remove some liquid with pipette, rest will be removed with wash. 
4. Rinse 3 times in ddH20 
5. Dehydrate 70%, 80%, 100% ethanol (r~ 10s each) 
6. Clear in xylene ,..., 2min 
7. Allow samples to air dry, permount and apply coverslip. 
Result 
Sites of mitochondrial SDH activity have blue/purple precipitate 
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B. Extended Results 
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Figurel. Plasma insulin-like growth hormone-1 (IGF-1) measured in placebo- and 
corticosterone-treated rats with and without HFD. Both CORT-treated rat groups had 
lower IGF-1 levels compared to placebo-RFD animals and tended to have lower levels 
compared to placebo-SD animals. Lower IGF·-1 levels indicate retarded growth or cell 
proliferation. Different letters denote statistical significance between groups. A student's 
unpaired t-test was performed to determine statistical significant with a criterion of 
p<0.05. N=3 for each group. Values are means± SE. 
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Figure2. Peripheral insulin resistance measured by HOMA-IR index in sedentary 
placebo-HFD and ROD animals, as weH as in exercised placebo-HFD and ROD 
animals. Insulin resistance increased by,..., 40-fold in CORT-SED (ROD) and CORT-EX 
(exercise) animals compared to placebo-SED and EX animals (p<0.001). No differences 
were found b.etween CORT-SED and EX animals indicating that 4 weeks of volitional 
wheel running were not sufficient to improve peripheral insulin action (p>0.05). Different 
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letters denote statistical significance between groups. A two-way ANOVA test was 
performed to determine statistical significant using Tukey's post-hoc criterion. N=6-10 
for each group. Values are means ± SE. 
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Figure3. Visceral adiposity measured by epididymal fat depots (A) and averaged 
food intake (B) after 10 days of ROD treatment in placebo and CORT-treated 
animals with and without exercise. Voluntary exercise lowered visceral adiposity in 
CORT-treated animals, while CORT-SED treatment increased visceral adiposity 
compared to placebo-treated animals (p<0.05). Food intake was increased with CORT-
treated animals, regardless of exercise or not, compared to placebo-treated animals 
(p<0.05). Different letters denote statistical significance between groups. A two-way 
ANOVA test was performed to determine statistical significant using Tukey's post-hoc 
criterion. N=6- l 0 for each group. Values are means ± SE. 
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Figure4. Absolute glucose stimulated insulin secretion (GSIS, ng/ml/islet/hour) with 
palmitate, and corticosterone in isolated islds from placebo-SD,, -HFD, CORT-SD 
and-HFD animals. High glucose media (16.7 mM) increased GSIS in CORT-HFD 
islets compared to all other treatment groups (p<0.05). Similarly, palmitate (0.3 mM) 
augmented GSIS in CORT-HFD islets compared to all other treatment groups (p<0.05). 
No differences were found between treatment groups when corticosterone ( 500 ng/ml) 
was added to the media (p>0.05). However, CORT-HFD islets had lower GSIS when 
corticosterone was added to the media compared to when palmitate was in the media 
(p<0.05). No differences were found when corticosterone and palmitate were added to the 
media (p>0.05). Different letters denote statistical significance between groups. A two-
way ANOVA test was performed to determine statistical significant using Tukey's post-
hoc criterion. N=5-6 for each group. Values are means ± SE. 
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Figures. Absolute glucose stimulated insulin secretion (GSIS, ng/ml/islet/hour) with 
palmitate, and corticosterone in isolated islets from placebo-SED, -EX, CORT-SED 
and -EX animals. High glucose media (16.7 mM) increased GSIS in CORT-SED and -
EX islets compared to placebo-SED and -EX (p<0.05). Palmitate (0.3 mM) in the media 
showed no differences in GSIS between treatment groups (p>0.05) whereas 
corticosterone (500 ng/ml) added to the media increased GSIS in CORT-SED and -EX 
islets (p<0.05). Different letters denote statistical significance between groups. A two-
way ANOVA test was performed to determine statistical significant using Tukey's post-
hoc criterion. N=3-5 for each group. Values are means± SE. 
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Figure6. Absolute glucose stimulated insullin secretion (GSIS, ng/ml/islet/hour) with 
palmitate, and corticosterone in isolated iislets from placebo-HFD (control), ROD, 
ROD+RU486, ROD+C108297, ROD+C1B1l76-treated animals. High glucose media 
(16.7 mM) increased GSIS in ROD and C108297 islets (p>0.05), but no differences were 
found between RU486 and Cl 13176 islets compared to control islet (p<0.05). Palmitate 
(0.3 mM) in the media showed no differences in GSIS between treatment groups 
(p>0.05) except in Cl 13176 treated islets that had the lowest GSIS compared to all 
treatment groups. Corticosterone (500 ng/ml) added to the media showed no differences 
in GSIS in between any treatment groups (p>0.05). ROD treatment increased GSIS when 
both palmitate and corticosterone were added to the media (p<0.05), but no differences 
were found between the other treatment groups (p>0.05). Therefore, these results suggest 
that ROD and C108297 treatment impair glucose sensitivity, GSIS was elevated with 
these two treatments, but RU486 and Cl 13176 normalize GSIS. Different letters denote 
statistical significance between groups. A one-way ANOVA test was performed to 
determine statistical significant using Tukey's post-hoc criterion. N=5 for each group. 
Values are means ± SE. 
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Figure7. Additional data to manuscript #4 that investigated the effect of the selective 
GRII antagonist, C118335 (80 mg/kg/day) in ROD animals on body weighit (A), 
visceral adiposity (B), glucose tolerance (C), acute insulin response (AIR) (D), 
insulin resistance (E) and P-cell functioni (F). Body weight gain was significantly 
decreased (--30%) with C118335 treatment at 10 day of ROD treatment compared to all 
other treatment groups (p<0.05). Visceral adiposity was normalized with C118335 
treatment, whereas it was elevated with all other antagonists compared to controls 
(p<0.05). Glucose intolerance, as measuredl by glucose under the curve (AUC) was 
increased with Cl 18335 administration compared to controls (p<0.05) and was similar to 
ROD treated animals. AIR was lowered with C118335 similar to levels of ROD and 
C 108297 treatment compared to controls (p<0.05). Peripheral insulin resistance, as 
measured by HOMA-IR index was elevated with C118335 treatment compared to 
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controls (p<0.05) and similar to ROD and C108297 treatment. P-cell function as 
measured by HOMA-P index was lower in C118335 treated animals compared to all 
other treatment groups (p<0.05). Overall, these results indicate that Cl 18335 treatment 
did not improve ROD development, although it did decrease visceral adiposity. Different 
letters denote statistical significance between groups. A one-way ANOVA test was 
performed to determine statistical significant using Tukey's post-hoc criterion. N=6-10 
for each group. Values are means ± SE. 
Table 1. Adrenal, absolute soleus and plantaris muscle mass (mg/kg of body mass). 
Placebo CORT 
-- ___ ___._____.... _____ _ 
~l]) illJITTID ~[ID [WrlJ1:0) 
~- -- -~ ------
Adrenal 0.09±0.004 0.10±:0.01 0.04±0.007 0.04±0.004 
Plantaris 0.31±0.01 0.30±0.02 0.21±0.02 0.17±0.02 
----------
Note: The* indicates significance from pla.cebo-SD. 
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C. Additional Contributions 
The following papers were published during the completion of this dissertation: 
A) First Authorships: 
1. Beaudry, J.L. and Riddell, M.C. Effects of Glucocorticoids and Exercise on 
Pancreatic ~ Cell Function and Diabetes Development. Diabetes Metab Res Rev. 
2012 Oct;28(7):560-73. doi: 10.l 002/dmrr.2310. 
2. Beaudry, J.L., D'souza, A., and Riddell, M.C. Physical activity and stress: 
Peripheral physiological adaptations. Chapter 23. Section 6: Psychological Stress. 
(In: Routledge Handbook of Physical .Activity and Mental Health, Editor: Mark 
Hamer). 
3. Beaudry, J.L., and Riddell, M.C. Stress and Pancreatic 6 Cell Function: Role of 
Glucocortoids, Exercise and Glucolipotoxicity. In: Beta Cells: Functions, 
Pathology and Research, Editor: Sarah E. Gallagher© 2010 Nova Science 
Publishers, Inc., ISBN: 978-1-61761-212-1. 
B) Second Authorships: 
1. Pereira, S., Yu, W.Q., Frigolet, M.E., Heaudry, J.L., Shpilberg, Y., Park, E., 
Dirlea, C., Nyomba, B.L., Riddell, M.C., Fantus, l.G., Giacca, A. Effectiveness of 
sodium salicylate in preventing fat-induced hepatic insulin resistance depends on 
duration of plasma free fatty acid elevation. J Endocrinol. 2013 Mar 
15;217(1):31-43. doi: 10.1530/JOE-12·-0214. 
2. Shikatani, E., Trifonova, A., Krylova, A., Szigiato, A., Beaudry, J., Riddell, 
M.C., and Haas, T.L. Inhibition of proliferation, migration and proteolysis 
contribute to corticosterone mediated inhibition of angiogenesis. PLoS One. 2012. 
7(10):e46625. doi: 10.1371/journal.pone.0046625. Epub 2012 Oct 2. 
3. D'souza, A., Beaudry, J.L., Szigiato, A., Trumble, S., Snook, L., Bonen, A., 
Giacca, A., and Riddell, M.C. Consumption of a High Fat Diet Rapidly 
Exacerbates the Development of Fatty Liver Disease that Occurs with Chronically 
Elevated Glucocorticoids. Am J Physiol Gastrointest Liver Physiol. 2012 Apr 
15 ;302(8):G850-63. 
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